Document_And_Entity_Informatio
| Document And Entity Information (USD $) | 6 Months Ended | ||
| Jun. 30, 2014 | Jul. 29, 2014 | Jun. 30, 2013 | |
| Document and Entity Information [Abstract] | ' | ' | ' |
| Entity Registrant Name | 'AtheroNova Inc. | ' | ' |
| Document Type | 'S-1 | ' | ' |
| Current Fiscal Year End Date | '--12-31 | ' | ' |
| Entity Common Stock, Shares Outstanding | ' | 4,808,748 | ' |
| Entity Public Float | ' | ' | $18,348,954 |
| Amendment Flag | 'true | ' | ' |
| Amendment Description | 'This Amendment No. 1 to the Registration Statement on Form S-1 originally filed with the Securities and Exchange Commission (the "SEC") on March 18, 2014 (the "Original Form S-1") contains interactive data files for the period ended December 31, 2013 that differ from the interactive data files filed by the Registrant with its Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the SEC on February 27, 2014, due to a retroactive restatement of the per share and common stock numbers set forth in such financial statements following a 1-for-10 reverse stock split approved by the Registrant's stockholders on April 16, 2014 and effected by the Registrant on April 22, 2014. | ' | ' |
| Entity Central Index Key | '0001377053 | ' | ' |
| Entity Current Reporting Status | 'Yes | ' | ' |
| Entity Voluntary Filers | 'No | ' | ' |
| Entity Filer Category | 'Smaller Reporting Company | ' | ' |
| Entity Well-known Seasoned Issuer | 'No | ' | ' |
| Document Period End Date | 30-Jun-14 | ' | ' |
| Document Fiscal Year Focus | '2014 | ' | ' |
| Document Fiscal Period Focus | 'Q2 | ' | ' |
Consolidated_Balance_Sheets
| Consolidated Balance Sheets (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
| Assets | ' | ' |
| Cash | $266,210 | $2,744,046 |
| Other current assets | 22,438 | 17,622 |
| Total Current Assets | 288,648 | 2,761,668 |
| Equipment, net | 7,405 | 8,514 |
| Deposits and other assets | 12,777 | 23,777 |
| Total Assets | 308,830 | 2,793,959 |
| Liabilities and Stockholders’ Equity (Deficit) | ' | ' |
| Accounts payable and accrued expenses | 811,404 | 603,629 |
| Interest payable | 76,462 | 37,016 |
| Current portion of 2.5% Senior convertible note, net of discount of $37,377 | 390,123 | ' |
| Total Current Liabilities | 1,277,989 | 640,645 |
| 2.5% Senior secured convertible notes | 1,170,333 | 1,762,833 |
| Discount on convertible notes | -807,200 | -1,402,030 |
| 2.5% Senior secured convertible notes, net of discount | 363,133 | 360,803 |
| Research & development costs payable in common stock-related party | 1,170,712 | ' |
| Stockholders’ Equity (Deficit): | ' | ' |
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized, none outstanding at December 31, 2013 and 2012 | 0 | 0 |
| Common stock, $0.0001 par value, 100,000,000 shares authorized, 4,158,402 and 3,722,364 outstanding at December 31, 2013 and , respectively | 416 | 371 |
| Additional paid in capital | 19,526,374 | 16,007,212 |
| Deficit accumulated during the development stage | -22,029,794 | -14,215,072 |
| Total Stockholders’ Equity (Deficit) | -2,503,004 | 1,792,511 |
| Total Liabilities and Stockholders’ Equity (Deficit) | $308,830 | $2,793,959 |
Consolidated_Balance_Sheets_Pa
| Consolidated Balance Sheets (Parentheticals) (USD $) | Jun. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Jun. 23, 2010 | 21-May-10 |
| Current portion of 2.5% Senior convertible notes, discount (in Dollars) | $0 | $37,377 | ' | ' | ' |
| Interest rate on senior secured convertible notes | 2.50% | 2.50% | 2.50% | ' | ' |
| Preferred stock par value (in Dollars per share) | $0.00 | $0.00 | $0.00 | ' | ' |
| Preferred stock shares authorized | 10,000,000 | 10,000,000 | 10,000,000 | ' | ' |
| Preferred stock outstanding | 0 | 0 | 0 | ' | ' |
| Common stock par value (in Dollars per share) | $0.00 | $0.00 | $0.00 | ' | $0.77 |
| Common stock shares authorized | 100,000,000 | 100,000,000 | 100,000,000 | ' | 100,000,000 |
| Common stock shares outstanding | 4,770,207 | 4,158,402 | 3,722,364 | 10,727,273 | ' |
Consolidated_Statements_of_Ope
| Consolidated Statements of Operations (USD $) | 12 Months Ended | 85 Months Ended | |
| Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | |
| Revenue, net | $0 | $0 | $0 |
| Operating expenses: | ' | ' | ' |
| Research and development | 2,030,285 | 986,261 | 3,889,621 |
| Research and development – related party | 2,369,009 | ' | 2,369,009 |
| General and administrative | 2,814,856 | 2,651,725 | 9,547,943 |
| Impairment charge-intellectual property | ' | ' | 572,868 |
| Loss from operations | -7,214,150 | -3,637,986 | -16,379,441 |
| Other income (expense): | ' | ' | ' |
| Other income | 2,457 | 2,832 | 8,839 |
| Cancellation of related-party debt | ' | ' | 100,000 |
| Merger-related expenses | ' | ' | -323,294 |
| Interest expense | -601,664 | -871,431 | -2,481,178 |
| Private Placement Costs | ' | ' | -2,148,307 |
| Cost to induce conversion of 12% notes | ' | -866,083 | -866,083 |
| Gain on extinguishment of derivative liabilities | ' | 97,975 | 909,368 |
| Change in fair value of derivative liabilities | ' | 2,640,497 | -839,569 |
| Total other income (expense) | -599,207 | 1,003,790 | -5,640,224 |
| Net loss before income taxes | -7,813,357 | -2,634,196 | -22,019,665 |
| Provision for income taxes | 1,365 | 1,365 | 10,129 |
| Net loss | ($7,814,722) | ($2,635,561) | ($22,029,794) |
| Loss per share – basic and diluted (in Dollars per share) | ($1.97) | ($0.86) | ' |
| Weighted average shares outstanding – basic and diluted (in Shares) | 3,973,028 | 3,063,525 | ' |
Consolidated_Statements_of_Sto
| Consolidated Statements of Stockholders’ Equity (USD $) | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | First Issuance [Member] | Second Issuance [Member] | Total |
| First Issuance [Member] | Second Issuance [Member] | First Issuance [Member] | Second Issuance [Member] | |||||||
| Balance at Dec. 31, 2008 | ' | ' | $202 | ' | ' | $224,798 | ($173,623) | ' | ' | $51,377 |
| Balance (in Shares) at Dec. 31, 2008 | ' | ' | 2,024,316 | ' | ' | ' | ' | ' | ' | ' |
| Net income (loss) | ' | ' | ' | ' | ' | ' | -12,322 | ' | ' | -12,322 |
| Issuance of common stock | ' | ' | 2 | ' | ' | 99,998 | ' | ' | ' | 100,000 |
| Issuance of common stock (in Shares) | ' | ' | 22,466 | ' | ' | ' | ' | ' | ' | ' |
| Fair value of common stock issued for services | ' | ' | 2 | ' | ' | 49,998 | ' | ' | ' | 50,000 |
| Fair value of common stock issued for services (in Shares) | ' | ' | 22,428 | ' | ' | ' | ' | ' | ' | ' |
| Balance at Dec. 31, 2009 | ' | ' | 206 | ' | ' | 374,794 | -185,945 | ' | ' | 189,055 |
| Balance (in Shares) at Dec. 31, 2009 | ' | ' | 2,069,210 | ' | ' | ' | ' | ' | ' | ' |
| Balance at Dec. 31, 2006 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Issuance of common stock to founders | ' | ' | 192 | ' | ' | -192 | ' | ' | ' | ' |
| Issuance of common stock to founders (in Shares) | ' | ' | 1,923,303 | ' | ' | ' | ' | ' | ' | ' |
| Balance at Dec. 31, 2007 | ' | ' | 192 | ' | ' | -192 | ' | ' | ' | ' |
| Balance (in Shares) at Dec. 31, 2007 | ' | ' | 1,923,303 | ' | ' | ' | ' | ' | ' | ' |
| Net income (loss) | ' | ' | ' | ' | ' | ' | -173,623 | ' | ' | -173,623 |
| Issuance of common stock | ' | ' | 10 | ' | ' | 224,990 | ' | ' | ' | 225,000 |
| Issuance of common stock (in Shares) | ' | ' | 101,013 | ' | ' | ' | ' | ' | ' | ' |
| Balance at Dec. 31, 2008 | ' | ' | 202 | ' | ' | 224,798 | -173,623 | ' | ' | 51,377 |
| Balance (in Shares) at Dec. 31, 2008 | ' | ' | 2,024,316 | ' | ' | ' | ' | ' | ' | ' |
| Balance at Dec. 31, 2009 | ' | ' | 206 | ' | ' | 374,794 | -185,945 | ' | ' | 189,055 |
| Balance (in Shares) at Dec. 31, 2009 | ' | ' | 2,069,210 | ' | ' | ' | ' | ' | ' | ' |
| Net income (loss) | ' | ' | ' | ' | ' | ' | -15,656,852 | ' | ' | -15,656,852 |
| Issuance of common stock | ' | ' | 10 | ' | ' | 224,990 | ' | ' | ' | 225,000 |
| Issuance of common stock (in Shares) | ' | ' | 101,013 | ' | ' | ' | ' | ' | ' | ' |
| Exercise of warrants | ' | ' | 4 | ' | ' | 87,523 | ' | ' | ' | 87,527 |
| Exercise of warrants (in Shares) | ' | ' | 39,250 | ' | ' | ' | ' | ' | ' | ' |
| Fair value of common stock issued for services | ' | ' | ' | ' | ' | 72,500 | ' | ' | ' | 72,500 |
| Fair value of common stock issued for services (in Shares) | ' | ' | 5,000 | ' | ' | ' | ' | ' | ' | ' |
| Fair value of warrants issued | ' | ' | ' | ' | ' | 518,000 | ' | ' | ' | 518,000 |
| Contribution of stockholder notes payable to capital | ' | ' | ' | ' | ' | 200,000 | ' | ' | ' | 200,000 |
| Fair value of vested options | ' | ' | ' | ' | ' | 287,355 | ' | ' | ' | 287,355 |
| Shares issued in reverse merger | ' | ' | 7 | ' | ' | 1,274 | ' | ' | ' | 1,281 |
| Shares issued in reverse merger (in Shares) | ' | ' | 60,765 | ' | ' | ' | ' | ' | ' | ' |
| Common stock issued upon conversion of notes payable | ' | ' | 2 | ' | ' | 99,012 | ' | ' | ' | 99,014 |
| Common stock issued upon conversion of notes payable (in Shares) | ' | ' | 25,194 | ' | ' | ' | ' | ' | ' | ' |
| Balance at Dec. 31, 2010 | ' | ' | 234 | ' | ' | 1,933,443 | -15,842,797 | ' | ' | -13,909,120 |
| Balance (in Shares) at Dec. 31, 2010 | ' | ' | 2,342,089 | ' | ' | ' | ' | ' | ' | ' |
| Net income (loss) | ' | ' | ' | ' | ' | ' | 4,263,286 | ' | ' | 4,263,286 |
| Issuance of common stock | 31 | 2 | ' | 1,730,110 | 149,998 | ' | ' | 1,730,141 | 150,000 | ' |
| Issuance of common stock (in Shares) | 314,570 | 15,464 | ' | ' | ' | ' | ' | ' | ' | ' |
| Fair value of common stock issued for services | ' | ' | 5 | ' | ' | 140,495 | ' | ' | ' | 140,500 |
| Fair value of common stock issued for services (in Shares) | ' | ' | 46,657 | ' | ' | ' | ' | ' | ' | ' |
| Fair value of warrants issued | ' | ' | ' | ' | ' | 22,470 | ' | ' | ' | 22,470 |
| Fair value of vested options | ' | ' | ' | ' | ' | 630,744 | ' | ' | ' | 630,744 |
| Fair value of common stock and warrants purchased by employees and vendors below of market price | ' | ' | ' | ' | ' | 309,417 | ' | ' | ' | 309,417 |
| Fair value of common stock issued to settle accounts payable | ' | ' | ' | ' | ' | 72,999 | ' | ' | ' | 72,999 |
| Fair value of common stock issued to settle accounts payable (in Shares) | ' | ' | 3,386 | ' | ' | ' | ' | ' | ' | ' |
| Common stock issued upon conversion of notes payable | ' | ' | 16 | ' | ' | 473,682 | ' | ' | ' | 473,698 |
| Common stock issued upon conversion of notes payable (in Shares) | ' | ' | 158,516 | ' | ' | ' | ' | ' | ' | ' |
| Balance at Dec. 31, 2011 | ' | ' | 283 | ' | ' | 5,395,363 | -11,579,511 | ' | ' | -6,183,865 |
| Balance (in Shares) at Dec. 31, 2011 | ' | ' | 2,839,025 | ' | ' | ' | ' | ' | ' | ' |
| Net income (loss) | ' | ' | ' | ' | ' | ' | -2,635,561 | ' | ' | -2,635,561 |
| Issuance of common stock | ' | ' | 45 | ' | ' | 2,061,742 | ' | ' | ' | 2,061,787 |
| Issuance of common stock (in Shares) | ' | ' | 448,000 | ' | ' | ' | ' | ' | ' | 448,000 |
| Fair value of common stock issued for services | ' | ' | 5 | ' | ' | 256,095 | ' | ' | ' | 256,100 |
| Fair value of common stock issued for services (in Shares) | ' | ' | 45,960 | ' | ' | ' | ' | ' | ' | ' |
| Fair value of shares transferred or sold | ' | ' | ' | ' | ' | 123,050 | ' | ' | ' | 123,050 |
| Fair value of warrants issued | ' | ' | ' | ' | ' | 58,387 | ' | ' | ' | 58,387 |
| Fair value of warrants and beneficial conversion feature due to changes to 12% convertible notes upon modification | ' | ' | ' | ' | ' | 866,083 | ' | ' | ' | 866,083 |
| Fair value of beneficial conversion feature of 2.5% senior convertible notes | ' | ' | ' | ' | ' | 1,498,333 | ' | ' | ' | 1,498,333 |
| Fair value of derivative liability extinguished upon modification of the 2.5% convertible notes | ' | ' | ' | ' | ' | 3,472,549 | ' | ' | ' | 3,472,549 |
| Fair value of vested options | ' | ' | ' | ' | ' | 803,770 | ' | ' | ' | 803,770 |
| Fair value of common stock issued to settle accounts payable | ' | ' | ' | ' | ' | 23,748 | ' | ' | ' | 23,748 |
| Fair value of common stock issued to settle accounts payable (in Shares) | ' | ' | 3,006 | ' | ' | ' | ' | ' | ' | ' |
| Common stock issued upon conversion of notes payable | ' | ' | 39 | ' | ' | 1,448,091 | ' | ' | ' | 1,448,130 |
| Common stock issued upon conversion of notes payable (in Shares) | ' | ' | 386,372 | ' | ' | ' | ' | ' | ' | ' |
| Balance at Dec. 31, 2012 | ' | ' | 372 | ' | ' | 16,007,211 | -14,215,072 | ' | ' | 1,792,511 |
| Balance (in Shares) at Dec. 31, 2012 | ' | ' | 3,722,363 | ' | ' | ' | ' | ' | ' | 3,722,364 |
| Net income (loss) | ' | ' | ' | ' | ' | ' | -7,814,722 | ' | ' | -7,814,722 |
| Issuance of common stock | 8 | 1 | ' | 519,993 | 116,999 | ' | ' | 520,001 | 117,000 | ' |
| Issuance of common stock (in Shares) | 80,000 | 12,062 | ' | ' | ' | ' | ' | ' | ' | 80,000 |
| Fair value of common stock issued for services | ' | ' | 20 | ' | ' | 1,198,277 | ' | ' | ' | 1,198,297 |
| Fair value of common stock issued for services (in Shares) | ' | ' | 199,716 | ' | ' | ' | ' | ' | ' | ' |
| Fair value of shares transferred or sold | ' | ' | ' | ' | ' | 481,400 | ' | ' | ' | 481,400 |
| Fair value of warrants issued | ' | ' | 9 | ' | ' | 150,038 | ' | ' | ' | 150,047 |
| Fair value of warrants issued (in Shares) | ' | ' | 85,924 | ' | ' | ' | ' | ' | ' | ' |
| Fair value of vested options | ' | ' | ' | ' | ' | 878,179 | ' | ' | ' | 878,179 |
| Fair value of common stock issued to settle accounts payable | ' | ' | ' | ' | ' | 4,518 | ' | ' | ' | 4,518 |
| Fair value of common stock issued to settle accounts payable (in Shares) | ' | ' | 646 | ' | ' | ' | ' | ' | ' | ' |
| Common stock issued upon conversion of notes payable | ' | ' | 6 | ' | ' | 169,759 | ' | ' | ' | 169,765 |
| Common stock issued upon conversion of notes payable (in Shares) | ' | ' | 57,691 | ' | ' | ' | ' | ' | ' | ' |
| Balance at Dec. 31, 2013 | ' | ' | 416 | ' | ' | 19,526,374 | -22,029,794 | ' | ' | -2,503,004 |
| Balance (in Shares) at Dec. 31, 2013 | ' | ' | 4,158,402 | ' | ' | ' | ' | ' | ' | 4,158,402 |
| Net income (loss) | ' | ' | ' | ' | ' | ' | -5,602,647 | ' | ' | -5,602,647 |
| Fair value of common stock issued for services | ' | ' | 1 | ' | ' | 23,394 | ' | ' | ' | 23,395 |
| Fair value of common stock issued for services (in Shares) | ' | ' | 6,535 | ' | ' | ' | ' | ' | ' | ' |
| Fair value of shares transferred or sold | ' | ' | ' | ' | ' | 249,528 | ' | ' | ' | 249,528 |
| Fair value of warrants issued | ' | ' | ' | ' | ' | 564,849 | ' | ' | ' | 564,849 |
| Common stock issued upon conversion of notes payable | ' | ' | 14 | ' | ' | 436,301 | ' | ' | ' | 436,315 |
| Common stock issued upon conversion of notes payable (in Shares) | ' | ' | 148,849 | ' | ' | ' | ' | ' | ' | ' |
| Balance at Jun. 30, 2014 | ' | ' | $477 | ' | ' | $22,953,135 | ($27,632,441) | ' | ' | ($4,678,829) |
| Balance (in Shares) at Jun. 30, 2014 | ' | ' | 4,770,207 | ' | ' | ' | ' | ' | ' | 4,770,207 |
Consolidated_Statements_of_Sto1
| Consolidated Statements of Stockholders’ Equity (Parentheticals) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | Dec. 31, 2009 | Dec. 31, 2008 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
| First Issuance [Member] | First Issuance [Member] | First Issuance [Member] | First Issuance [Member] | First Issuance [Member] | First Issuance [Member] | Second Issuance [Member] | Second Issuance [Member] | Second Issuance [Member] | |
| Issuance of common stock, per share amount | $6.50 | $0.50 | $5.50 | $2.23 | $2.23 | $2.23 | $9.70 | ' | $9.70 |
| Debt instrument, stated percent | ' | 12.00% | ' | ' | ' | ' | ' | 2.50% | ' |
| Issuance of common stock, per share amount (in Dollars per Share) | $2.23 | ' | ' | ' | ' | ' | ' | ' | ' |
Consolidated_Statements_of_Cas
| Consolidated Statements of Cash Flows (USD $) | 12 Months Ended | 85 Months Ended | |
| Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | |
| Operating Activities: | ' | ' | ' |
| Net loss | ($7,814,722) | ($2,635,561) | ($22,029,794) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ' | ' | ' |
| Loss on settlement of accounts payables | 6,980 | 44,356 | 105,713 |
| Amortization of debt discount | 557,453 | 769,185 | 2,266,942 |
| Depreciation | 4,169 | 3,399 | 11,674 |
| Fair value of vested options and warrants | 878,179 | 803,770 | 3,449,935 |
| Fair value of common stock issued for services | 1,198,297 | 256,100 | 1,717,397 |
| Research and development costs payable in common stock | 1,170,712 | ' | 1,170,712 |
| Fair value of shares transferred or sold to employees, directors and vendors by controlling stockholder | 481,400 | 123,050 | 604,450 |
| Impairment charge-intellectual property | ' | ' | 572,867 |
| Cost of private placement | ' | ' | 2,148,307 |
| Cost to induce conversion of 12% senior secured notes payable | ' | 866,083 | 866,083 |
| Gain on extinguishment of derivative liabilities | ' | -97,975 | -909,368 |
| Gain due to change in fair value of derivative liabilities | ' | -2,640,497 | 839,569 |
| Gain due to cancellation of debt | ' | ' | -100,000 |
| Changes in operating assets and liabilities: | ' | ' | ' |
| Accounts payable and interest payable | 249,524 | 482,152 | 1,087,561 |
| Other current assets, deposits and other assets | 6,184 | -28,490 | -35,215 |
| Net cash used in operating activities | -3,261,824 | -2,054,428 | -8,233,167 |
| Investing Activities | ' | ' | ' |
| Purchase of equipment | -3,060 | -7,913 | -19,079 |
| Investment in intellectual property | ' | ' | -372,867 |
| Cash received from reverse merger | ' | ' | 1,281 |
| Net cash used in investing activities | -3,060 | -7,913 | -390,665 |
| Financing Activities | ' | ' | ' |
| Proceeds from issuance of common stock, net | 787,048 | 2,061,787 | 5,366,503 |
| Proceeds from 12% convertible notes-net | ' | 645,200 | 645,200 |
| Repayment of convertible notes-short term | ' | -15,000 | -15,000 |
| Proceeds from sale of 2.5% senior secured convertible notes, net | ' | 1,498,333 | 2,893,339 |
| Net cash provided by financing activities | 787,048 | 4,190,320 | 8,890,042 |
| Net change in cash | -2,477,836 | 2,127,979 | 266,210 |
| Cash - beginning balance | 2,744,046 | 616,067 | ' |
| Cash - ending balance | 266,210 | 2,744,046 | 266,210 |
| Supplemental disclosure of cash flow information: | ' | ' | ' |
| Cash paid for interest | ' | ' | 32,666 |
| Cash paid for income taxes | 1,365 | 1,365 | 10,129 |
| Supplemental disclosure of non-cash investing and financing transactions: | ' | ' | ' |
| Stockholder notes issued in exchange for intellectual property | ' | ' | 200,000 |
| Conversion of convertible notes payable and accrued interest to equity | 169,765 | 1,448,130 | 2,190,616 |
| Derivative liability created upon issuance of the 2.5% senior secured convertible notes and attached warrants | ' | ' | 1,500,000 |
| Conversion of accounts payable to related party notes | ' | ' | 100,000 |
| Fair value of warrants and beneficial conversion feature associated with issued convertible notes | ' | 1,556,720 | 1,556,720 |
| Common stock issued to settle accounts payable | 9,283 | 23,748 | 106,030 |
| Fair value of derivative liability extinguished upon modification of the 2.5% convertible notes | ' | $3,472,549 | $3,472,549 |
Condensed_Consolidated_Balance
| Condensed Consolidated Balance Sheets (Current Period Unaudited) (USD $) | Jun. 30, 2014 | Feb. 12, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Jun. 15, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | Dec. 31, 2009 | Dec. 31, 2008 |
| Assets | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Cash | $319,779 | ' | $266,210 | $2,744,046 | ' | ' | ' | ' | ' |
| Other current assets | 31,123 | ' | 22,438 | 17,622 | ' | ' | ' | ' | ' |
| Total Current Assets | 350,902 | ' | 288,648 | 2,761,668 | ' | ' | ' | ' | ' |
| Equipment, net | 7,510 | ' | 7,405 | 8,514 | ' | ' | ' | ' | ' |
| Deposits and other assets | 8,917 | ' | 12,777 | 23,777 | ' | ' | ' | ' | ' |
| Total Assets | 367,329 | ' | 308,830 | 2,793,959 | ' | ' | ' | ' | ' |
| Liabilities and Stockholders’ Deficiency | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Accounts payable and accrued expenses | 1,412,642 | ' | 811,404 | 603,629 | ' | ' | ' | ' | ' |
| Interest payable | 123,086 | ' | 76,462 | 37,016 | ' | ' | ' | ' | ' |
| Derivative liabilities | 2,348,484 | 4,587,566 | ' | ' | 3,472,549 | ' | ' | ' | ' |
| Current portion of 2.5% Senior secured convertible note, net of discount of $0 as of June 30, 2014 and $37,377 as of December 31, 2013 | 427,500 | ' | 390,123 | ' | ' | ' | ' | ' | ' |
| Total Current Liabilities | 4,311,712 | ' | 1,277,989 | 640,645 | ' | ' | ' | ' | ' |
| Senior secured convertible notes, net of current portion | 2,660,167 | ' | 1,170,333 | 1,762,833 | ' | ' | ' | ' | ' |
| Discount on convertible notes | -2,080,795 | ' | -807,200 | -1,402,030 | ' | ' | ' | ' | ' |
| Senior secured convertible notes, net of discount | 579,372 | ' | 363,133 | 360,803 | ' | ' | ' | ' | ' |
| Research and development costs payable in common stock | 155,074 | ' | 1,170,712 | ' | ' | ' | ' | ' | ' |
| Stockholders’ Deficiency: | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Preferred stock $0.0001 par value, 10,000,000 shares authorized, none outstanding at June 30, 2014 and December 31, 2013 | 0 | ' | 0 | 0 | ' | ' | ' | ' | ' |
| Common stock $0.0001 par value, 100,000,000 shares authorized, 4,770,207 and 4,158,402 outstanding at June 30, 2014 and December 31, 2013, respectively | 477 | ' | 416 | 371 | ' | ' | ' | ' | ' |
| Additional paid in capital | 22,953,135 | ' | 19,526,374 | 16,007,212 | ' | ' | ' | ' | ' |
| Accumulated deficit | -27,632,441 | ' | -22,029,794 | -14,215,072 | ' | ' | ' | ' | ' |
| Total stockholders’ deficiency | -4,678,829 | ' | -2,503,004 | 1,792,511 | ' | -6,183,865 | -13,909,120 | 189,055 | 51,377 |
| Total Liabilities and Stockholders’ Deficiency | $367,329 | ' | $308,830 | $2,793,959 | ' | ' | ' | ' | ' |
Condensed_Consolidated_Balance1
| Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) (USD $) | Jun. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Jun. 23, 2010 | 21-May-10 |
| Current portion of 2.5% Senior secured convertible note, discount (in Dollars) | $0 | $37,377 | ' | ' | ' |
| Senior secured convertible note | 2.50% | 2.50% | 2.50% | ' | ' |
| Preferred stock par value (in Dollars per share) | $0.00 | $0.00 | $0.00 | ' | ' |
| Preferred stock shares authorized | 10,000,000 | 10,000,000 | 10,000,000 | ' | ' |
| Preferred stock outstanding | 0 | 0 | 0 | ' | ' |
| Common stock par value (in Dollars per share) | $0.00 | $0.00 | $0.00 | ' | $0.77 |
| Common stock shares authorized | 100,000,000 | 100,000,000 | 100,000,000 | ' | 100,000,000 |
| Common stock shares outstanding | 4,770,207 | 4,158,402 | 3,722,364 | 10,727,273 | ' |
Condensed_Consolidated_Stateme
| Condensed Consolidated Statements of Operations (Unaudited) (USD $) | 3 Months Ended | 6 Months Ended | ||
| Jun. 30, 2014 | Jun. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2013 | |
| Operating expenses: | ' | ' | ' | ' |
| Research and development | $833,893 | $438,157 | $1,401,046 | $872,916 |
| Research and development-related party | 155,074 | 1,198,297 | 1,137,097 | 1,198,297 |
| General and administrative expenses | 710,951 | 669,847 | 1,225,456 | 1,737,824 |
| Total operating expenses | 1,699,918 | 2,306,301 | 3,763,599 | 3,809,037 |
| Loss from operations | -1,699,918 | -2,306,301 | -3,763,599 | -3,809,037 |
| Other income (expenses): | ' | ' | ' | ' |
| Other income (expense) | 292 | 697 | 618 | 2,093 |
| Interest expense | -254,143 | -260,323 | -736,553 | -381,518 |
| Private placement costs | ' | ' | -3,340,030 | ' |
| Change in fair value of derivative liabilities | 2,484,433 | ' | 2,239,082 | ' |
| Net income (loss) before income taxes | 530,664 | -2,565,927 | -5,600,482 | -4,188,462 |
| Provision for income taxes | ' | ' | 2,165 | 1,365 |
| Net income (loss) | $530,664 | ($2,565,927) | ($5,602,647) | ($4,189,827) |
| Basic income (loss) per share (in Dollars per share) | $0.11 | ($0.64) | ($1.26) | ($1.07) |
| Diluted income (loss) per share (in Dollars per share) | $0.10 | ($0.64) | ($1.26) | ($1.07) |
| Basic weighted average shares outstanding (in Shares) | 4,618,409 | 4,003,358 | 4,415,392 | 3,900,847 |
| Diluted weighted average shares outstanding (in Shares) | 5,156,956 | 4,003,358 | 4,415,392 | 3,900,847 |
Condensed_Consolidated_Stateme1
| Condensed Consolidated Statements of Stockholders' Deficiency (Unaudited) (USD $) | 6 Months Ended | ||||
| Jun. 30, 2014 | Jun. 30, 2014 | Jun. 30, 2014 | Jun. 30, 2014 | Jun. 30, 2014 | |
| CardioNova [Member] | CardioNova [Member] | CardioNova [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | |
| Common Stock [Member] | Additional Paid-in Capital [Member] | ||||
| Balance | ' | ' | ' | $416 | $19,526,374 |
| Balance (in Shares) | ' | ' | ' | 4,158,402 | ' |
| Fair value of common stock issued for services | 42 | 2,152,693 | 2,152,735 | 1 | 23,394 |
| Fair value of common stock issued for services (in Shares) | 422,105 | ' | ' | 6,535 | ' |
| Fair value of vested options and warrants | ' | ' | ' | ' | 249,528 |
| Fair value of modified warrants to induce purchase of 6% Secured convertible notes | ' | ' | ' | ' | 564,849 |
| Common stock issued for reverse split | ' | ' | ' | 4 | -4 |
| Common stock issued for reverse split (in Shares) | ' | ' | ' | 34,316 | ' |
| Fair value of common stock issued upon conversion of notes payable and accrued interest | ' | ' | ' | 14 | 436,301 |
| Fair value of common stock issued upon conversion of notes payable and accrued interest (in Shares) | ' | ' | ' | 148,849 | ' |
| Balance | ' | ' | ' | $477 | $22,953,135 |
| Balance (in Shares) | ' | ' | ' | 4,770,207 | ' |
Condensed_Consolidated_Stateme2
| Condensed Consolidated Statements of Stockholders' Deficiency (Unaudited) (Parentheticals) | Jun. 30, 2014 |
| Additional Paid-in Capital [Member] | |
| 6% Secured Convertible Notes [Member] | |
| Secured convertible notes | 6.00% |
Condensed_Consolidated_Stateme3
| Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) | 6 Months Ended |
| Jun. 30, 2014 | |
| Operating Activities: | ' |
| Net loss | ($5,602,647) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ' |
| Loss on settlement of payables and accrued interest | 4,654 |
| Amortization of debt discount | 670,282 |
| Depreciation | 2,036 |
| Fair value of vested options and warrants | 249,528 |
| Fair value of common stock issued for services | 1,005,418 |
| Fair value of warrant modifications | 564,849 |
| Research and development costs payable in common stock | 155,074 |
| Cost of private placement | 2,681,066 |
| Change in fair value of derivative liabilities | -2,239,082 |
| Changes in operating assets and liabilities: | ' |
| Other assets | -4,825 |
| Accounts payable and accrued expenses | 662,857 |
| Net cash used in operating activities | -1,850,790 |
| Investing Activities | ' |
| Purchase of equipment | -2,141 |
| Net cash used in investing activities | -2,141 |
| Financing Activities | ' |
| Proceeds from sale of 6% senior secured convertible notes-net | 1,906,500 |
| Net cash provided by financing activities | 1,906,500 |
| Net change in cash | 53,569 |
| Cash - beginning balance | 266,210 |
| Cash - ending balance | 319,779 |
| Supplemental disclosure of cash flow information: | ' |
| Cash paid for income taxes | 2,165 |
| Supplemental disclosure of non-cash investing and financing transactions: | ' |
| Conversion of convertible notes and accrued interest payable to common stock | 436,315 |
| Accrued research and development costs paid in shares of common stock | 1,170,712 |
| Derivative liability created on issuance of convertible notes and warrants | $4,587,566 |
Condensed_Consolidated_Stateme4
| Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) | Jun. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Jun. 30, 2014 | Feb. 28, 2014 | Feb. 12, 2014 |
| 6% Secured Convertible Notes [Member] | 6% Secured Convertible Notes [Member] | 6% Secured Convertible Notes [Member] | ||||
| Senior secured convertible notes | 2.50% | 2.50% | 2.50% | 6.00% | 6.00% | 6.00% |
Note_1_Organization
| Note 1 - Organization | 6 Months Ended | 12 Months Ended |
| Jun. 30, 2014 | Dec. 31, 2013 | |
| Disclosure Text Block [Abstract] | ' | ' |
| Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | ' | ' |
| 1. ORGANIZATION | 1. ORGANIZATION | |
| Z&Z Medical Holdings, Inc. (“Z&Z Nevada”) was incorporated under the laws of the State of Nevada on December 13, 2006 (Inception). On November 30, 2009, a separate corporation named Z&Z Medical Holdings, Inc. (“Z&Z Delaware”) was incorporated under the laws of the State of Delaware and on March 3, 2010 Z&Z Nevada was merged into Z&Z Delaware. On May 13, 2010, pursuant to an Agreement and Plan of Merger dated March 26, 2010 and our subsidiary, Z&Z Merger Corporation, merged with and into Z&Z Delaware and the surviving subsidiary corporation changed its name to AtheroNova Operations, Inc. (“AtheroNova Operations”). | Z&Z Medical Holdings, Inc. (“Z&Z Nevada”) was incorporated under the laws of the State of Nevada on December 13, 2006 (Inception). Z&Z Nevada had its headquarters located in Laguna Niguel, California. On November 30, 2009, a separate corporation named Z&Z Medical Holdings, Inc. (“Z&Z Delaware”) was incorporated under the laws of the State of Delaware and on March 3, 2010, Z&Z Nevada was merged into Z&Z Delaware. On May 13, 2010, pursuant to an Agreement and Plan of Merger dated March 26, 2010, (i) our subsidiary, Z&Z Merger Corporation, merged with and into Z&Z Delaware (the “Merger”) and the surviving subsidiary corporation changed its name to AtheroNova Operations, Inc. (“AtheroNova Operations”), (ii) we assumed all the outstanding options and warrants of Z&Z Delaware and (iii) we completed a capital raise transaction in which we sold $1,500,000 in 2.5% Senior Secured Convertible Notes. The former holders of AtheroNova Operations’ common stock became holders of approximately 98% of our outstanding common stock. On May 21, 2010, holders of approximately 76.7% of the then outstanding shares of our Super-Voting Common Stock, approximately 90.7% of the then outstanding shares of our common stock, and approximately 77.1% of the combined voting power of the then outstanding shares of our Super-Voting Common Stock and our common stock approved an amendment of our certificate of incorporation that (i) decreased the authorized number of shares of our common stock to 100,000,000, (ii) designated 10,000,000 shares of blank check preferred stock, and (iii) adopted a 1 - for - 200 reverse stock split. The amendment to our certificate of incorporation became effective on June 23, 2010. | |
| As a result of the merger AtheroNova is now engaged, through AtheroNova Operations, in development of pharmaceutical preparations and pharmaceutical intellectual property. The Company will continue to be a development stage company for the foreseeable future. | As a result of the Merger, AtheroNova is now engaged, through AtheroNova Operations, in development of pharmaceutical preparations and pharmaceutical intellectual property. We will continue to be a development stage company for the foreseeable future. We have entered into contracts with two research sites for our second round of pre-clinical trials. | |
| On April 22, 2014, the Company effected a 1 - for - 10 reverse stock split through the amendment of its certificate of incorporation. As a result, all share and per share amounts have been retroactively restated as of the beginning of the earliest period presented to effect the reverse stock split. | Immediately prior to the Merger, we had 10,727,273 shares of our common stock issued and outstanding. In connection with the Merger, we issued 88,575,048 shares of our Super-Voting Common stock in exchange for the issued and outstanding shares of common stock of AtheroNova Operations, and assumed AtheroNova Operations’ outstanding options and warrants which became exercisable to purchase an aggregate of up to 16,552,227 shares of our Super-Voting Common Stock. Upon the effectiveness of the 1 - for - 200 reverse stock split all shares of our Super-Voting Common Stock were automatically converted on a 50 - to - 1 basis into our common stock, resulting in the issuance of 2,214,376 shares of our common stock to the former holders of AtheroNova Operation’s common stock, and the outstanding shares of common stock held by our existing stockholders were combined into 60,765 shares of our common stock including 9,017 shares subsequently adjusted for rounding. | |
| In June 10, 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU)2014-10 (ASU 2014-10), Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. ASU 2014-10 eliminates the requirement to present inception-to-date information about income statement line items, cash flows, and equity transactions, and clarifies how entities should disclose the risks and uncertainties related to their activities. ASU 2014-10 also eliminates an exception provided to development stage entities in Consolidations (ASC Topic 810) for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The presentation and disclosure requirements in Topic 915 are no longer required for interim and annual reporting periods beginning after December 15, 2014. The revised consolidation standards will take effect in annual periods beginning after December 15, 2015, however, early adoption is permitted. The Company adopted the provisions of ASU 2014-10 for this quarterly report on Form 10-Q for the period ended June 30, 2014. | Since former holders of AtheroNova Operation’s common stock owned, after the Merger, approximately 98% of our shares of common stock, and as a result of certain other factors, including that all members of our executive management are members of AtheroNova Operation’s management, AtheroNova Operations is deemed to be the acquiring company for accounting purposes and the Merger was accounted for as a reverse merger and a recapitalization in accordance with generally accepted accounting principles in the United States (“GAAP”). These consolidated financial statements reflect the historical results of AtheroNova Operations prior to the merger and that of the combined company following the Merger, and do not include the historical financial results of AtheroNova Inc. prior to the completion of the merger. | |
| On April 22, 2014, the Company effected a 1 - for - 10 reverse stock split through the amendment of its certificate of incorporation. As a result, all share and per share amounts have been retroactively restated as of the beginning of the earliest period presented to effect the reverse stock split. |
Note_2_Basis_of_Presentation_a
| Note 2 - Basis of Presentation and Summary of Significant Accounting Policies | 6 Months Ended | 12 Months Ended | ||||||||||||||||||||||||
| Jun. 30, 2014 | Dec. 31, 2013 | |||||||||||||||||||||||||
| Accounting Policies [Abstract] | ' | ' | ||||||||||||||||||||||||
| Significant Accounting Policies [Text Block] | ' | ' | ||||||||||||||||||||||||
| 2. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 2. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | |||||||||||||||||||||||||
| The summary of significant accounting policies presented below is designed to assist in understanding the Company’s condensed consolidated financial statements. | The summary of significant accounting policies presented below is designed to assist in understanding our consolidated financial statements. Such consolidated financial statements and accompanying notes are the representation of our management, who are responsible for their integrity and objectivity. | |||||||||||||||||||||||||
| Use of Estimates | Development Stage | |||||||||||||||||||||||||
| In preparing these condensed consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the condensed consolidated financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Significant estimates and assumptions included in the Company’s condensed consolidated financial statements relate to the valuation of long-lived assets, accrued other liabilities, and valuation assumptions related to share based payments and derivative liability. | We are currently in the development stage, and our business plan is to develop commercial relationships with third parties for the development, marketing and sale of products based on our Intellectual Property (“IP”) and to derive revenue through the licensing of our IP to such third parties. | |||||||||||||||||||||||||
| Going Concern | Use of Estimates | |||||||||||||||||||||||||
| The accompanying condensed consolidated financial statements have been prepared under the assumption that the Company will continue as a going concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any revenues from operations to date, and does not expect to do so in the foreseeable future. The Company has incurred operating losses and negative operating cash flows since inception and has financed its working capital requirements through recurring sales of its convertible notes and equity securities. As reflected in the accompanying condensed consolidated financial statements, the Company had a net loss of $5,602,647 and negative cash flow from operations of $1,850,790 for the period ended June 30, 2014 and stockholders’ deficiency of $4,678,829 at June 30, 2014. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. As a result, the Company’s independent registered public accounting firm, in its report on the Company’s December 31, 2013 financial statements, has raised substantial doubt about the Company’s ability to continue as a going concern. | In preparing these consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Significant estimates and assumptions included in our consolidated financial statements relate to the valuation of long-lived assets, accrued liabilities, and valuation assumptions related to the calculation of equity based compensation and in the calculation of the derivative liability. | |||||||||||||||||||||||||
| Management is currently in the process of exploring equity placements of securities by the Company to accredited investors, funds and institutional investors. The Company received $1,906,500 through the sale of its 6% Secured Convertible Notes as of February 2014. Management believes that current funds will be sufficient to fund operations through August 2014. Significant additional capital will be needed to advance the Company’s research and development and clinical trials as well as providing general working capital. There can be no assurances that sufficient subsequent funding, if any at all, will be raised by this or future offerings or that the cost of such funding will be reasonable. | Going Concern | |||||||||||||||||||||||||
| In light of the foregoing, management will continue to seek funding through short-term and long-term loans, grants and other such funds available from private and public sources established to further research in health care and advancement of science. Additionally, the Company has filed a registration statement on form S-1 for a possible sale of equity to generate sufficient funds to continue operations for the next 12 to 15 months. Management continues to meet with representatives of private and public sources of funding to continue the ongoing process of capital development sufficient enough to cover negative cash flows expected in future periods and will continue to do so in the coming months. | The accompanying consolidated financial statements have been prepared under the assumption that we will continue as a going concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As of December 31, 2013, we have an accumulated deficit of $22,029,794 and a stockholders’ deficit of $2,503,004. We have incurred recurring losses from operations since inception, and utilized cash flow from operating activities of $3,261,824 during the year ended December 31, 2013. These factors, among others, raise substantial doubt about our ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern. | |||||||||||||||||||||||||
| Principles of Consolidation | During 2013, we secured funding through the exercise of warrants issued in previous financings with proceeds of $150,047, the sale of a second tranche of common stock to CardioNova upon delivery of clinical trial material with proceeds of $117,000 and closed a private placement with net proceeds of $520,001. | |||||||||||||||||||||||||
| The condensed consolidated financial statements include the accounts of the Company and its majority-owned subsidiary. Intercompany transactions and balances have been eliminated in consolidation. | In February 2014, the Company placed $1,906,500 of Senior Secured 6% Notes to investors (See Note 11 Subsequent Events) and continues to seek additional long-term funding sources. Management expects that the current funds on hand will be sufficient to continue operations through April of 2014. There can be no assurances that the proceeds from these note sales will be sufficient to fund the Company operations for a sufficient period of time in order to secure significant additional funding. There can be no assurances that sufficient funding, if any at all, will be raised by these or future discussions or the cost of such investments will be reasonable. | |||||||||||||||||||||||||
| Accounting for Share based Research and Development Costs | In light of the foregoing, management will also seek funding through grants and other such funds available from private and public sources established to further research in health care and advancement of science. Management continues to meet with representatives of private and public sources of funding and will continue to do so in the coming months. | |||||||||||||||||||||||||
| Under its research and development (R&D) agreements, the Company is obligated to issue shares of common stock if milestones are met by the R&D vendor. It is the Company’s policy to recognize expense for these shares when it is estimated that there is a high probability of meeting the milestone. The Company accrues the share based expense based upon the estimated percentage of completion of the milestone. The shares are valued at the market price at the end of the period and revalued at each period until issued. At June 30, 2014, approximately 83,824 shares of common stock were expected to be issued pursuant to the agreement with a fair value of $155,074. Accordingly, a liability was recorded as part of “Research and development costs-payable in stock” in the accompanying balance sheet below long term liabilities as such liability is only payable in shares of common stock. | Principles of Consolidation | |||||||||||||||||||||||||
| Reclassifications | The consolidated financial statements include the accounts of our Company and our wholly-owned subsidiary, AtheroNova Operations. Intercompany transactions and balances have been eliminated in consolidation. | |||||||||||||||||||||||||
| The condensed consolidated financial statements include a reclassification of consulting fees in prior periods to properly compare to current period presentation. Such reclassification did not change the reported net loss during that period. | Research and Development Costs | |||||||||||||||||||||||||
| In presenting the Company’s statement of operations for the three and six month periods ended June 30, 2013, the Company reclassified consulting fees of $140,076 and $251,911, respectively, that were previously reflected as operating expenses to research and development expenses. | Costs incurred for research and development are expensed as incurred. Purchased materials that do not have an alternative future use are also expensed. For the years ended December 31, 2013 and 2012, and for the period from inception to December 31, 2013, research and development costs incurred were $4,399,294, $986,261 and $6,258,630, respectively. | |||||||||||||||||||||||||
| Earnings and Loss per Share | Accounting for share based research and development costs | |||||||||||||||||||||||||
| The Company’s computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. | Under its Research and Development (R&D) agreements, the Company is obligated to issue shares of common stock if milestones are met by the R&D vendor. It is the Company’s policy to recognize expense for these shares when it is estimated that there is a high probability of meeting the milestone. The Company accrues the share based expense based upon the estimated percentage of completion of the milestone. The shares are valued at the market price at the end of the period and revalued at each period until issued. At December 31, 2013, approximately 3 million shares of common stock are to be issued pursuant to the agreement with a fair value of $1,170,712. The liability was recorded as part of Research and development costs - payable in stock in the accompanying balance sheet below long term liabilities as it is only payable in shares of common stock. | |||||||||||||||||||||||||
| Income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted (loss) per common share is the same for periods in which the company reported an operating loss because all warrants and stock options outstanding are anti-dilutive. | Income Taxes | |||||||||||||||||||||||||
| A reconciliation of basic and diluted shares for the three months ended June 30, 2014 and 2013 follows: | Current income tax expense is the amount of income taxes expected to be payable for the current year. A deferred income tax asset or liability is established for the expected future consequences of temporary differences in the financial reporting and tax bases of assets and liabilities. We consider future taxable income and ongoing, prudent and feasible tax planning strategies, in assessing the value of its deferred tax assets. If we determine that it is more likely than not that these assets will not be realized, we will reduce the value of these assets to their expected realizable value, thereby decreasing net income. Evaluating the value of these assets is necessarily based on our judgment. If we subsequently determine that the deferred tax assets, which had been written down, would be realized in the future, the value of the deferred tax assets would be increased, thereby increasing net income in the period when that determination was made. | |||||||||||||||||||||||||
| June 30, | June 30, | Basic and Diluted Income/Loss per Share | ||||||||||||||||||||||||
| 2014 | 2013 | |||||||||||||||||||||||||
| Our computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted income (loss) per share reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income (loss) of the Company as if they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted income (loss) per share, the treasury stock method assumes that outstanding options and warrants are exercised and the proceeds are used to purchase common stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options and warrants. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. | ||||||||||||||||||||||||||
| Average common shares outstanding-basic | 4,618,409 | 4,003,358 | Income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted (loss) per common share is the same for periods in which the Company reported an operating loss because all warrants and stock options outstanding are anti-dilutive. | |||||||||||||||||||||||
| Effect of dilutive securities- | ||||||||||||||||||||||||||
| Warrants | 516,797 | -- | There were no adjustments to net loss required for purposes of computing diluted earnings per share. | |||||||||||||||||||||||
| Employee and director stock options | 21,750 | -- | ||||||||||||||||||||||||
| At December 31, 2013 and 2012, we excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from our calculation of earnings per share, as their effect would have been anti-dilutive. | ||||||||||||||||||||||||||
| Average diluted shares | $ | 5,156,956 | $ | 4,003,358 | ||||||||||||||||||||||
| December 31, | ||||||||||||||||||||||||||
| There were no adjustments to net loss required for purposes of computing diluted earnings per share. | 2013 | 2012 | ||||||||||||||||||||||||
| Convertible Notes | 550,977 | 607,873 | ||||||||||||||||||||||||
| Warrants, options and other potentially dilutive securities that are antidilutive have been excluded from the dilutive calculations when their exercise or conversion price exceeds the average stock market price during the period or the effect would be anti-dilutive when applied to a net loss during the period(s) presented. The following table sets forth the shares excluded from the diluted calculation for the three month periods presented as follows: | Warrants | 853,937 | 931,472 | |||||||||||||||||||||||
| Stock Options | 568,950 | 460,700 | ||||||||||||||||||||||||
| June 30, | June 30, | Total | 1,973,863 | 2,000,045 | ||||||||||||||||||||||
| 2014 | 2013 | |||||||||||||||||||||||||
| Stock-Based Compensation | ||||||||||||||||||||||||||
| Senior secured Convertible notes | 1,236,212 | 550,977 | We periodically issue stock options and warrants to officers, directors and consultants for services rendered under our 2010 Stock Incentive Plan. We also assumed stock options in connection with the reverse merger consummated on May 13, 2010 which are not issued under any stockholder approved option plan. Options vest and expire according to terms established at the grant date. We account for share-based payments to officers and directors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense in our financial statements over the vesting period of the awards. We account for share-based payments to consultants and non-employees by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached or (b) at the date at which the necessary performance to earn the equity instruments is complete. Certain share based awards may contain milestones that need to be achieved before the option begins vesting. Management estimates the probability of achievement of such milestones at each reporting date in calculating the estimate of the share-based cost. | |||||||||||||||||||||||
| Warrants | 711,455 | 835,544 | ||||||||||||||||||||||||
| Employee and director stock options | 527,200 | 520,950 | The fair value of the Company's common stock option grants is estimated using the Black-Scholes-Merton option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton option pricing model, and based on actual experience. The assumptions used in the Black-Scholes-Merton option pricing model could materially affect compensation expense recorded in future periods. | |||||||||||||||||||||||
| Total potentially dilutive shares | 2,474,867 | 1,907,471 | Derivative Financial Instruments | |||||||||||||||||||||||
| Such securities could potentially dilute earnings per share in the future. | We evaluate all of our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, we use a weighted-average Black-Scholes-Merton option pricing model which approximates a Monte Carlo model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. | |||||||||||||||||||||||||
| Derivative Financial Instruments | Revenue Recognition | |||||||||||||||||||||||||
| The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a probability based weighted-average Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. | As of December 31, 2013, we have not generated any revenues from the development of our intellectual property (“IP”) and are therefore still considered a development stage company. | |||||||||||||||||||||||||
| The Company has derivative liabilities relating to conversion price adjustments on convertible notes and warrants issued in February 2014. Accordingly, the Company has calculated the value of the derivative liabilities as of the date of issuance of the notes and warrants and has revalued them as of the period ending June 30, 2014. | Fair Value of Financial Instruments | |||||||||||||||||||||||||
| Fair Value of Financial Instruments | Effective January 1, 2008, fair value measurements are determined by our adoption of authoritative guidance issued by the FASB, with the exception of the application of the statement to non-recurring, non-financial assets and liabilities as permitted. The adoption of the authoritative guidance did not have a material impact on our fair value measurements. Fair value is defined in the authoritative guidance as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows: | |||||||||||||||||||||||||
| Effective January 1, 2008, fair value measurements are determined by the Company’s adoption of authoritative guidance issued by the Financial Accounting Standards Board (FASB), with the exception of the application of the statement to non-recurring, non-financial assets and liabilities as permitted. The adoption of the authoritative guidance did not have a material impact on the Company’s fair value measurements. Fair value is defined in the authoritative guidance as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows: | Level 1—Quoted prices in active markets for identical assets or liabilities. | |||||||||||||||||||||||||
| Level 1—Quoted prices in active markets for identical assets or liabilities. | Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly. | |||||||||||||||||||||||||
| Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly. | Level 3—Unobservable inputs based on our assumptions. | |||||||||||||||||||||||||
| Level 3—Unobservable inputs based on the Company’s assumptions. | We are required to use observable market data if such data is available without undue cost and effort. | |||||||||||||||||||||||||
| The Company is required to use observable market data if such data is available without undue cost and effort. | At December 31, 2013 and December 31, 2012, the fair values of cash and cash equivalents, and accounts payable approximate their carrying values. | |||||||||||||||||||||||||
| The following table presents certain liabilities of the Company measured and recorded at fair value on the Company’s condensed consolidated balance sheets on a recurring basis and their level within the fair value hierarchy as of June 30, 2014. | Recently Issued Accounting Standards | |||||||||||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | In January 2013, the FASB issued Accounting Standard Update (“ASU”) 2013-01, Balance Sheet (Topic 210): Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. This ASU clarifies which instruments and transactions are subject to the offsetting disclosure requirements established by ASU 2011-11. This guidance is effective for annual and interim reporting periods beginning January 1, 2013. The Company does not believe the adoption of this update will have a material effect on its financial position and results of operations. | ||||||||||||||||||||||
| Fair Value of Derivative Liability | $ | -- | $ | 2,348,484 | $ | -- | $ | 2,348,484 | ||||||||||||||||||
| On March 4, 2013, the FASB issued ASU 2013-05, “Foreign Currency Matters (Topic 830): Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity” (“ASU 2013-05”). ASU 2013-05 updates accounting guidance related to the application of consolidation guidance and foreign currency matters. This guidance resolves the diversity in practice about what guidance applies to the release of the cumulative translation adjustment into net income. This guidance is effective for interim and annual periods beginning after December 15, 2013. The Company does not believe the adoption of this update will have a material effect on its financial position and results of operations. | ||||||||||||||||||||||||||
| There was no corresponding derivative liability as of December 31, 2013. | ||||||||||||||||||||||||||
| In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Loss, or a Tax Credit Carryforward Exists. Topic 740, Income Taxes, does not include explicit guidance on the financial statement presented of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. There is diversity in practice in the presentation of unrecognized tax benefits in those instances and the amendments in this update are intended to eliminate that diversity in practice. The amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Early adoption is permitted. The Company does not believe the adoption of this update will have a material effect on its financial position and results of operations. | ||||||||||||||||||||||||||
| At June 30, 2014 and December 31, 2013, the fair values of cash and cash equivalents, and accounts payable approximate their carrying values. | ||||||||||||||||||||||||||
| Other accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements. | ||||||||||||||||||||||||||
| Recently Issued Accounting Standards | ||||||||||||||||||||||||||
| As discussed in Note 1, on June 10, 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. ASU 2014-10 eliminates the requirement to present inception-to-date information about income statement line items, cash flows, and equity transactions, and clarifies how entities should disclose the risks and uncertainties related to their activities. ASU 2014-10 also eliminates an exception provided to development stage entities in Consolidations (ASC Topic 810) for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The presentation and disclosure requirements in Topic 915 are no longer required for interim and annual reporting periods beginning after December 15, 2014. The revised consolidation standards will take effect in annual periods beginning after December 15, 2015, however, early adoption is permitted. The Company adopted the provisions of ASU 2014-10 for this quarterly report on Form 10-Q for the period ended June 30, 2014 | ||||||||||||||||||||||||||
| In April 2014, the FASB issued ASU 2014-08, "Presentation of Financial Statements (Topic 205) and Property, Plant and Equipment (Topic 360)." ASU 2014-08 amends the requirements for reporting discontinued operations and requires additional disclosures about discontinued operations. Under the new guidance, only disposals representing a strategic shift in operations or that have a major effect on the Company's operations and financial results should be presented as discontinued operations. This new accounting guidance is effective for annual periods beginning after December 15, 2014. The Company is currently evaluating the impact of adopting ASU 2014-08 on the Company's results of operations or financial condition. | ||||||||||||||||||||||||||
| On May 28, 2014, the FASB issued ASU 2014-09 , “Revenue from Contracts with Customers”. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for reporting periods beginning after December 15, 2016, and early adoption is not permitted. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. Management has not yet determined the effect of adopting ASU 2014-09 on our ongoing financial reporting. | ||||||||||||||||||||||||||
| Other recent accounting pronouncements did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements. | ||||||||||||||||||||||||||
Note_3_25_Senior_Secured_Conve
| Note 3 - 2.5% Senior Secured Convertible Notes Payable | 6 Months Ended | 12 Months Ended | ||||||||||||||||
| Jun. 30, 2014 | Dec. 31, 2013 | |||||||||||||||||
| Debt Disclosure [Abstract] | ' | ' | ||||||||||||||||
| Debt Disclosure [Text Block] | ' | ' | ||||||||||||||||
| 3. SENIOR SECURED CONVERTIBLE NOTES PAYABLE | 3. 2.5% SENIOR SECURED CONVERTIBLE NOTES PAYABLE | |||||||||||||||||
| Convertible notes payable consist of the following as of June 30, 2014 and December 31, 2013: | Convertible notes payable consist of the following as of December 31, 2013 and December 31, 2012: | |||||||||||||||||
| June 30, | December 31, | December 31, | December 31, | |||||||||||||||
| 2014 | 2013 | 2013 | 2012 | |||||||||||||||
| a. 2010 2.5% Convertible Notes | $ | 427,500 | $ | 427,500 | 2010 Convertible Notes | $ | 427,500 | $ | 427,500 | |||||||||
| b. 2012 2.5% Convertible Notes | 753,667 | 1,170,333 | 2012 Convertible Notes | 1,170,333 | 1,335,333 | |||||||||||||
| c. 2014 6% Convertible Notes | 1,906,500 | -- | $ | 1,597,833 | $ | 1,762,833 | ||||||||||||
| 3,087,667 | 1,597,833 | Less Valuation Discount | (844,577 | ) | (1,402,030 | ) | ||||||||||||
| Less Valuation Discount | (2,080,795 | ) | (844,577 | ) | ||||||||||||||
| 1,006,872 | 753,256 | Convertible Notes Payable, net | $ | 753,256 | $ | 360,803 | ||||||||||||
| Less Current Portion | (427,500 | ) | (390,123 | ) | ||||||||||||||
| Convertible Notes Payable, net | $ | 579,372 | $ | 363,133 | 2010 Convertible Notes | |||||||||||||
| a. | 2010 2.5% Convertible Notes | On May 13, 2010, we entered into a Securities Purchase Agreement with W-Net Fund I, L.P. (“W-Net”), Europa International, Inc. (“Europa”) and MKM Opportunity Master Fund, Ltd. (“MKM” and together with W-Net and Europa, the “Purchasers”), pursuant to which the Purchasers, on May 13, 2010, purchased from us (i) 2.5% Senior Secured Convertible Notes (the “Original Notes”) for a cash purchase price of $1,500,000, and (ii) Common Stock Purchase Warrants pursuant to which the Purchasers may purchase up to 190,880 shares of our common stock at an exercise price equal to approximately $3.90 per share (the “Capital Raise Transaction”). | ||||||||||||||||
| On May 13, 2010, we entered into a Securities Purchase Agreement with W-Net Fund I, L.P. (“W-Net”), Europa International, Inc. (“Europa”) and MKM Opportunity Master Fund, Ltd. (“MKM” and together with W-Net and Europa, the “Purchasers”), pursuant to which the Purchasers, on May 13, 2010, purchased from us (i) 2.5% Senior Secured Convertible Notes (the “Original Notes”) for a cash purchase price of $1,500,000, and (ii) Common Stock Purchase Warrants pursuant to which the Purchasers may purchase up to 190,880 shares of our common stock at an exercise price equal to approximately $2.90 per share, as amended, (the “Capital Raise Transaction”). We also entered into a Security Agreement and an Intellectual Property Security Agreement with the Purchasers and AtheroNova Operations, pursuant to which all of our obligations are secured by first priority security interests in all of our assets and the assets of AtheroNova Operations, including intellectual property. Upon an event of default note holders may be entitled to foreclose on any of such assets or exercise other rights generally available to a secured creditor under California and Delaware law. In addition, under a Subsidiary Guarantee, AtheroNova Operations guaranteed all of our obligations under the Original Notes. | The Original Notes accrued 2.5% interest per annum with a maturity of 4 years after the closing of the Capital Raise Transaction. No cash interest payments were required, except that accrued and unconverted interest is due on the maturity date and on each conversion date with respect to the principal amount being converted, provided that such interest may be added to and included with the principal amount being converted. If there is an uncured event of default (as defined in the Original Notes), ), of which one event of default would be the departure of Thomas Gardner without us obtaining a suitable full-time replacement within 90 days of such departure, the holder of each Original Note may declare the entire principal and accrued interest amount immediately due and payable. Default interest will accrue after an event of default at an annual rate of 12%. If there is an acceleration, a mandatory default amount equal to 120% of the unpaid Original Note principal plus accrued interest may be payable. | |||||||||||||||||
| On July 6, 2011, we entered into the First Amendment and Exchange Agreement under which the Original Notes were exchanged for the Amended and Restated 2.5% Senior Secured Convertible Notes (the “first Amended Notes”). | The warrants may be exercised on a cashless basis under which a portion of the shares subject to the exercise are not issued in payment of the purchase price, based on the then fair market value of the shares. | |||||||||||||||||
| On June 15, 2012, we entered into the Second Amendment and Exchange Agreement pursuant to which the First Amended Notes were exchanged for the Second Amended and Restated 2.5% Senior Secured Convertible Notes (the “Second Amended Notes”). The Second Amended Notes accrued 2.5% interest per annum with a maturity of four years after the closing of the original Capital Raise Transaction in 2010. No cash interest payments were required, except that accrued and unconverted interest is due on the maturity date and on each conversion date with respect to the principal amount being converted, provided that such interest may be added to and included with the principal amount being converted. If there is an uncured event of default (as defined in the Original Notes), the holder of each Original Note may declare the entire principal and accrued interest amount immediately due and payable. Default interest will accrue after an event of default at an annual rate of 12%. If there is an acceleration, a mandatory default amount equal to 120% of the unpaid Original Note principal plus accrued interest may be payable. The Second Amended Notes greatly restrict the ability of the Company and AtheroNova Operations to issue indebtedness or grant liens on our or its respective assets without the Original Note holders’ consent. They also limit and impose financial costs on our acquisition by any third party. | The Original Notes may not be prepaid, or forced by us to be converted in connection with an acquisition of our Company, except in a limited case more than a year after the Original Note issuance where the average of our stock trading price for 30 days on a national trading market other than the OTC Bulletin Board (“OTCBB”) is at least three times the conversion price, in which event, and subject to the satisfaction of certain other requirements, the Original Note holders may elect to receive at least double the unpaid principal amounts in cash and other requirements are satisfied. In such a limited case acquisition, there could also be a forced cashless exercise of the warrants subject to similar requirements and optional cash payments to the warrant holders of at least double the exercise prices of their warrants. | |||||||||||||||||
| As of December 31, 2013, the outstanding balance of the notes amounted to $427,500, unpaid interest of $31,453 and unamortized note discount of $37,375. | The Original Notes greatly restrict the ability of the Company or AtheroNova Operations to issue indebtedness or grant liens on our or its respective assets without the Original Note holders’ consent. They also limit and impose financial costs on our acquisition by any third party. | |||||||||||||||||
| In May 2014, the Second Amended Notes were amended with the consent of the holder thereof to extend the maturity date from May 12, 2014 to September 12, 2014. All other terms and conditions of the Second Amended Notes remain unchanged. | On May 13, 2010, we also entered into a Security Agreement and an Intellectual Property Security Agreement with the Purchasers and AtheroNova Operations, pursuant to which all of our obligations under the Original Notes are secured by first priority security interests in all of our assets and the assets of AtheroNova Operations, including intellectual property. Upon an event of default under the Original Notes or such agreements, the Original Note holders may be entitled to foreclose on any of such assets or exercise other rights available to a secured creditor under California and Delaware law. In addition, under a Subsidiary Guarantee, AtheroNova Operations will guarantee all of our obligations under the Notes. | |||||||||||||||||
| During the period ended June 30, 2014, the Company recognized interest expense of $5,373 for the 2.5% interest rate and $37,375 to amortize the discount associated with the Second Amended Notes. The aggregate principal balance of the Second Amended Notes outstanding, unpaid interest and unamortized note discount as of June 30, 2014 amounted to $427,500, $44,900 and none, respectively. | On July 6, 2011, we entered into the First Amendment and Exchange Agreement with each of W-Net, Europa and MKM pursuant to which the Purchasers agreed to exchange the Original Notes for the Amended and Restated 2.5% Senior Secured Convertible Notes (the “Amended Notes”). The Amended Notes had the same terms as the Original Notes (as described above), except that each Amended Note was convertible at any time into common stock at a per share conversion price of $2.90, subject to adjustment. | |||||||||||||||||
| b. | 2012 2.5% Convertible Notes | On June 15, 2012, the Company entered into the Second Amendment and Exchange Agreement with each W-Net, Europa and MKM pursuant to which the Purchasers agreed to exchange the Amended Notes for Second Amended and Restated 2.5% Senior Secured Convertible Notes (the “Second Amended Notes”). The Second Amended Notes have the same terms as the Amended Notes (as described above) except as follows: (i) each Second Amended Note has an automatic conversion provision and removal of the applicable beneficial ownership limitations effective the later of 61 days following the Company’s notice to the Purchasers of its application to list or quote its securities on a national securities exchange or the date immediately prior to the effective date of the Company’s listing or quotation of its securities on the applicable exchange; (ii) the price-based anti-dilution provisions contained in the Amended Notes have been removed; and (iii) under the Securities Purchase Agreement, as currently amended, if we met two specified operating benchmarks during the first twenty-nine months after the closing of the first Senior Note purchase, an additional $1,500,000 in note purchases, substantially in the form of the Second Amended Notes (without warrants), could be requested by us from the Purchasers. The determination of whether we had met the benchmarks was solely at the discretion of the Purchasers. If the benchmarks were determined to have been achieved, then we could have required the Purchasers to make the additional $1,500,000 of note purchases. If such benchmarks were not attained in the 29-month period or we did not exercise the option to request the additional notes, then the Purchasers, in their discretion, during the next 10 days may elect to purchase up to $1,500,000 of notes, substantially in the form of the Second Amended Notes (without warrants), having an initial conversion price which is 100% of the conversion price in the Second Amended Notes. On July 23, 2012 the Purchasers notified us of their intention of putting the additional $1,500,000 in notes in 3 tranches (see 2012 convertible notes below). | ||||||||||||||||
| During 2012, the Company issued $1,498,333 of its 2.5% convertible notes (“2012 Notes”) that are due in 2016. The 2012 Notes are convertible into common stock at a per share price of $2.90 per share. As the market price on the date of the issuance of the 2012 Notes ranged between $5.80 and $8.00 per share, the Company recorded a beneficial conversion feature up to the face value of the 2012 Notes in the aggregate of $1,498,333 representing the difference between the market price and the note’s conversion price on the date of issuance. The beneficial conversion feature was recorded as a valuation discount and is being amortized over the term of the 2012 Notes. As of December 31, 2013, the outstanding balance on the 2012 Notes amounted to $1,170,333 and unamortized discount $807,202. | The Company considered the amendment of the note resulted in a modification for accounting purposes with no change to the net book value of notes as the value of the note’s conversion feature and attached warrants were not changed. Furthermore, the derivative liability recorded when the notes and warrants were originally issued were deemed extinguished. At December 31, 2011, the balance of the outstanding notes was $955,351. | |||||||||||||||||
| During the period ended June 30, 2014, $416,667 in aggregate principal amount of the 2012 Notes was converted at a per share price of $2.90 into 143,678 shares of the Company’s common stock. The Company also issued 5,171 shares of its common stock with a market value of $19,647 to settle accrued but unpaid interest associated with the converted 2012 Notes $14,994. The issuance of these shares of common stock resulted in an additional charge of $4,653 that has been reflected as part of interest expense in the accompanying statement of operations. Furthermore, the Company also recorded interest expense of $270,439 to amortize the corresponding note discount of the converted notes. | During the year ended December 31, 2012, principal in the amount of $527,851 was converted at a per share price of $2.90 into 182,057 shares of our common stock. In addition, the Company also issued 10,727 shares of our common stock with a market value of $69,552 to settle $31,191 of accrued interest relating to these notes. The issuance of these common shares resulted in an additional charge of $38,372 that has been reflected as part of interest expense in the accompanying 2012 statement of operations. The balance of these Senior Notes outstanding as of December 31, 2013 and 2012 amounted to $427,500 respectively. The notes are due on May 12, 2014 and have been reclassified as a current liability in the 2013 balance sheet. During the year ended December 31, 2013 and 2012, the Company recognized interest expense of $10,836 and $20,098, respectively based on the 2.5% interest rate of the note. | |||||||||||||||||
| During the period ended June 30, 2014, the Company recognized interest expense of $11,759 and $117,360 to amortize the note discount. The aggregate balance of the 2012 Notes outstanding, unpaid interest and unamortized note discount as of June 30, 2014 amounted to $753,667, $33,701 and $419,405 respectively. | Upon issuance of the notes, the Company accounted the notes and the attached warrants as a derivative liability and determined that the fair value of the conversion feature to be $2,370,245, and that the fair value of the warrant to be $1,172,103, based on a weighted average Black-Scholes-Merton calculation. The Company recorded the full value of the derivative as a liability at issuance with an offset to valuation discount, which is being amortized over the life of the Notes. As the aggregate fair value of these liabilities of $3,542,348 exceeded the aggregate value of the Notes of $1,500,000 at issuance, the excess of the liability over the aggregate value of the Notes of $2,042,348 was considered as a cost of the private placement in 2010. The note discount is being amortized to interest expense over the term of the notes. At December 31, 2011, the unamortized note discount was $559,696. | |||||||||||||||||
| Total 2.5% convertible notes purchased and held by Europa were $1,094,167 at both June 30, 2014 and December 31, 2013. Europa is an entity controlled by Knoll Capital Management of which Mr. Knoll, one of our directors, is the managing director. | During the year ended December 31, 2013 and 2012, the Company amortized note discount amounting to $106,878 and $415,444 respectively. At December 31, 2013 and 2012, the unamortized note discount was $37,375 and $144,252 respectively. | |||||||||||||||||
| c. | 2014 6% Convertible Notes | 2012 Convertible Notes | ||||||||||||||||
| In January and February 2014, we entered into Securities Purchase Agreements with approximately 31 accredited investors (the “Investors”), pursuant to which the Investors, on February 12, 2014, purchased from us (i) 6% Senior Secured Convertible Notes (the “6% Notes”) for a cash purchase price of $1,906,500, and (ii) Common Stock Purchase Warrants pursuant to which the Investors may purchase up to 414,457 shares of our common stock at an exercise price equal to approximately $2.30 per share (the “6% Notes Placement”). The 6% Notes have a three year term and are convertible into common stock at any time at the lesser of i) $2.30 per share and ii) seventy percent of the average of the three lowest daily volume-weighted average prices (“VWAPs”) occurring during the 20 consecutive trading days immediately preceding the applicable conversion date. The associated warrants are exercisable at $2.30 per share. The warrants may be exercised on a cashless basis under which a portion of the shares subject to exercise are not issued in payment of the purchase price, based on the then fair market value of the shares. | On July 23, 2012 the Purchasers notified us of their intention of putting the additional $1,500,000 in Notes in 3 tranches. The first $500,000 was put to us and we issued Notes on September 4, 2012. These Notes mature on September 3, 2016. The second tranche of $498,333 was put to us and we issued Notes on October 1, 2012 that matures on September 30, 2016. The final tranche of $500,000 was put to us and we issued Notes on October 31, 2012 that matures on October 30, 2016, for an aggregate issuance of $1,498,333 during the year ended December 31, 2012. The Convertible Notes are convertible into common stock at a per share price of $2.90 per share. | |||||||||||||||||
| The 6% Notes accrue 6% interest per annum and do not require periodic cash interest payments, except that accrued and unconverted interest is due on the maturity date and on each conversion date with respect to the principal amount being converted, provided that such interest may be added to and included with the principal amount being converted. If there is an uncured event of default (as defined in the 6% Notes), the holder of each 6% Note may declare the entire principal and accrued interest amount immediately due and payable. Default interest will accrue after an event of default at an annual rate of 12%. If there is an acceleration, a mandatory default amount equal to 120% of the unpaid 6% Note principal plus accrued interest may be payable. | During the year ended December 31, 2012, $163,000 of these notes was converted into 56,167 shares of our common stock. In addition, the Company also issued 421 shares of our common stock with a market value of $2,727 to settle $1,210 of accrued interest relating to these notes. The issuance of these common shares resulted in an additional charge of $1,505 that has been reflected as part of interest expense in the accompanying 2012 statement of operations. The balance of these Senior Notes outstanding as of December 31, 2012 was $1,335,333. During the year ended December 31, 2013, $165,000 of these notes was converted into 56,896 shares of our common stock. In addition, the Company also issued 4,794 shares of our common stock with a market value of $4,765 to settle $2,303 of accrued interest relating to these notes. The issuance of these common shares resulted in an additional charge of $2,462 that has been reflected as part of interest expense in the accompanying 2013 statement of operations. The balance of these Senior Notes outstanding as of December 31, 2013 amounted to $1,170,333. | |||||||||||||||||
| The 6% Notes and associated warrants include an anti-dilution provision that allows for the automatic reset of the conversion or exercise price upon any future sale of common stock instruments at or below the current conversion or exercise price, as applicable, and, as such, were accounted for as derivative liability. The value of the derivative liability at the date of issuance was $4,443,569, of which $1,906,500 was reflected as a note discount and the remaining balance of $2,537,069 has been reflected in the statement of operations as part of cost of the private placement (see Note 4 below for further discussion of Derivative Liability). | During the year ended December 31, 2013 and 2012, the Company recognized interest expense of $30,914 and $9,605 respectively based on the 2.5% interest rate of the note. | |||||||||||||||||
| We also entered into a Security Agreement and an Intellectual Property Security Agreement with the Investors and AtheroNova Operations, pursuant to which all of our obligations under the 6% Notes are secured by security interests in all of our assets and the assets of AtheroNova Operations, including intellectual property on a pari passu basis with the 2.5% Senior Secured Convertible Notes outstanding. Upon an event of default under the 6% Notes or associated agreements, the 6% Note holders may be entitled to foreclose on any of such assets or exercise other rights generally available to a secured creditor under California and Delaware law. In addition, under a Subsidiary Guarantee, AtheroNova Operations guaranteed all of our obligations under the 6% Notes. | As the market price on the date of the issuance of the notes ranged between $5.80 and $8.00 per share, the Company calculated a beneficial conversion feature up to the face value of the note in the aggregate of $1,498,333 representing the difference between the market price and the exercise price on the date of issuance. The beneficial conversion feature was recorded as a valuation discount and is being amortized over the term of the notes. During the year ended December 31, 2013 and 2012, the Company amortized note discount amounting to $450,575 and $240,555 respectively. As of December 31, 2013 and 2012, the unamortized note discount was $807,203 and $1,257,778 respectively. | |||||||||||||||||
| Additionally, several of the individuals or entities who participated in this offering were also existing holders of warrants to purchase 542,246 shares of common stock. As an incentive for their participation, the expiration dates of these warrants were extended to ten years from the date of each respective warrant’s original issuance while all other remaining provisions stayed the same. At the date of modification, the difference in the fair value of these warrants before and after the modification amounted to $564,849 using the Black-Scholes Merton valuation and was included as a cost of the private placement in the accompanying statement of operations. Furthermore, in August 2013, the Company agreed to issue similar warrants to participants of a private placement sale of our common stock held at that time. As a result, we issued warrants to purchase an additional 40,000 shares of our common stock with the same terms and conditions as the warrants issued in the note placement. These warrants included an anti-dilution provision that allows for the automatic reset of the conversion or exercise price upon any future sale of common stock instruments at or below the current conversion or exercise price, and, as such, were accounted for as derivative liability. Upon their issuance, the fair value of these warrants was determined to be $143,997 using a probability based weighted average Black-Scholes Merton valuation and was recorded as a derivative liability upon issuance and included in the cost of the private placement in the accompanying statement of operations (see Note 4 below for further discussion of derivative liability). | Convertible notes purchased and held by Europa International, Inc. were $1,094,167 and $1,094,167 as of December 31, 2013 and 2012, respectively. Europa is an entity controlled by Knoll Capital Management of which Mr. Knoll, one of the Company’s directors, is the managing director. | |||||||||||||||||
| As a result of this offering, the Company recognized private placement costs in the aggregate of $3,340,030 to account for the following (i) commission and fees paid of $70,720; (ii) issuance of 6,535 shares of common stock to a placement agent with a fair value of $23,395; (iii) fair value of warrants modified of $564,849; (iv) fair value of warrants issued of $143,997; and (v) fair value of the note’s conversion feature and warrants accounted as derivative liability of $2,537,069. | ||||||||||||||||||
| As of June 30, 2014, Europa held $300,000 in aggregate principal amount of the 6% Notes . Europa is an entity controlled by Knoll Capital Management of which Mr. Knoll, one of our directors, is the managing director. | ||||||||||||||||||
Note_4_CardioNova_Research_Agr
| Note 4 - CardioNova Research Agreement | 12 Months Ended |
| Dec. 31, 2013 | |
| Equity Method Investments and Joint Ventures [Abstract] | ' |
| Equity Method Investments and Joint Ventures Disclosure [Text Block] | ' |
| 4. CardioNova Research Agreement | |
| In October 2011, we entered into two definitive agreements with OOO CardioNova, a wholly-owned subsidiary of Maxwell Biotech Group, a Russian biotech fund, covering our AHRO-001 compound. The agreements cover a territory represented by the Russian Federation, the Ukraine and various countries in central Asia (the “Territory”). | |
| Under the Licensing Agreement, OOO CardioNova (“CardioNova”) became an equity investor in our Company in exchange for the funding of Phase 1 and 2 human clinical trials conducted by a Clinical Research Organization (“CRO”) located in Russia. Pursuant to the agreement, a Joint Steering Committee was established between both entities and determined final clinical protocols and research budget of $3.8 million. Pursuant to the agreement, common stock equal to 10%, 20%, 40%, and 30% of the research budget of $3.8 million will be issued to CardioNova upon achievement of four milestones of the research and testing. The shares to be issued will be determined based upon a 20 day average price prior to issuance up to $9.70/share. | |
| For accounting purposes, the costs to be incurred in connection with this agreement are considered compensatory and are recognized as a Research and Development expense. Recognition of these costs as expense will generally occur when certain development projects are commenced and performance milestones become probable of achievement and are deemed earned. | |
| During 2012, we reviewed the clinical development milestones as to their probability of achievement and, if probable, the estimated percentage of completion of the milestone. As of December 31, 2012, we determined that none of the milestones had a probable likelihood of achievement and therefore we recorded no estimated expense during 2012. | |
| During 2013, several clinical development milestones were considered probable or were achieved. Upon acceptance of the development plan which occurred on April 25, 2013, 39,175 shares of common stock (10% of the research budget) were be issued to CardioNova at a 20-day weighted average prior to signature of the initial term sheet, or $9.70 per share. On April 29, 2013 the Russian Ministry of Healthcare approved the protocol submitted on January 22, 2013, upon which the Joint Steering Committee had based the Phase 1 protocol. Accordingly, 160,541 shares of our common stock were issued at the weighted 20-day average of $4.73, representing 20% of the approved budget. As of December 31, 2013, the Company had issued 199,716 shares of its common stock representing 30% of the research budget. | |
| Significant judgment is required in assessing when a performance milestone is probable of achievement and estimating the timing of when the performance of these milestones will be completed. These determinations are based on discussion between the Company and CardioNova personnel that address qualitative and quantitative factors, including, but not limited to, overall complexity associated with the assessment, stage of the clinical trial, progress made to date, results of testing, and consideration of the nature of the work remaining in the trial(s). We have completed the evaluation of the performance of the two remaining milestones as of December 31, 2013. The milestones specify that additional common stock issuances of 40% and 30% of the approved budget shall be issued upon the announcement of Phase 1 results and announcement of Phase 2 results, respectively. Each tranche will be priced at the lower of the weighted 20-day average immediately prior to each issuance event, or $9.70 per share, whichever is lower. Our review of the progress by CardioNova on the milestone relating to Phase 1 work was estimated at approximately 80% completed and we determined that the achievement of the milestone was probable. As a result, we accrued $1,170,712 based upon the December 31, 2013 fair value of the estimated shares of common stock issuable at the end of fiscal year 2013 and was recorded as part of Research and Development – Related Party in the 2013 Statement of Operations. A corresponding liability for the estimate of the fair value of the shares to be issued is shown as a contingent liability in our consolidated balance sheets as of December 31, 2013. The remaining value will be recognized as Research and Development expense in future periods based on actual progress toward this milestone and any variation of the actual total value of common stock issued or issuable upon future valuation measurement dates or upon completion of the milestone when compared to this periodic estimate will be expensed or credited to our statement of operations. | |
| As of December 31, 2013, the final milestone relating to the Phase 2 clinical trial calling for additional issuance of our common stock is currently not yet believed to be probable of achievement and no estimated liability or expense has been recorded. | |
| If CardioNova successfully develops and commercializes AHRO-001 in the Territory, we will be entitled to receive a quarterly royalty, based on net sales during the period using an escalating scale. The royalty agreement shall remain in force for the period in which intellectual property rights for AHRO-001 are in full force and effect in the Territory. As of December 31, 2013, no royalty has been recorded as AHRO-001 has not been successfully developed and commercialized. | |
| Under the Securities Purchase Agreement, CardioNova purchased 27,526 shares of our common stock for a cash purchase price of $9.70 per share, which took place in two installments. The first installment, which took place on December 22, 2011, was for the issuance of 15,464 shares upon receipt of $150,000 as specified in the Licensing Agreement. The 2nd installment of 12,062 shares took place on June 14, 2013 upon delivery of final clinical product to be used in Phase 1 clinical trials for proceeds of $117,000. |
Note_5_Research_and_Developmen
| Note 5 - Research and Development Projects | 12 Months Ended | |
| Dec. 31, 2013 | ||
| Research and Development [Abstract] | ' | |
| Research, Development, and Computer Software Disclosure [Text Block] | ' | |
| 5 | Research and Development Projects | |
| We have a research agreement signed in September 2012, amended in April 2013 and again in September 2013, with a major university in Southern California to conduct contract research in additional compounds covered under our pending patents. This agreement calls for payment of all research costs relating to the study of dosage and efficacy of bile salts on the atherosclerotic plaque in a non-human model. The total cost of the amended project was $236,323, paid in four installments over the estimated one year length of the study. During the year ended December 31, 2013 and 2012, we recorded $120,327 and $115,996, respectively, to Research and Development pursuant to the agreement. The final report on this research project was received in early 2014. | ||
| The Company has multiple testing agreements signed in 2012 and in August 2013 for testing of the oral toxicity of AHRO-001 in non-human models. Each agreement can be terminated anytime and there are no commitments or guarantees other than to reimburse costs incurred prior to termination. | ||
| A study initiated in September 2012, with a cost of approximately $507,000, has been completed and final research reports were received during 2013. Project costs of $389,785 and $116,545 have been recorded as part of Research and Development costs on the accompanying statement of operations for the year ended December 31, 2013 and 2012 respectively. | ||
| Studies authorized in August 2013, with a cost of approximately $224,600, have both completed the active phase of testing and are in the initial data analysis stage of the projects. The process is ongoing and to date, $175,950 has been expensed, all of which has been recorded as part of Research and development costs on the accompanying statement of operations for the year ended December 31, 2013. The remaining costs of approximately $49,000 will be recorded in future period once the service has been rendered. | ||
| We have a development agreement with a Pennsylvania-based Clinical Research Organization (“CRO”) specializing in formulation and manufacturing of clinical research grade pharmaceutical products. The agreement calls for the CRO to use our API to formulate and manufacture Phase1 and 2 clinical trial pharmaceutical products. The total cost of the project was $385,000, paid in progress installments over the length of the development and compounding process. The process was completed upon shipment of clinical supplies to Russia and during the year ended December 31, 2013. The Company recognized $166,422 and $218,847 pursuant to the agreement which was recorded as part of Research and Development costs on the accompanying consolidated statement of operations for the years ended December 31, 2013 and 2012, respectively. | ||
| During the year ended December 31, 2013 and 2012, we recorded additional research and development costs of $1,451,041 and $534,873 respectively representing fees paid to research and development consultants, purchase of testing materials, development of tablet formulation services and other testing costs and fees incurred. | ||
Note_6_Committments
| Note 6 - Committments | 6 Months Ended | 12 Months Ended | |||||||||||||||||||||||||
| Jun. 30, 2014 | Dec. 31, 2013 | ||||||||||||||||||||||||||
| Commitments and Contingencies Disclosure [Abstract] | ' | ' | |||||||||||||||||||||||||
| Commitments and Contingencies Disclosure [Text Block] | ' | ' | |||||||||||||||||||||||||
| 6 | COMMITTMENTS | 6 | COMMITTMENTS | ||||||||||||||||||||||||
| CardioNova Agreement | Facility Lease Agreement | ||||||||||||||||||||||||||
| In October 2011, we entered into two definitive agreements with OOO CardioNova, a wholly-owned subsidiary of Maxwell Biotech Group, a Russian biotech fund, covering our AHRO-001 compound. The agreements cover a territory represented by the Russian Federation, the Ukraine and various countries in central Asia (the “Territory”). | In June 2012, we entered into a 69 month lease agreement, on existing and expansion office space, with a final amended commencement date of October 1, 2012 on a 66 month term. The total occupancy encompasses 1,930 square feet of general use office space. Monthly rent started at $3,570 per month and annual escalators will increase the rent to $4,053 per month in the final year of the lease. This office space will continue to be our administrative and corporate headquarters. During the year ended December 31, 2013, the Company recognized $47,214 in lease expense pursuant to this agreement. | ||||||||||||||||||||||||||
| Under the licensing agreement OOO CardioNova (“CardioNova”) became an equity investor in our company in exchange for the funding of Phase 1 and 2 human clinical trials conducted by a Clinical Research Organization (“CRO”) located in Russia. A Joint Steering Committee was subsequently established between both entities and determined the final clinical protocols and approved a research budget of $3.8 million. | The following table presents the minimum future rent obligations under the lease agreement: | ||||||||||||||||||||||||||
| Pursuant to the agreement, common stock equal to specified percentages of the approved research budget of $3.8 million would be issued to CardioNova upon achievement of four milestones in the research plan. Through December 31, 2013, the Company had issued a total of 199,730 of non-refundable shares of common stock representing the first two milestones and 30% of the total budget with a fair value of $1,198,297, or $6.00 per share. Additionally, the Company determined that the achievement of the third milestone was probable and the percentage of achievement at 80% complete, therefore accrued additional research and development expense – related party of $1,170,712 as of December 31, 2013. There had been no work performed with respect to the fourth and last milestone through that date. | 2014 | 2015 | 2016 | 2017 | 2018 | Thereafter | |||||||||||||||||||||
| Minimum future payments | $ | 44,873 | $ | 46,030 | $ | 47,189 | $ | 48,346 | $ | 12,159 | -- | ||||||||||||||||
| In February 2014, the third milestone was achieved. Pursuant to the agreement, the Company issued 422,105 shares of common stock to CardioNova with a fair value of $2,152,736. As a result, the Company recorded $982,024 in additional Research and development expense to account for the remaining fair value of the shares issued as $1,170,712 was already accrued in 2013. | |||||||||||||||||||||||||||
| As of June 30, 2014, the Company determined that the achievement of the final milestone was probable and the percentage of achievement at 15% complete. Accordingly, the Company accrued additional research and development expense-related party in the accompanying statement of operations of $155,074 and $155,074 for the three and six months ended June 30, 2014, respectively. | |||||||||||||||||||||||||||
| If CardioNova successfully develops and commercializes AHRO-001 in the Territory, we will be entitled to receive a quarterly royalty, based on net sales during the period using an escalating scale. The royalty agreement shall remain in force for the period in which intellectual property rights for AHRO-001 are in full force and effect in the Territory. | |||||||||||||||||||||||||||
| Under the Securities Purchase Agreement, CardioNova purchased a total of 27,526 shares of our common stock for a cash purchase price of $9.70 per share. This transaction took place in two installments. The first installment, which took place in December 2011, was for the issuance of 15,464 shares upon receipt of $150,000 as specified in the License Agreement. The second installment of 12,062 shares was issued in June 2013 upon the receipt of the final $117,000 due upon shipment of clinical product used in the initial Phase 1 trial, which occurred in June 2013. | |||||||||||||||||||||||||||
| Research Agreements | |||||||||||||||||||||||||||
| We have a research agreement signed in September 2012, and amended in April 2013 and again in September 2013, with a major university in Southern California to conduct contract research in additional compounds covered under our issued patents. This agreement calls for payment of all research costs relating to the study of dosage and efficacy of bile salts on the atherosclerotic plaque in a non-human model. The total potential cost of the project is $236,323, to be paid in four installments over the length of the study. The process is ongoing and to date, the entire $236,323 has been expensed in prior periods. As of June 31, 2014, $81,662 is still outstanding pending issuance of final research reports and is reported as part of Accounts payable and accrued expenses in the accompanying balance sheet. | |||||||||||||||||||||||||||
| We have additional studies authorized in February and April 2014 for toxicology and other metabolic evaluations with expected aggregate cost of approximately $738,000, that are in various stages of planning or active execution of their protocols. The process is ongoing and to date, $349,785 and $521,965 has been expensed to Research and development costs on the accompanying statement of operations for the three and six month periods ended June 30, 2014, respectively. The remaining $216,035 will be recorded in future periods once service has been rendered. | |||||||||||||||||||||||||||
| We also have a research agreement finalized in March 2014 with an Australian hospital/research institution for a metabolic study of AHRO-001 in a standard animal model used in evaluation of plaque regression. The study plan has been completed and a pilot study to measure tolerability is expected to be undertaken in the 3rd quarter of 2014, with the main study to commence after successful completion of the pilot study. The total cost of approximately $187,400 will be recognized as Research and development costs in the company’s statement of operations in future periods once services have been rendered. | |||||||||||||||||||||||||||
| Formulation Development Agreement | |||||||||||||||||||||||||||
| We have a development agreement entered into in February 2014 with a Pennsylvania-based Clinical Research Organization (‘CRO”) specializing in formulation and manufacturing of clinical research grade pharmaceutical products. The agreement calls for the CRO to use our Active Pharmaceutical Ingredient to manufacture clinical trial pharmaceutical products for use in the next clinical trial conducted in Russia. The total expected cost of the project is $220,650, as amended, to be paid in progress installments over the length of the manufacturing and packaging process. The process is ongoing and to date, $67,715 and $160,309 has been recorded as part of Research and development costs on the accompanying statement of operations for the three and six month periods ending June 30, 2014, respectively. The remaining $60,341 will be recorded in future periods once service has been rendered. | |||||||||||||||||||||||||||
| Bioanalytical Analysis Agreements | |||||||||||||||||||||||||||
| We have analysis agreements for our next clinical trial in Russia entered into in May 2014, as amended, with several analytical laboratories to perform specialized serum analyses for biomarkers of certain gene expressions activated in previous non-human experiments when exposed to our Active Pharmaceutical Ingredient. The expected aggregate cost of these agreements is approximately $339,400 to be paid in installments upon progress completion points as the analyses are performed. The process is ongoing and to date, $96,047 has been recorded as part of Research and development costs on the accompanying statement of operations for both the three and six month periods ended June 30, 2014. The remaining $243,353 will be recorded in future periods once services have been rendered. | |||||||||||||||||||||||||||
Note_7_Stockholders_Equity_Def
| Note 7 - Stockholders' Equity (Deficit) | 6 Months Ended | 12 Months Ended | |||||||||||||||||||||||||||||||||||||
| Jun. 30, 2014 | Dec. 31, 2013 | ||||||||||||||||||||||||||||||||||||||
| Stockholders' Equity Note [Abstract] | ' | ' | |||||||||||||||||||||||||||||||||||||
| Stockholders' Equity Note Disclosure [Text Block] | ' | ' | |||||||||||||||||||||||||||||||||||||
| 5. STOCKHOLDERS’ EQUITY | 7 | STOCKHOLDERS’ EQUITY (DEFICIT) | |||||||||||||||||||||||||||||||||||||
| Common Stock | In March 2013, a controlling stockholder sold a total of 162,500 shares of common stock to certain directors of the Company. As the shares of common stock were sold at a price lower than the market price, the Company considered this transaction as contribution of capital and recorded compensation expense amounting to $422,500 to record the difference between the sales price and market price at the date of sale. In addition, the controlling stockholder also transferred, at no cost, 9,500 shares of common stock to certain officers and directors of the Company. The Company considered this transaction as contribution of capital and recorded compensation expense amount to $58,900 to account for the fair value of the shares of common stock at the date of transfer. | ||||||||||||||||||||||||||||||||||||||
| On February 12, 2014, in satisfaction of the equity portion of a compensation arrangement with an accredited broker who assisted in the placement of the 6% Notes, we issued 6,535 shares of our common stock, with a fair value of $23,395. This cost was recorded as a cost of the private placement in our statement of operations. | Common Stock | ||||||||||||||||||||||||||||||||||||||
| In May 2014, the Company issued 422,105 shares of its common stock valued at $2,152,693 to CardioNova pursuant to the terms of a licensing agreement to which the Company is a party, in connection with a milestone achievement in February 2014 (see Note 6). | 2013 | ||||||||||||||||||||||||||||||||||||||
| In April and May 2014, The Company issued a total of 34,316 shares of our common stock to adjust for the round lot treatment for stockholders holding under 500 shares of our common stock as approved by the stockholders in effectuating the 1 - for - 10 reverse stock split effective as of April 22, 2014. | During the year ended December 31, 2013, we sold 80,000 units for $6.50 per unit, each unit consisting of one share of common stock and a warrant to purchase 0.30 shares of common stock resulting in proceeds to us of $520,001. There were no commissions paid on this transaction. The sale of these units resulted in the issuance of 80,000 shares of our common stock and the issuance of warrants to acquire 24,001 shares of our common stock. The warrants are exercisable up to ten years from the date of issuance at a price of $7.50 per share. | ||||||||||||||||||||||||||||||||||||||
| Stock Options | During the year ended December 31, 2013, holders of warrants to purchase 67,286 shares of our common stock at $2.23 exercised the warrants, resulting in cash proceeds to us of $150,047. | ||||||||||||||||||||||||||||||||||||||
| The Company has a stockholder-approved stock incentive plan for employees under which it has granted stock options. In May 2010, the Company established the 2010 Stock Incentive Plan (the “2010 Plan”), which provides for the granting of awards to officers, directors, employees and consultants to purchase or acquire up to 7,362,964 shares, as amended, of the Company’s common stock. The awards have a maximum term of 10 years and vest over a period determined by the Company’s Board of Directors and are issued at an exercise price determined by the Board of Directors. Options issued under the 2010 Plan will have an exercise price equal to or greater than the fair market value of a share of the Company’s common stock at the date of grant. The 2010 Plan expires on May 20, 2020 as to any further granting of options. In the six months ended June 30, 2014, a total of 10,000 options to purchase shares of the Company’s common stock were granted under the 2010 Plan. Additionally, options to purchase 22,500 shares of the Company’s common stock originally granted outside of the 2010 Plan were cancelled in accordance with the grant terms. There were options outstanding to purchase a total of 556,450 shares granted under the 2010 Plan as well as outside the 2010 Plan as of June 30, 2014. There were 292,297 shares reserved for future grants under the 2010 Plan as of June 30, 2014. | During the year ended December 31, 2013, a director of the Company and a holder of a warrant to purchase 33,643 shares of our common stock at $2.23 exercised the warrant on a “cashless exercise” basis, resulting in issuance of 18,638 shares of our common stock and cancellation of 15,005 shares purchasable under the warrant. | ||||||||||||||||||||||||||||||||||||||
| A summary of the status of the Company’s stock options as of June 30, 2014 and changes during the period then ended is presented below: | During the year ended December 31, 2013, we sold 12,062 shares of our common stock to CardioNova under the Securities Purchase Agreement resulting in proceeds to us of $117,000 or $9.70 per share. There were no commissions paid on this transaction. (see Note 4). | ||||||||||||||||||||||||||||||||||||||
| Shares | Weighted | Weighted | Aggregate | During the year ended December 31, 2013, we issued an aggregate of 199,716 shares of our common stock valued at $7.30 per share, or $1,198,297 to CardioNova in consideration for the achievement of milestones under the 2011 Licensing Agreement (see Note 4). The shares issued were valued at the trading price on the approval date of the Company’s Board of Directors and recorded as part of research and development expenses. | |||||||||||||||||||||||||||||||||||
| average | Average | Intrinsic Value | |||||||||||||||||||||||||||||||||||||
| exercise | Remaining | During the year ended December 31, 2013, we issued an aggregate of 57,691 shares of our common stock pursuant to the conversion of the Company’s 2.5% Senior Secured Convertible Notes Payable amounting to $165,000 and accrued interest of $2,303 (see Note 3). Additionally, the Company also recognized an additional charge of $2,462 as part of interest expense in the accompanying statement of operations to account for the current market price of the shares issued to settle the unpaid interest. | |||||||||||||||||||||||||||||||||||||
| price | Contractual | ||||||||||||||||||||||||||||||||||||||
| Term (years) | During the year ended December 31, 2013, we issued 646 shares of our common stock valued at $4,518 to settle accounts payable with a balance of $4,200 to a director of the Company. The shares issued were valued at the trading price at the date of issuance and the difference over the accounts payable balance of $318 was recognized as part of General and Administrative Expenses on the accompanying consolidated statement of operations. | ||||||||||||||||||||||||||||||||||||||
| Outstanding at December 31, 2013 | 568,950 | $ | 8.32 | 4.849 | $ | 86,271 | |||||||||||||||||||||||||||||||||
| Granted | 10,000 | 3.8 | 7 | -- | 2012 | ||||||||||||||||||||||||||||||||||
| Exercised | -- | -- | -- | -- | |||||||||||||||||||||||||||||||||||
| Cancelled | (30,000 | ) | (5.000 | ) | -- | -- | During the year ended December 31, 2012, we sold 448,000 units for $5.00 per unit, each unit consisting of one share of common stock and a warrant to purchase 0.50 shares of common stock resulting in proceeds to us of $2,061,787 after payment of commissions $161,800 to a placement agent and $16,413 in various legal and miscellaneous fees directly associated with these sales. The sale of these units resulted in the issuance of 448,000 shares of our common stock and the issuance of warrants to acquire 224,000 shares of our common stock. The warrants are exercisable up to four years from the date of issuance at a price of $6.25 per share. Warrants to acquire up to 9,960 shares of common stock at the same terms were also issued to our placement agent. Due to the principals of the placement agent also being holders of the 12% Convertible Notes Payable, commissions of $54,800 were also paid to them on the short term notes converted to common stock (see Note 3). | ||||||||||||||||||||||||||||||||
| Outstanding at June 30, 2014 | 548,950 | $ | 8.423 | 4.321 | $ | 0 | |||||||||||||||||||||||||||||||||
| Exercisable at June 30, 2014 | 390,105 | $ | 9.042 | 3.809 | $ | 0 | During the year ended December 31, 2012, we issued an aggregate of 45,960 shares of our common stock valued at $256,100 at prices ranging between $6.20 and $10.10 per share in exchange for services provided. The shares issued were valued at the trading price at the date of the agreements. | ||||||||||||||||||||||||||||||||
| In March 2014, the Company granted options to purchase 10,000 shares of common stock to a consultant to the Company. The options have an exercise price of $3.80 per share, vest over a three month period and expire seven years form the date of grant. During the period ended June 30, 2014, the Company recognized compensation costs of $17,921 based on the fair value of options that vested using the Black-Scholes-Merton calculation and presented as part of general and administrative expense in the accompanying statement of operations. | During the year ended December 31, 2012, we issued an aggregate of 137,000 shares of our common stock pursuant to the conversion of the Company’s Short Term 12% Convertible Notes Payable amounting to $685,000 (see Note 10). | ||||||||||||||||||||||||||||||||||||||
| During the six months ended June 30, 2014, the Company recognized $231,607 of compensation costs as part of general and administrative expense related to the vesting of options granted in prior periods. As of June 30, 2014, future compensation cost related to non-vested options is estimated to be approximately $487,000. The weighted average period over which it is expected to be recognized is approximately 2.50 years. | During the year ended December 31, 2012, we issued an aggregate of 249,372 shares of our common stock pursuant to the conversion of the Company’s 2.5% Senior Secured Convertible Notes Payable amounting to $690,851 and accrued interest of $32,401 (see Note 3). Additionally, the Company also recognized an additional charge of $39,878 as part of interest expense in the accompanying statement of operations to account for the current market price of the shares issued to settle the unpaid interest. | ||||||||||||||||||||||||||||||||||||||
| The following table shows the weighted average assumptions the Company used to develop the fair value estimates for the determination of the compensation charges in the three and six months ended June 30, 2014 and 2013: | During the year ended December 31, 2012, we issued 3,006 shares of our common stock valued at $23,748 to settle accounts payable with a balance of $19,269. The shares issued were valued at the trading price at the date of issuance and the difference over the accounts payable balance of $4,479 was recognized as part of General and Administrative Expenses on the accompanying consolidated statement of operations. | ||||||||||||||||||||||||||||||||||||||
| Three months ended June 30, | Six months ended June 30, | In March 2012 a controlling stockholder transferred a total of 11,500 shares of common stock to directors, officers, employees and service providers of the Company. Compensation expense totaling $123,050 was recognized on the date of approval of the transfers based upon the market value of the shares on the approval date. | |||||||||||||||||||||||||||||||||||||
| 2014 | 2013 | 2014 | 2013 | ||||||||||||||||||||||||||||||||||||
| Stock Options | |||||||||||||||||||||||||||||||||||||||
| Expected volatility | 198% | 218 | % | 198%- 201 | % | 113%-226 | % | ||||||||||||||||||||||||||||||||
| Dividend yield | -- | -- | -- | -- | We have a stockholder-approved stock incentive plan for employees under which we have granted stock options. In May 2010, we established the 2010 Stock Incentive Plan (the “2010 Plan”), which provides for the granting of awards to officers, directors, employees and consultants to purchase or acquire up to 436,296 shares of our common stock. The plan was amended in 2013 to increase the number of shares authorized under the plan up to 436,296 shares of our common stock. The awards have a maximum term of 10 years and vest over a period determined by the administrator of the 2010 Plan and are issued at an exercise price determined by the administrator. Options issued under the 2010 Plan will have an exercise price equal to or greater than the fair market value of a share of our common stock at the date of grant. The 2010 Plan expires on May 20, 2020 as to any further granting of options. At the year ended December 31, 2013 there were options to purchase up to 434,000 shares of the Company’s common stock granted and outstanding under the 2010 Plan. | ||||||||||||||||||||||||||||||||||
| Expected term (in years) | 6.25 | 6.25 | 6.25 | 6.25 | |||||||||||||||||||||||||||||||||||
| Risk-free interest rate | 2.73 | % | 2.05 | % | 2.73 | % | 1.38-2.05 | % | We have granted options to individual employees, directors, and consultants pursuant to our 2010 Plan that was approved by stockholders. In addition, we assumed options granted by AtheroNova Operations to its employees prior to the Merger. The assumption of these options was not approved by our stockholders. | ||||||||||||||||||||||||||||||
| To compute compensation expense, the Company estimated the fair value of each option award on the date of grant using the Black-Scholes-Merton option pricing model for employees, and calculated the fair value of each option award at the end of the period for non-employees. In the prior periods, the Company based the expected volatility assumption on a volatility index of peer companies as the Company did not have sufficient historical market information to estimate the volatility of its own stock. Starting in April of 2013, the Company determined that its stock price had matured and there was a consistent level of trading activity, as such, the Company used the volatility percentage of its common stock. The expected term of options granted represents the period of time that options are expected to be outstanding. The Company estimated the expected term of stock options by using the simplified method. To determine the risk-free interest rate, the Company utilized the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected term of the Company’s awards. The Company has not declared a dividend on its common stock since its inception and has no intentions of declaring a dividend in the foreseeable future and therefore used a dividend yield of zero. | The following table provides information, as of December 31, 2013, with respect to all stock option compensation arrangements. | ||||||||||||||||||||||||||||||||||||||
| Warrants | Number of | Number of securities | |||||||||||||||||||||||||||||||||||||
| securities to be | remaining available for | ||||||||||||||||||||||||||||||||||||||
| A summary of the status of our issued and outstanding warrants as of June 30, 2014 and changes during the period then ended is presented below: | issued upon | Weighted-average | future issuance under | ||||||||||||||||||||||||||||||||||||
| exercise of | exercise price of | equity compensation | |||||||||||||||||||||||||||||||||||||
| Shares | Weighted | Weighted | Aggregate | outstanding | outstanding | plans (excluding | |||||||||||||||||||||||||||||||||
| average | Average | Intrinsic Value | options, | options, | securities reflected in | ||||||||||||||||||||||||||||||||||
| exercise | Remaining | and rights | and rights | column (a) | |||||||||||||||||||||||||||||||||||
| price | Contractual | Plan Category | (a) | (b) | (c) | ||||||||||||||||||||||||||||||||||
| Term (years) | Equity compensation plans approved by stockholders | 434,000 | $ | 9.7 | 302,296 | ||||||||||||||||||||||||||||||||||
| Outstanding at December 31, 2013 | 853,946 | $ | 3.77 | 2.665 | $ | 783,258 | Equity compensation plans approved by the Board of Directors | 134,950 | 3.9 | -- | |||||||||||||||||||||||||||||
| Granted | 454,457 | 2.3 | 9.667 | -- | Total | 568,950 | $ | 8.3 | 302,296 | ||||||||||||||||||||||||||||||
| Exercised | -- | -- | -- | -- | |||||||||||||||||||||||||||||||||||
| Cancelled | (80,139 | ) | (5.973 | ) | -- | -- | 2013 | ||||||||||||||||||||||||||||||||
| Outstanding at June 30, 2014 | 1,228,264 | $ | 3.987 | 7.039 | $ | 0 | |||||||||||||||||||||||||||||||||
| Exercisable at June 30, 2014 | 1,228,264 | $ | 3.987 | 7.039 | $ | 0 | During the year ended December 31, 2013, options to purchase an aggregate of 50,250 shares of the Company’s common stock were granted under the 2010 Plan to an employee and members of the Company’s Board of Directors valued at $258,497 using the Black-Scholes-Merton option pricing model. The options have an exercise price of $4.30 up to $6.90 per share, vest over a three to four year period and expire seven years from the date of grant. During the period ended December 31, 2013, the Company recognized compensation costs of $52,652 based on the vesting of these options. | ||||||||||||||||||||||||||||||||
| In February 2014, pursuant to the issuance of the 6% Notes, the Company issued warrants to purchase 414,457 shares of common stock. The warrants are exercisable at $2.30/share and will expire in ten years. The Company also issued warrants to purchase 40,000 shares of common stock to purchasers in the August 2013 private placement. The warrants have an exercise price of $2.30 per share, vest immediately and expire 10 years from date of grant. See Note 3 for further discussion. | During the year ended December 31, 2013, options to purchase 158,000 shares of the Company’s common stock were granted to consultants valued at $881,688 using the Black-Scholes –Merton calculation. The options have an exercise price of $4.30 up to $6.90 per share, vest over a four year period and expire seven years from the grant date. During the year ended December 31, 2013, the Company recognized compensation expense of $98,094 based on the vesting of these options. | ||||||||||||||||||||||||||||||||||||||
| In May 2011, the Company granted a consultant a total of 150,000 options to purchase share of the Company’s common stock at $10.10/share. These options would only become fully vested upon achievement of certain milestones and will expire seven years from the date of grant. At the beginning of 2013, a total of 135,000 options remained unvested. In March and May 2013, certain milestones were achieved resulting in a total of 35,000 options becoming fully vested and the Company recognized compensation costs of $117,257 based on the fair value of these options using the Black-Scholes-Merton calculation. In June 2013, the Company and the consultant agreed to cancel the remaining unvested options to purchase 100,000 shares of common stock at $10.10 per share. | |||||||||||||||||||||||||||||||||||||||
| During the year ended December 31, 2013, we recognized an additional $596,676 of compensation costs related to the vesting of approximately 460,000 options granted to other employees and directors in prior years. As of December 31, 2013, the total compensation cost related to nonvested option awards not yet recognized was $1,183,387. The weighted average period over which it is expected to be recognized is approximately 0.88 years. | |||||||||||||||||||||||||||||||||||||||
| 2012 | |||||||||||||||||||||||||||||||||||||||
| During the year ended December 31, 2012, options to purchase an aggregate of 10,000 shares of the Company’s common stock were granted to directors under the 2010 Plan. The options vest 25% upon issuance, and then vest 25% on each anniversary date thereafter until fully vested. The options have an average exercise price of $10.00 per share and expire on the 7th anniversary of the date of grant. The options were valued using the Black-Scholes-Merton option pricing model at $88,500 of which $38,124 was expensed during the year ended December 31, 2012 based upon the options’ vesting schedules. | |||||||||||||||||||||||||||||||||||||||
| In June 2012, the exercise price of options granted to a consultant in fiscal 2011 to purchase an aggregate of 150,000 shares of the Company’s common stock at an average price per share of $12.50 were repriced to $10.10 per share to reflect the contractual intent to grant all shares under the contract at the time of initiation of the consulting contract. The closing price of the Company’s common stock on the date of the adjustment was $7.90. During the year ended December 31, 2012, the Company recognized a total of $219,015 in stock compensation expense based upon the vesting of these options using the Black-Scholes-Merton option pricing model. Compensation expense to be recognize in future periods amounted to approximately $427,000. The weighted average period over which it is expected to be recognized is approximately 3.6 years. | |||||||||||||||||||||||||||||||||||||||
| During the year ended December 31, 2012, we recognized an additional $546,631 of compensation costs related to the vesting of approximately 450,000 options granted to other employees and directors in prior years. As of December 31, 2012, the total compensation cost related to nonvested option awards not yet recognized was $1,304,110. The weighted average period over which it is expected to be recognized is approximately 3.5 years. | |||||||||||||||||||||||||||||||||||||||
| A summary of the status of our stock options as of December 31, 2013 and 2012 and changes during the periods then ended is presented below: | |||||||||||||||||||||||||||||||||||||||
| Shares | Weighted | Weighted | Aggregate | ||||||||||||||||||||||||||||||||||||
| average | Average | Intrinsic Value | |||||||||||||||||||||||||||||||||||||
| exercise | Remaining | ||||||||||||||||||||||||||||||||||||||
| price | Contractual | ||||||||||||||||||||||||||||||||||||||
| Term (years) | |||||||||||||||||||||||||||||||||||||||
| Outstanding at December 31, 2011 | 451,950 | $ | 11.29 | 6.163 | $ | 1,140,059 | |||||||||||||||||||||||||||||||||
| Granted | 10,000 | $ | 10 | 6.5 | -- | ||||||||||||||||||||||||||||||||||
| Exercised | -- | -- | -- | -- | |||||||||||||||||||||||||||||||||||
| Cancelled | (1,250 | ) | $ | 11.1 | -- | -- | |||||||||||||||||||||||||||||||||
| Outstanding at December 31, 2012 | 460,700 | $ | 9.87 | 5.189 | $ | 119,241 | |||||||||||||||||||||||||||||||||
| Granted | 208,250 | $ | 5.74 | 6.376 | -- | ||||||||||||||||||||||||||||||||||
| Exercised | -- | -- | -- | -- | |||||||||||||||||||||||||||||||||||
| Cancelled | (100,000 | ) | $ | 10.1 | -- | -- | |||||||||||||||||||||||||||||||||
| Outstanding at December 31, 2013 | 568,950 | $ | 8.32 | 4.849 | $ | 86,271 | |||||||||||||||||||||||||||||||||
| Exercisable at December 31, 2013 | 305,471 | $ | 9.52 | 3.942 | $ | 84,475 | |||||||||||||||||||||||||||||||||
| To compute compensation expense in 2013, we estimated the fair value of each option award on the date of measurement using the Black-Scholes-Merton option pricing model. In prior periods, the Company based the expected volatility assumption on a volatility index of publicly traded peer companies. During the current year, the Company determined that its stock price has matured and there is a consistent level of trading activity, as such, the Company used the volatility percentage of its common stock. The expected term of options granted represents the period of time that options are expected to be outstanding. We estimated the expected term of stock options by using the simplified method. The expected forfeiture rates are based on the historical forfeiture experiences. To determine the risk-free interest rate, we utilized the U.S. Treasury yield curve in effect at the time of measurement with a term consistent with the expected term of our awards. We have not declared a dividend on our common stock since its inception and have no intentions of declaring a dividend in the foreseeable future and therefore used a dividend yield of zero. | |||||||||||||||||||||||||||||||||||||||
| The following table provides detail with regard to options outstanding, vested and exercisable at December 31, 2013: | |||||||||||||||||||||||||||||||||||||||
| Outstanding | Vested and Exercisable Weighted-Average | ||||||||||||||||||||||||||||||||||||||
| Price per share | Shares | Weighted- | Weighted- | Shares | Weighted- | Weighted- | |||||||||||||||||||||||||||||||||
| Average Price | Average | Average Price | Average | ||||||||||||||||||||||||||||||||||||
| per Share | Remaining | per Share | Remaining | ||||||||||||||||||||||||||||||||||||
| Contractual | Contractual | ||||||||||||||||||||||||||||||||||||||
| Life | Life | ||||||||||||||||||||||||||||||||||||||
| (in years) | (in years) | ||||||||||||||||||||||||||||||||||||||
| $2.23 – $6.90 | 263,200 | $ | 5.01 | 5.69 | 61,243 | $ | 2.57 | 3.48 | |||||||||||||||||||||||||||||||
| $7.00 – $12.50 | 279,750 | $ | 10.62 | 4.08 | 228,979 | $ | 10.64 | 4.05 | |||||||||||||||||||||||||||||||
| $13.00 – $23.80 | 26,000 | $ | 17.23 | 4.57 | 17,999 | $ | 19.5 | 4.37 | |||||||||||||||||||||||||||||||
| 568,950 | 308,221 | ||||||||||||||||||||||||||||||||||||||
| The following table shows the weighted average assumptions we used to develop the fair value estimates for the determination of the compensation charges in 2013: | |||||||||||||||||||||||||||||||||||||||
| Year ended December 31, | |||||||||||||||||||||||||||||||||||||||
| 2013 | 2012 | ||||||||||||||||||||||||||||||||||||||
| Expected volatility | 113-226 | % | 111-134 | % | |||||||||||||||||||||||||||||||||||
| Dividend yield | -- | -- | |||||||||||||||||||||||||||||||||||||
| Expected term (in years) | 5.50-6.25 | 1.75-6.25 | |||||||||||||||||||||||||||||||||||||
| Risk-free interest rate | 1.38-2.09 | % | 1.19-1.41 | % | |||||||||||||||||||||||||||||||||||
| Warrants | |||||||||||||||||||||||||||||||||||||||
| 2013 | |||||||||||||||||||||||||||||||||||||||
| During the year ended December 31, 2013 as part of our sale of units of our common stock, we issued 24,001 warrants to purchase shares of our common stock. The warrants have a ten year term from the date of purchase of the unit and are exercisable at $7.50 per share. | |||||||||||||||||||||||||||||||||||||||
| During the year ended December 31, 2013 we issued warrants to a service provider to purchase 5,000 shares of our common stock. The warrants vest immediately, had a term of three years and are exercisable at a purchase price of $5.00. the warrants were valued using the Black-Scholes-Merton option pricing model at $13,500 with the following assumptions risk free interest rate of 0.40%, dividend yield of 0%, volatility factors of the expected market price of common stock of 114%, and an expected life of 2.5 years. | |||||||||||||||||||||||||||||||||||||||
| During the year ended December 31, 2013, a holder of warrants to purchase 56,071 shares of our common stock at $2.233 per share exercised the warrant, resulting in cash proceeds to the Company of $125,039 and issuance of the shares upon receipt of the purchase price. | |||||||||||||||||||||||||||||||||||||||
| During the year ended December 31, 2013 a director of the Company and holder of a warrant to purchase 33,643 shares of our common stock at $2.23 exercised the warrant on a “cashless exercise” basis, resulting in issuance of 18,636 shares of our common stock and cancellation of 15,006 shares purchasable under the warrant. The Company did not receive any cash proceeds as a result of this transaction. | |||||||||||||||||||||||||||||||||||||||
| During the year ended December 31, 2013 a holder of warrants to purchase 11,214 shares of our common stock at $2.23 per share exercised the warrant, resulting in cash proceeds to the Company of $25,007 and issuance of the shares upon receipt of the purchase price. | |||||||||||||||||||||||||||||||||||||||
| 2012 | |||||||||||||||||||||||||||||||||||||||
| During the year ended December 31, 2012 as part of its sale of units of its common stock, we issued 224,000 warrants to purchase shares of our common stock. The warrants have a 4 year term from the date of purchase of the unit and are exercisable at $6.25 per share. | |||||||||||||||||||||||||||||||||||||||
| On May 15, 2012, we issued 14,000 warrants to the purchasers of the short term 12% notes issued as of that date. The warrants are exercisable at $9.00 per share with the provision to adjust the purchase price based on the issuance price of the private placement in process at the time of the issuance of the notes and a term of 66 months from the date of the original issuance. The fair value of the warrants amounted to $58,387 using a Black-Scholes-Merton option pricing model and was recognized as a note discount upon its issuance and amortized in full to interest expense based upon the original term of the notes. In October 2012 concurrent with the closing of the private placement, the warrants were repriced to $5.75 to reflect the transaction price. As a result, we recognized an additional cost of $34,220 to account for the fair value of these revalued warrants as part of Changes to short-term notes and warrants in the accompanying consolidated statements of operations. See Note 3. | |||||||||||||||||||||||||||||||||||||||
| In October 2012, we issued a total of 68,500 warrants to purchase shares of our common stock in conjunction with the conversion of our short term 12% convertible notes payable. The warrants have a 4 year term from the date of purchase of the unit and are exercisable at $6.25 per share. Total fair value of the warrants issued were calculated to be $420,863 using the Black-Scholes-Merton option pricing model and was recorded as part of Changes to 12% Notes and Warrants in the accompanying consolidated statements of operations. | |||||||||||||||||||||||||||||||||||||||
| The following table provides detail with regard to warrants outstanding, vested and exercisable at December 31, 2013: | |||||||||||||||||||||||||||||||||||||||
| Outstanding | Vested and Exercisable Weighted-Average | ||||||||||||||||||||||||||||||||||||||
| Price per share | Shares | Weighted- | Weighted- | Shares | Weighted- | Weighted- | |||||||||||||||||||||||||||||||||
| Average Price | Average | Average Price | Average | ||||||||||||||||||||||||||||||||||||
| per Share | Remaining | per Share | Remaining | ||||||||||||||||||||||||||||||||||||
| Contractual | Contractual | ||||||||||||||||||||||||||||||||||||||
| Life | Life | ||||||||||||||||||||||||||||||||||||||
| (in years) | (in years) | ||||||||||||||||||||||||||||||||||||||
| $ | 2.23 | 213,071 | $ | 2.23 | 1.2 | 213,071 | $ | 2.23 | 1.2 | ||||||||||||||||||||||||||||||
| $ | 3.93 | 190,880 | $ | 3.9393 | 0.42 | 190,880 | $ | 3.93 | 0.42 | ||||||||||||||||||||||||||||||
| $ | 5 | 7,100 | $ | 5 | 1.48 | 7,100 | $ | 5 | 1.48 | ||||||||||||||||||||||||||||||
| $ | 5.75 | 14,000 | $ | 5.75 | 3.83 | 14,000 | $ | 5.75 | 3.83 | ||||||||||||||||||||||||||||||
| $ | 6 | 92,386 | $ | 6 | 0.6 | 92,386 | $ | 6 | 0.6 | ||||||||||||||||||||||||||||||
| $ | 6.25 | 292,500 | $ | 6.25 | 2.75 | 292,500 | $ | 6.25 | 2.75 | ||||||||||||||||||||||||||||||
| $ | 7.5 | 24,001 | $ | 7.5 | 9.67 | 24,001 | $ | 7.5 | 9.67 | ||||||||||||||||||||||||||||||
| $ | 16.4 | 20,000 | $ | 16.4 | 2 | 20,000 | $ | 16.4 | 2 | ||||||||||||||||||||||||||||||
| 853,937 | 853,937 | ||||||||||||||||||||||||||||||||||||||
| As of December 31, 2013 there are warrants to purchase 853,937 shares of our common stock outstanding with expiration dates ranging from February 2014 through August 2023 and exercise prices ranging from $2.23 to $16.40. A summary of the status of our warrants as of December 31, 2013 and 2012 and changes during the periods then ended is presented below: | |||||||||||||||||||||||||||||||||||||||
| Shares | |||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2011 (at $2.23-$16.40) | 624,972 | ||||||||||||||||||||||||||||||||||||||
| Granted (at $0.575 - $0.625) | 306,500 | ||||||||||||||||||||||||||||||||||||||
| Exercised | -- | ||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2012 (at $2.23 - $16.40) | 931,472 | ||||||||||||||||||||||||||||||||||||||
| Granted (at $5.00 - $7.50) | 29,001 | ||||||||||||||||||||||||||||||||||||||
| Exercised | (85,923 | ) | |||||||||||||||||||||||||||||||||||||
| Cancelled | (20,612 | ) | |||||||||||||||||||||||||||||||||||||
| Ending balance at December 31, 2013 (at $2.23 - $16.40) | 853,937 | ||||||||||||||||||||||||||||||||||||||
| The intrinsic value of the warrants at December 31, 2013 was $334,521. | |||||||||||||||||||||||||||||||||||||||
Note_8_Income_Taxes
| Note 8 - Income Taxes | 12 Months Ended | ||||||||
| Dec. 31, 2013 | |||||||||
| Income Tax Disclosure [Abstract] | ' | ||||||||
| Income Tax Disclosure [Text Block] | ' | ||||||||
| 8. INCOME TAXES | |||||||||
| Income Taxes | |||||||||
| The provision for income taxes for the periods ended December 31, 2013, and 2012, was as follows (using a 42.8 percent effective Federal and state income tax rate): | |||||||||
| 2013 | 2012 | ||||||||
| Current Tax Provision: | |||||||||
| Federal | $ | -- | $ | -- | |||||
| State | 1,365 | 1,365 | |||||||
| Total current tax provision | $ | 1,365 | $ | 1,365 | |||||
| Deferred Tax Provision: | |||||||||
| Federal and state | |||||||||
| Loss carryforwards | $ | (2,360,000 | ) | $ | (933,000 | ) | |||
| Valuation allowance | 2,360,000 | 933,000 | |||||||
| Total deferred tax provision | $ | -- | $ | -- | |||||
| We had deferred income tax assets as of December 31, 2013, and 2012, as follows: | |||||||||
| 2013 | 2012 | ||||||||
| Loss carryforwards | $ | (4,261,000 | ) | $ | (1,901,000 | ) | |||
| Less – valuation allowance | 4,261,000 | 1,901,000 | |||||||
| Total net deferred tax assets | $ | -- | $ | -- | |||||
| As of December 31, 2013, we had net operating loss carryforwards for income tax reporting purposes of approximately $8,861,000 that may be offset against future taxable income. Current tax laws limit the amount of loss available to be offset against future taxable income when a substantial change in ownership occurs or a change in the nature of the business. Therefore, the amount available to offset future taxable income may be limited. | |||||||||
| No tax benefit has been reported in our financial statements for the realization of loss carryforwards, as we believe there is high probability that the carryforwards will not be utilized in the foreseeable future. Accordingly, the potential tax benefits of the loss carryforwards are offset by a valuation allowance of the same amount. | |||||||||
| We are primarily subject to U.S. federal and state income tax. As a result of the implementation of certain provisions of ASC 740, Income Taxes, (formerly FIN 48, Accounting for Uncertainty in Income Taxes – An Interpretation of FASB Statement No. 109), we performed an analysis of our previous tax filings and determined that there were no positions taken that we considered uncertain. Therefore, there were no unrecognized tax benefits as of December 31, 2013. | |||||||||
| Future changes in the unrecognized tax benefit are not expected to have an impact on the effective tax rate due to the existence of the valuation allowance. We estimate that the unrecognized tax benefit will not change within the next twelve months. We will continue to classify income tax penalties and interest, if any, as part of interest and other expenses in our statements of operations. | |||||||||
Note_9_Derivative_Liability
| Note 9 - Derivative Liability | 6 Months Ended | 12 Months Ended | ||||||||||||||
| Jun. 30, 2014 | Dec. 31, 2013 | |||||||||||||||
| Derivative Instruments and Hedging Activities Disclosure [Abstract] | ' | ' | ||||||||||||||
| Derivative Instruments and Hedging Activities Disclosure [Text Block] | ' | ' | ||||||||||||||
| 4. DERIVATIVE LIABILITY | 9. DERIVATIVE LIABILITY | |||||||||||||||
| In April 2008, the FASB issued a pronouncement which provides guidance on determining what types of instruments or embedded features in an instrument held by a reporting entity can be considered indexed to its own stock for the purpose of evaluating the first criteria of the scope exception in the pronouncement on accounting for derivatives. This pronouncement was effective for financial statements issued for fiscal years beginning after December 15, 2008. The adoption of these requirements can affect the accounting for warrants and many convertible instruments with provisions that protect holders from a decline in the stock price (or “down-round” provisions). For example, warrants with such provisions will no longer be recorded in equity. Down-round provisions reduce the exercise price of a warrant or convertible instrument if a company either issues equity shares for a price that is lower than the exercise price of those instruments or issues new warrants or convertible instruments that have a lower exercise price. | In April 2008, the FASB issued a pronouncement which provides guidance on determining what types of instruments or embedded features in an instrument held by a reporting entity can be considered indexed to its own stock for the purpose of evaluating the first criteria of the scope exception in the pronouncement on accounting for derivatives. This pronouncement was effective for financial statements issued for fiscal years beginning after December 15, 2008. The adoption of these requirements can affect the accounting for warrants and many convertible instruments with provisions that protect holders from a decline in the stock price (or “down-round” provisions). For example, warrants with such provisions are no longer to be recorded in equity. Down-round provisions reduce the exercise price of a warrant or convertible instrument if a company either issues equity shares for a price that is lower than the exercise price of those instruments or issues new warrants or convertible instruments that have a lower exercise price. | |||||||||||||||
| We determined that the 6% Notes and related warrants issued to the Investors in February 2014 and the additional 40,000 warrants issued to the August 2013 Investors concurrent with the issuance of the 6% Notes and related warrants contained provisions that protect holders from declines in the stock price or otherwise could result in modification of the exercise price under the respective convertible debt and warrant agreements. As a result, these instruments were recorded as derivative liability and valued using a probability based weighted-average Black-Scholes-Merton valuation with the following assumptions: | We evaluated whether convertible debt and warrants to acquire our common stock contain such provisions that protect holders from declines in the stock price or otherwise could result in modification of the exercise price under the respective convertible debt and warrant agreements. We determined that the Senior Notes and warrants issued to W-Net, Europa and MKM in May 2010 as described in Note 3 contained such provisions and were recorded as derivative liabilities upon their issuance. FASB’s guidance requires the fair value of these liabilities be re-measured every reporting period with the change in value reported in the statements of operations. | |||||||||||||||
| June 30, | February 12, | On June 15, 2012, pursuant to the amendments of the Senior Notes and associated warrants as discussed in Note 3, we determined the conversion features of the notes and the exercise prices of the warrants were no longer required to be accounted for as a derivative liability due to the elimination of the price-based anti-dilution provisions contained in the Senior Amended Notes and warrants. As a result, the Company recognized the fair value of the derivative liability at the date of extinguishment of $3,472,549 as part of its contributed capital. | ||||||||||||||
| 2014 | 2014 (Issuance) | |||||||||||||||
| (Unaudited) | (Unaudited) | The derivative liabilities and restatement were valued using a probability weighted-average Black-Scholes-Merton option pricing model, which approximates the Monte Carlo and other binominal valuation techniques with the following assumptions: | ||||||||||||||
| Conversion Feature : | ||||||||||||||||
| Risk-free interest rate | 0.88 | % | 0.74 | % | 15-Jun-12 | |||||||||||
| Expected volatility | 198 | % | 211 | % | (Note & | |||||||||||
| Expected life (in years) | 2.63 | 3 | Warrant | |||||||||||||
| Expected dividend yield | 0 | % | 0 | % | Amendment | |||||||||||
| and | ||||||||||||||||
| Warrants : | Restatement | |||||||||||||||
| Risk-free interest rate | 2.53 | % | 2.8 | % | Date) | |||||||||||
| Expected volatility | 198 | % | 211 | % | Conversion feature : | |||||||||||
| Expected weighted average life (in years) | 9.58 | 10 | Risk-free interest rate | 0.29% | ||||||||||||
| Expected dividend yield | 0 | % | 0 | % | Expected volatility | 111% | ||||||||||
| Expected life (in years) | 1.87 | |||||||||||||||
| Fair Value : | Expected dividend yield | 0.00% | ||||||||||||||
| Conversion feature | $ | 1,508,202 | $ | 2,951,785 | ||||||||||||
| Warrants | 840,282 | 1,635,781 | Warrants : | |||||||||||||
| $ | 2,348,484 | $ | 4,587,566 | Risk-free interest rate | 0.29% | |||||||||||
| Expected volatility | 111% | |||||||||||||||
| The risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its common stock based upon the expected term of the instrument, and the expected life of the instrument is determined by the expiration date of the instrument. The expected dividend yield was based on the fact that the Company has not paid dividends to common stockholders in the past and does not expect to pay dividends to common stockholders in the future. | Expected weighted average life (in years) | 1.87 | ||||||||||||||
| Expected dividend yield | 0.00% | |||||||||||||||
| The Company measured the aggregate fair value of the conversion feature and the warrants issued on the date of issuance of February 12, 2014 as $4,587,566. At June 30, 2014, the aggregate fair value of the derivative liabilities amounted to $2,348,483. As a result, the Company recorded the change in fair value of the derivative liabilities of $2,239,083 in the accompanying statement of operations for the six months ending June 30, 2014. | ||||||||||||||||
| Fair Value : | ||||||||||||||||
| Conversion feature | $ | 2,295,881 | ||||||||||||||
| Warrants | 1,176,668 | |||||||||||||||
| $ | 3,472,549 | |||||||||||||||
| The risk-free interest rate was based on rates established by the Federal Reserve Bank, expected volatility was based on a volatility index of peer companies as we did not have sufficient market information in 2012 to estimate the volatility of our own stock, and the expected life of the instruments was determined by the expiration date of the instruments. The expected dividend yield was based on the fact that we have not paid dividends to common stockholders in the past and do not expect to pay dividends to common stockholders in the foreseeable future. | ||||||||||||||||
| During the year ended December 31, 2012, the Company recognized a gain of $97,975, to account for the corresponding extinguishment of derivative liability upon partial conversion of the principal balance of a convertible note into shares of common stock and recognized a gain of $2,640,497 to account for the change in the fair value of derivative liabilities. As of December 31, 2012, all such derivative liabilities had been extinguished. | ||||||||||||||||
Note_10_12_Convertible_Notes_P
| Note 10 - 12 % Convertible Notes Payable | 12 Months Ended |
| Dec. 31, 2013 | |
| Disclosure Text Block [Abstract] | ' |
| Short-term Debt [Text Block] | ' |
| 10. 12 % CONVERTIBLE NOTES PAYABLE | |
| On May 15, 2012, we entered into a Securities Purchase Agreement with ACT Capital Partners and Amir L. Ecker pursuant to which the purchasers, purchased from us (i) 12% Convertible Notes (“Bridge Notes”) for a cash purchase price of $700,000, and (ii) Common Stock Purchase Warrants pursuant to which the purchasers of Bridge Notes may purchase up to 14,000 shares of our common stock at an exercise price of $9.00 per share, subject to adjustment. The Bridge Notes are secured by the Company’s assets, accrued 12% interest per annum with a maturity date of September 30, 2012. On September 27, 2012 the maturity date of these Bridge Notes was extended to October 15, 2012. All other terms and conditions remained unchanged. No cash interest payments were required, except that accrued and unconverted interest would be due on the maturity date and on each conversion date with respect to the principal amount being converted, provided that such interest could be added to and included with the principal amount being converted. Upon the occurrence of an event of default (as defined in the Bridge Notes), the holder of each Bridge Note could have declared the entire principal and accrued interest amount immediately due and payable. Total proceeds received amounted to $645,200, net of commission fee of $54,800. | |
| Upon issuance of the Bridge Notes, we calculated the fair value of the warrants to be $58,387 that was determined using a Black-Scholes-Merton option pricing model with the following assumptions: stock price of $5.50; exercise price of $9.00; term of 5.5 years; interest rate of 0.70%; dividend rate of 0%; and volatility of 113%. The fair value of the warrants and the commission fee, in the aggregate of $113,186, was recorded as a discount to the Bridge Notes and was amortized in full to interest expense over the original term of the Bridge Notes. | |
| Each Bridge Note was convertible at any time into common stock at a specified conversion price, which was approximately $0.90 per share, subject to adjustment. The Company did not recognize a beneficial conversion feature upon issuance of the Bridge Notes as the conversion price was in excess of the trading price of its common stock at the date of the Bridge Note agreement. | |
| The Bridge Notes could not be prepaid, or forced by us to be converted in connection with an acquisition of our company. In connection with an acquisition of our company the Bridge Notes could have been be assigned or sold by the holders or converted into equivalent equity in any acquiring company. The Bridge Notes were secured by a Subsidiary Guarantee and were subordinated to our senior notes to the amounts then outstanding under our senior notes. | |
| In October 2012, the Company paid $15,000 of the note principal and converted the remaining principal balance of $685,000 to 137,000 shares of the Company's common stock at a conversion price of $5.00 per share. As such, there was no balance due on this note as of December 31, 2013. This conversion price was modified to $5.00 per share corresponded with the per unit price for the purchasers in a private placement closed by us in that month. The modified conversion price was considered an inducement to convert the notes. Accordingly, the Company recognized a beneficial conversion feature cost of $411,000 to account for the intrinsic value in the conversion price of the notes and the market price of the Company’s stock at the date of conversion. Furthermore, the warrants issued initially under the Securities Purchase Agreement as disclosed above were modified to $5.75 per share using the closing price of warrants issued in a concurrent private placement. As a result, the Company recognized an additional cost of $34,220 to account for the change in fair value of these revalued warrants. | |
| Additionally, upon conversion of these notes, the Company granted these note holders additional warrants to purchase 68,500 shares of the Company’s common stock at $6.30 per share. The warrants are fully exercisable and will expire in four years. The Company considered these warrants as an inducement to the note holders to convert their notes into common stock. Total fair value of the warrants issued were calculated to be $420,863 using the Black-Scholes-Merton option pricing model with the following assumptions: stock price of $8.00; exercise price of $6.30; term of 4 years; interest rate of 1.4%; dividend rate of 0%; and volatility of 110%. | |
| The aggregate of cost of $866,083 due to changes in the conversion price of the notes and issuance of additional warrants that have been reflected in the accompanying statement of operations for the year ended December 31, 2012. During the year ended December 31, 2012, the Company paid these note holders $32,666 for interest due. |
Note_11_Subsequent_Events
| Note 11 - Subsequent Events | 6 Months Ended | 12 Months Ended |
| Jun. 30, 2014 | Dec. 31, 2013 | |
| Subsequent Events [Abstract] | ' | ' |
| Subsequent Events [Text Block] | ' | ' |
| 8. SUBSEQUENT EVENTS | 11. SUBSEQUENT EVENTS | |
| On July 29, 2014, the Company issued 14,453 shares of its common stock upon conversion of $15,000 of principal and $393 of accrued interest thereon of its 6% Notes originally issued on February 12, 2014. | On January 14, 2014 we granted 40,001 warrants to certain investors in an equity placement during August 2013. During January and February 2014, we entered into Securities Purchase Agreements with accredited investors under which the participants purchased, on February 12, 2014, $1,906,500 of our 6% Senior Secured Convertible Notes with 414,456 associated warrants. In connection with this note placement, the Company paid cash commissions of $68,720 and issued 6,535 shares of common stock, with a fair value of $23,395, to an accredited broker that assisted in this note placement. The 6% Notes are secured by a first priority security interest of all assets of the Company and its subsidiaries, including intellectual property. The 6% Notes have a 3 year term and are convertible into common stock at any time at the lesser of i) $2.30 per share and ii) seventy percent of the average of the three lowest daily VWAPs occurring during the 20 consecutive trading days immediately preceding the applicable conversion date. Each purchaser also received a warrant with a 10 year life entitling the holder to purchase common stock representing 50% of the number of conversion shares of the purchased note at $2.30 per share. Additionally, as an incentive, the life of existing warrants held by participants in the Note purchase were extended to ten years from the date of each respective warrant’s original issuance. | |
| On July 29, 2014, the Company issued 24,088 shares of its common stock upon conversion of $25,000 of principal and $654 of accrued interest thereon of its 6% Notes originally issued on February 12, 2014. | The 6% Notes and associated warrants included an anti-dilution provision that allows for the automatic reset of the conversion or exercise price upon any future sale of common stock instruments at or below the current conversion or exercise price, as applicable. We considered the current Financial Accounting Standards Board guidance of “Determining Whether an Instrument Indexed to an Entity’s Own Stock” which indicates that any adjustment to the fixed amount (either conversion price or number of shares) of the instrument regardless of the probability or whether or not within the issuers’ control, means the instrument is not indexed to the issuers own stock. Accordingly, we determined that the conversion price of the 6% Notes and the strike price of the associated warrants contain conversion or exercise prices, as applicable, that may fluctuate based on the occurrence of future offerings or events, and as such are not fixed amounts. As a result, we determined that the conversion features of the 6% Notes and the associated warrants are not considered indexed to our own stock and characterized the fair value of the 6% Notes and the associated warrants as derivative liabilities upon issuance. | |
| On September 12, 2014, the Company issued 8% Secured Convertible Notes for gross aggregate proceeds of $500,000. These notes have a maturity of one year from the date of issuance, are secured by the assets of the Company and are convertible at any time into common stock at a conversion price of $1.11 per share or 450,457 shares of common stock. Upon consummation of an underwritten offering of common stock the notes will mandatorily convert into common stock with a value of 115% of the amount of principal purchased or 225,228 shares of common stock. The notes also included a warrant to purchase 50% of the principal value purchased at a purchase price of $2.00 per share for up to five years from the date of closing of the offering. | Upon issuances, we determined that the fair values of the conversion feature of the 6% Notes and the associated warrants to be approximately $2,951,776 and $ 1,491,780, respectively based upon a weighted average Black-Sholes-Merton calculation. We will record the full value of the derivative as a liability at issuance with an offset to valuation discount, which will be amortized over the life of the 6% Notes. As the aggregate fair value of these liabilities of $4,443,556 exceeded the aggregate 6% Note value of $1,906,500 the excess of the liability over the 6% Note value of $2,537,056 will be considered as a cost of the private placement. Additionally, the Black-Scholes-Merton calculations of the value of each of the warrants immediately before and after the life extension resulted in a valuation increase of an aggregate of $564,849, which will be recorded and an additional cost of the private placement. The derivative liability will be revalued at each subsequent reporting date. | |
| The Company expects to record a valuation discount of $500,000 that will be amortized to interest expense over the life of the notes. The valuation discount relates to the relative value of the warrants issued with the convertible notes, and the beneficial conversion feature of the notes. The relative fair value of the warrants issued in connection with 8% Secured Convertible Notes was determined to be $224,644 using the Black-Scholes-Merton option valuation model with the following assumptions; risk-free interest rate of 1.83%; dividend yield of 0%; volatility rate based upon our historical stock price of 136%; and an expected life of five years (statutory term) and vest immediately upon issuance. The Company also determined the beneficial conversion feature to be $275,356 based upon the relative value of the conversion price based upon the historical stock price. | On April 22, 2014, the Company effected a 1 - for - 10 reverse stock split through the amendment of its certificate of incorporation. As a result, all share and per share amounts have been retroactively restated as of the beginning of the earliest period presented to effect the reverse stock split. |
Disclosure
| Disclosure | 6 Months Ended |
| Jun. 30, 2014 | |
| Disclosure Text Block [Abstract] | ' |
| Basis of Accounting [Text Block] | ' |
| The accompanying unaudited condensed consolidated financial statements of AtheroNova Inc. and subsidiary (“AtheroNova,” “we,” “us, “our” and “our Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the rules and regulations of the Securities and Exchange Commission. Accordingly, the unaudited condensed consolidated financial statements do not include all information and footnotes required by accounting principles generally accepted in the United States of America for complete annual financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of only normal recurring adjustments, considered necessary for a fair presentation. Interim operating results are not necessarily indicative of results that may be expected for the year ending December 31, 2014 or for any other interim period. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements as of and for the year ended December 31, 2013, which are included in the Company’s Report on Form 10-K for such year filed on February 27, 2014. The condensed consolidated balance sheet as of December 31, 2013 has been derived from the audited financial statements included in the Form 10-K for that year. |
Note_7_Related_Party_Transacti
| Note 7 - Related Party Transactions | 6 Months Ended |
| Jun. 30, 2014 | |
| Related Party Transactions [Abstract] | ' |
| Related Party Transactions Disclosure [Text Block] | ' |
| 7. RELATED PARTY TRANSACTIONS | |
| Accounts payable includes $65,917 and $50,841 as of June 30, 2014 and December 31, 2013, respectively, that are payable to officers and directors of the Company. | |
| As of June 30, 2014, Europa held $1,094,167 in aggregate principal amount of the 2.5% Notes and $300,000 in aggregate principal of the 6% Notes. Europa is an entity controlled by Knoll Capital Management of which Mr. Knoll, one of our directors, is the managing directors. |
Accounting_Policies_by_Policy_
| Accounting Policies, by Policy (Policies) | 6 Months Ended | 12 Months Ended | ||||||||||||||||||||||||
| Jun. 30, 2014 | Dec. 31, 2013 | |||||||||||||||||||||||||
| Accounting Policies [Abstract] | ' | ' | ||||||||||||||||||||||||
| Use of Estimates, Policy [Policy Text Block] | ' | ' | ||||||||||||||||||||||||
| Use of Estimates | In preparing these consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Significant estimates and assumptions included in our consolidated financial statements relate to the valuation of long-lived assets, accrued liabilities, and valuation assumptions related to the calculation of equity based compensation and in the calculation of the derivative liability. | |||||||||||||||||||||||||
| In preparing these condensed consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the condensed consolidated financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Significant estimates and assumptions included in the Company’s condensed consolidated financial statements relate to the valuation of long-lived assets, accrued other liabilities, and valuation assumptions related to share based payments and derivative liability. | ||||||||||||||||||||||||||
| Liquidity Disclosure [Policy Text Block] | ' | ' | ||||||||||||||||||||||||
| Going Concern | The accompanying consolidated financial statements have been prepared under the assumption that we will continue as a going concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As of December 31, 2013, we have an accumulated deficit of $22,029,794 and a stockholders’ deficit of $2,503,004. We have incurred recurring losses from operations since inception, and utilized cash flow from operating activities of $3,261,824 during the year ended December 31, 2013. These factors, among others, raise substantial doubt about our ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern. | |||||||||||||||||||||||||
| The accompanying condensed consolidated financial statements have been prepared under the assumption that the Company will continue as a going concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any revenues from operations to date, and does not expect to do so in the foreseeable future. The Company has incurred operating losses and negative operating cash flows since inception and has financed its working capital requirements through recurring sales of its convertible notes and equity securities. As reflected in the accompanying condensed consolidated financial statements, the Company had a net loss of $5,602,647 and negative cash flow from operations of $1,850,790 for the period ended June 30, 2014 and stockholders’ deficiency of $4,678,829 at June 30, 2014. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. As a result, the Company’s independent registered public accounting firm, in its report on the Company’s December 31, 2013 financial statements, has raised substantial doubt about the Company’s ability to continue as a going concern. | During 2013, we secured funding through the exercise of warrants issued in previous financings with proceeds of $150,047, the sale of a second tranche of common stock to CardioNova upon delivery of clinical trial material with proceeds of $117,000 and closed a private placement with net proceeds of $520,001. | |||||||||||||||||||||||||
| Management is currently in the process of exploring equity placements of securities by the Company to accredited investors, funds and institutional investors. The Company received $1,906,500 through the sale of its 6% Secured Convertible Notes as of February 2014. Management believes that current funds will be sufficient to fund operations through August 2014. Significant additional capital will be needed to advance the Company’s research and development and clinical trials as well as providing general working capital. There can be no assurances that sufficient subsequent funding, if any at all, will be raised by this or future offerings or that the cost of such funding will be reasonable. | In February 2014, the Company placed $1,906,500 of Senior Secured 6% Notes to investors (See Note 11 Subsequent Events) and continues to seek additional long-term funding sources. Management expects that the current funds on hand will be sufficient to continue operations through April of 2014. There can be no assurances that the proceeds from these note sales will be sufficient to fund the Company operations for a sufficient period of time in order to secure significant additional funding. There can be no assurances that sufficient funding, if any at all, will be raised by these or future discussions or the cost of such investments will be reasonable. | |||||||||||||||||||||||||
| In light of the foregoing, management will continue to seek funding through short-term and long-term loans, grants and other such funds available from private and public sources established to further research in health care and advancement of science. Additionally, the Company has filed a registration statement on form S-1 for a possible sale of equity to generate sufficient funds to continue operations for the next 12 to 15 months. Management continues to meet with representatives of private and public sources of funding to continue the ongoing process of capital development sufficient enough to cover negative cash flows expected in future periods and will continue to do so in the coming months. | In light of the foregoing, management will also seek funding through grants and other such funds available from private and public sources established to further research in health care and advancement of science. Management continues to meet with representatives of private and public sources of funding and will continue to do so in the coming months. | |||||||||||||||||||||||||
| Consolidation, Policy [Policy Text Block] | ' | ' | ||||||||||||||||||||||||
| Principles of Consolidation | The consolidated financial statements include the accounts of our Company and our wholly-owned subsidiary, AtheroNova Operations. Intercompany transactions and balances have been eliminated in consolidation. | |||||||||||||||||||||||||
| The condensed consolidated financial statements include the accounts of the Company and its majority-owned subsidiary. Intercompany transactions and balances have been eliminated in consolidation. | ||||||||||||||||||||||||||
| Research and Development Expense, Policy [Policy Text Block] | ' | ' | ||||||||||||||||||||||||
| Accounting for Share based Research and Development Costs | Costs incurred for research and development are expensed as incurred. Purchased materials that do not have an alternative future use are also expensed. For the years ended December 31, 2013 and 2012, and for the period from inception to December 31, 2013, research and development costs incurred were $4,399,294, $986,261 and $6,258,630, respectively. | |||||||||||||||||||||||||
| Under its research and development (R&D) agreements, the Company is obligated to issue shares of common stock if milestones are met by the R&D vendor. It is the Company’s policy to recognize expense for these shares when it is estimated that there is a high probability of meeting the milestone. The Company accrues the share based expense based upon the estimated percentage of completion of the milestone. The shares are valued at the market price at the end of the period and revalued at each period until issued. At June 30, 2014, approximately 83,824 shares of common stock were expected to be issued pursuant to the agreement with a fair value of $155,074. Accordingly, a liability was recorded as part of “Research and development costs-payable in stock” in the accompanying balance sheet below long term liabilities as such liability is only payable in shares of common stock. | Accounting for share based research and development costs | |||||||||||||||||||||||||
| Under its Research and Development (R&D) agreements, the Company is obligated to issue shares of common stock if milestones are met by the R&D vendor. It is the Company’s policy to recognize expense for these shares when it is estimated that there is a high probability of meeting the milestone. The Company accrues the share based expense based upon the estimated percentage of completion of the milestone. The shares are valued at the market price at the end of the period and revalued at each period until issued. At December 31, 2013, approximately 3 million shares of common stock are to be issued pursuant to the agreement with a fair value of $1,170,712. The liability was recorded as part of Research and development costs - payable in stock in the accompanying balance sheet below long term liabilities as it is only payable in shares of common stock. | ||||||||||||||||||||||||||
| Income Taxes | ||||||||||||||||||||||||||
| Current income tax expense is the amount of income taxes expected to be payable for the current year. A deferred income tax asset or liability is established for the expected future consequences of temporary differences in the financial reporting and tax bases of assets and liabilities. We consider future taxable income and ongoing, prudent and feasible tax planning strategies, in assessing the value of its deferred tax assets. If we determine that it is more likely than not that these assets will not be realized, we will reduce the value of these assets to their expected realizable value, thereby decreasing net income. Evaluating the value of these assets is necessarily based on our judgment. If we subsequently determine that the deferred tax assets, which had been written down, would be realized in the future, the value of the deferred tax assets would be increased, thereby increasing net income in the period when that determination was made. | ||||||||||||||||||||||||||
| Basic and Diluted Income/Loss per Share | ||||||||||||||||||||||||||
| Our computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted income (loss) per share reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income (loss) of the Company as if they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted income (loss) per share, the treasury stock method assumes that outstanding options and warrants are exercised and the proceeds are used to purchase common stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options and warrants. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. | ||||||||||||||||||||||||||
| Income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted (loss) per common share is the same for periods in which the Company reported an operating loss because all warrants and stock options outstanding are anti-dilutive. | ||||||||||||||||||||||||||
| There were no adjustments to net loss required for purposes of computing diluted earnings per share. | ||||||||||||||||||||||||||
| At December 31, 2013 and 2012, we excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from our calculation of earnings per share, as their effect would have been anti-dilutive. | ||||||||||||||||||||||||||
| December 31, | ||||||||||||||||||||||||||
| 2013 | 2012 | |||||||||||||||||||||||||
| Convertible Notes | 550,977 | 607,873 | ||||||||||||||||||||||||
| Warrants | 853,937 | 931,472 | ||||||||||||||||||||||||
| Stock Options | 568,950 | 460,700 | ||||||||||||||||||||||||
| Total | 1,973,863 | 2,000,045 | ||||||||||||||||||||||||
| Stock-Based Compensation | ||||||||||||||||||||||||||
| We periodically issue stock options and warrants to officers, directors and consultants for services rendered under our 2010 Stock Incentive Plan. We also assumed stock options in connection with the reverse merger consummated on May 13, 2010 which are not issued under any stockholder approved option plan. Options vest and expire according to terms established at the grant date. We account for share-based payments to officers and directors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense in our financial statements over the vesting period of the awards. We account for share-based payments to consultants and non-employees by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached or (b) at the date at which the necessary performance to earn the equity instruments is complete. | ||||||||||||||||||||||||||
| Income Tax, Policy [Policy Text Block] | ' | ' | ||||||||||||||||||||||||
| Current income tax expense is the amount of income taxes expected to be payable for the current year. A deferred income tax asset or liability is established for the expected future consequences of temporary differences in the financial reporting and tax bases of assets and liabilities. We consider future taxable income and ongoing, prudent and feasible tax planning strategies, in assessing the value of its deferred tax assets. If we determine that it is more likely than not that these assets will not be realized, we will reduce the value of these assets to their expected realizable value, thereby decreasing net income. Evaluating the value of these assets is necessarily based on our judgment. If we subsequently determine that the deferred tax assets, which had been written down, would be realized in the future, the value of the deferred tax assets would be increased, thereby increasing net income in the period when that determination was made. | ||||||||||||||||||||||||||
| Earnings Per Share, Policy [Policy Text Block] | ' | ' | ||||||||||||||||||||||||
| Earnings and Loss per Share | Our computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted income (loss) per share reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income (loss) of the Company as if they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted income (loss) per share, the treasury stock method assumes that outstanding options and warrants are exercised and the proceeds are used to purchase common stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options and warrants. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. | |||||||||||||||||||||||||
| The Company’s computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. | Income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted (loss) per common share is the same for periods in which the Company reported an operating loss because all warrants and stock options outstanding are anti-dilutive. | |||||||||||||||||||||||||
| Income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted (loss) per common share is the same for periods in which the company reported an operating loss because all warrants and stock options outstanding are anti-dilutive. | There were no adjustments to net loss required for purposes of computing diluted earnings per share. | |||||||||||||||||||||||||
| A reconciliation of basic and diluted shares for the three months ended June 30, 2014 and 2013 follows: | At December 31, 2013 and 2012, we excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from our calculation of earnings per share, as their effect would have been anti-dilutive. | |||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||
| 2014 | 2013 | |||||||||||||||||||||||||
| Average common shares outstanding-basic | 4,618,409 | 4,003,358 | ||||||||||||||||||||||||
| Effect of dilutive securities- | ||||||||||||||||||||||||||
| Warrants | 516,797 | -- | ||||||||||||||||||||||||
| Employee and director stock options | 21,750 | -- | ||||||||||||||||||||||||
| Average diluted shares | $ | 5,156,956 | $ | 4,003,358 | ||||||||||||||||||||||
| There were no adjustments to net loss required for purposes of computing diluted earnings per share. | ||||||||||||||||||||||||||
| Warrants, options and other potentially dilutive securities that are antidilutive have been excluded from the dilutive calculations when their exercise or conversion price exceeds the average stock market price during the period or the effect would be anti-dilutive when applied to a net loss during the period(s) presented. The following table sets forth the shares excluded from the diluted calculation for the three month periods presented as follows: | ||||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||
| 2014 | 2013 | |||||||||||||||||||||||||
| Senior secured Convertible notes | 1,236,212 | 550,977 | ||||||||||||||||||||||||
| Warrants | 711,455 | 835,544 | ||||||||||||||||||||||||
| Employee and director stock options | 527,200 | 520,950 | ||||||||||||||||||||||||
| Total potentially dilutive shares | 2,474,867 | 1,907,471 | ||||||||||||||||||||||||
| Such securities could potentially dilute earnings per share in the future. | ||||||||||||||||||||||||||
| Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] | ' | ' | ||||||||||||||||||||||||
| We periodically issue stock options and warrants to officers, directors and consultants for services rendered under our 2010 Stock Incentive Plan. We also assumed stock options in connection with the reverse merger consummated on May 13, 2010 which are not issued under any stockholder approved option plan. Options vest and expire according to terms established at the grant date. We account for share-based payments to officers and directors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense in our financial statements over the vesting period of the awards. We account for share-based payments to consultants and non-employees by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached or (b) at the date at which the necessary performance to earn the equity instruments is complete. Certain share based awards may contain milestones that need to be achieved before the option begins vesting. Management estimates the probability of achievement of such milestones at each reporting date in calculating the estimate of the share-based cost. | ||||||||||||||||||||||||||
| The fair value of the Company's common stock option grants is estimated using the Black-Scholes-Merton option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton option pricing model, and based on actual experience. The assumptions used in the Black-Scholes-Merton option pricing model could materially affect compensation expense recorded in future periods. | ||||||||||||||||||||||||||
| Derivatives, Policy [Policy Text Block] | ' | ' | ||||||||||||||||||||||||
| Derivative Financial Instruments | We evaluate all of our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, we use a weighted-average Black-Scholes-Merton option pricing model which approximates a Monte Carlo model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. | |||||||||||||||||||||||||
| The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a probability based weighted-average Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. | ||||||||||||||||||||||||||
| The Company has derivative liabilities relating to conversion price adjustments on convertible notes and warrants issued in February 2014. Accordingly, the Company has calculated the value of the derivative liabilities as of the date of issuance of the notes and warrants and has revalued them as of the period ending June 30, 2014. | ||||||||||||||||||||||||||
| Revenue Recognition, Policy [Policy Text Block] | ' | ' | ||||||||||||||||||||||||
| As of December 31, 2013, we have not generated any revenues from the development of our intellectual property (“IP”) and are therefore still considered a development stage company. | ||||||||||||||||||||||||||
| Fair Value Measurement, Policy [Policy Text Block] | ' | ' | ||||||||||||||||||||||||
| Fair Value of Financial Instruments | Effective January 1, 2008, fair value measurements are determined by our adoption of authoritative guidance issued by the FASB, with the exception of the application of the statement to non-recurring, non-financial assets and liabilities as permitted. The adoption of the authoritative guidance did not have a material impact on our fair value measurements. Fair value is defined in the authoritative guidance as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows: | |||||||||||||||||||||||||
| Effective January 1, 2008, fair value measurements are determined by the Company’s adoption of authoritative guidance issued by the Financial Accounting Standards Board (FASB), with the exception of the application of the statement to non-recurring, non-financial assets and liabilities as permitted. The adoption of the authoritative guidance did not have a material impact on the Company’s fair value measurements. Fair value is defined in the authoritative guidance as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows: | Level 1—Quoted prices in active markets for identical assets or liabilities. | |||||||||||||||||||||||||
| Level 1—Quoted prices in active markets for identical assets or liabilities. | Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly. | |||||||||||||||||||||||||
| Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly. | Level 3—Unobservable inputs based on our assumptions. | |||||||||||||||||||||||||
| Level 3—Unobservable inputs based on the Company’s assumptions. | We are required to use observable market data if such data is available without undue cost and effort. | |||||||||||||||||||||||||
| The Company is required to use observable market data if such data is available without undue cost and effort. | At December 31, 2013 and December 31, 2012, the fair values of cash and cash equivalents, and accounts payable approximate their carrying values. | |||||||||||||||||||||||||
| The following table presents certain liabilities of the Company measured and recorded at fair value on the Company’s condensed consolidated balance sheets on a recurring basis and their level within the fair value hierarchy as of June 30, 2014. | ||||||||||||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||||||
| Fair Value of Derivative Liability | $ | -- | $ | 2,348,484 | $ | -- | $ | 2,348,484 | ||||||||||||||||||
| There was no corresponding derivative liability as of December 31, 2013. | ||||||||||||||||||||||||||
| At June 30, 2014 and December 31, 2013, the fair values of cash and cash equivalents, and accounts payable approximate their carrying values. | ||||||||||||||||||||||||||
| New Accounting Pronouncements, Policy [Policy Text Block] | ' | ' | ||||||||||||||||||||||||
| Recently Issued Accounting Standards | In January 2013, the FASB issued Accounting Standard Update (“ASU”) 2013-01, Balance Sheet (Topic 210): Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. This ASU clarifies which instruments and transactions are subject to the offsetting disclosure requirements established by ASU 2011-11. This guidance is effective for annual and interim reporting periods beginning January 1, 2013. The Company does not believe the adoption of this update will have a material effect on its financial position and results of operations. | |||||||||||||||||||||||||
| As discussed in Note 1, on June 10, 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. ASU 2014-10 eliminates the requirement to present inception-to-date information about income statement line items, cash flows, and equity transactions, and clarifies how entities should disclose the risks and uncertainties related to their activities. ASU 2014-10 also eliminates an exception provided to development stage entities in Consolidations (ASC Topic 810) for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The presentation and disclosure requirements in Topic 915 are no longer required for interim and annual reporting periods beginning after December 15, 2014. The revised consolidation standards will take effect in annual periods beginning after December 15, 2015, however, early adoption is permitted. The Company adopted the provisions of ASU 2014-10 for this quarterly report on Form 10-Q for the period ended June 30, 2014 | On March 4, 2013, the FASB issued ASU 2013-05, “Foreign Currency Matters (Topic 830): Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity” (“ASU 2013-05”). ASU 2013-05 updates accounting guidance related to the application of consolidation guidance and foreign currency matters. This guidance resolves the diversity in practice about what guidance applies to the release of the cumulative translation adjustment into net income. This guidance is effective for interim and annual periods beginning after December 15, 2013. The Company does not believe the adoption of this update will have a material effect on its financial position and results of operations. | |||||||||||||||||||||||||
| In April 2014, the FASB issued ASU 2014-08, "Presentation of Financial Statements (Topic 205) and Property, Plant and Equipment (Topic 360)." ASU 2014-08 amends the requirements for reporting discontinued operations and requires additional disclosures about discontinued operations. Under the new guidance, only disposals representing a strategic shift in operations or that have a major effect on the Company's operations and financial results should be presented as discontinued operations. This new accounting guidance is effective for annual periods beginning after December 15, 2014. The Company is currently evaluating the impact of adopting ASU 2014-08 on the Company's results of operations or financial condition. | In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Loss, or a Tax Credit Carryforward Exists. Topic 740, Income Taxes, does not include explicit guidance on the financial statement presented of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. There is diversity in practice in the presentation of unrecognized tax benefits in those instances and the amendments in this update are intended to eliminate that diversity in practice. The amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Early adoption is permitted. The Company does not believe the adoption of this update will have a material effect on its financial position and results of operations. | |||||||||||||||||||||||||
| On May 28, 2014, the FASB issued ASU 2014-09 , “Revenue from Contracts with Customers”. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for reporting periods beginning after December 15, 2016, and early adoption is not permitted. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. Management has not yet determined the effect of adopting ASU 2014-09 on our ongoing financial reporting. | Other accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements. | |||||||||||||||||||||||||
| Other recent accounting pronouncements did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements. | ||||||||||||||||||||||||||
| Reclassification, Policy [Policy Text Block] | ' | ' | ||||||||||||||||||||||||
| Reclassifications | ||||||||||||||||||||||||||
| The condensed consolidated financial statements include a reclassification of consulting fees in prior periods to properly compare to current period presentation. Such reclassification did not change the reported net loss during that period. | ||||||||||||||||||||||||||
| In presenting the Company’s statement of operations for the three and six month periods ended June 30, 2013, the Company reclassified consulting fees of $140,076 and $251,911, respectively, that were previously reflected as operating expenses to research and development expenses. | ||||||||||||||||||||||||||
Note_2_Basis_of_Presentation_a1
| Note 2 - Basis of Presentation and Summary of Significant Accounting Policies (Tables) | 6 Months Ended | 12 Months Ended | ||||||||||||||||||||||||
| Jun. 30, 2014 | Dec. 31, 2013 | |||||||||||||||||||||||||
| Accounting Policies [Abstract] | ' | ' | ||||||||||||||||||||||||
| Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | ' | ' | ||||||||||||||||||||||||
| June 30, | June 30, | December 31, | ||||||||||||||||||||||||
| 2014 | 2013 | 2013 | 2012 | |||||||||||||||||||||||
| Convertible Notes | 550,977 | 607,873 | ||||||||||||||||||||||||
| Warrants | 853,937 | 931,472 | ||||||||||||||||||||||||
| Senior secured Convertible notes | 1,236,212 | 550,977 | Stock Options | 568,950 | 460,700 | |||||||||||||||||||||
| Warrants | 711,455 | 835,544 | Total | 1,973,863 | 2,000,045 | |||||||||||||||||||||
| Employee and director stock options | 527,200 | 520,950 | ||||||||||||||||||||||||
| Total potentially dilutive shares | 2,474,867 | 1,907,471 | ||||||||||||||||||||||||
| Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | ' | ' | ||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||
| 2014 | 2013 | |||||||||||||||||||||||||
| Average common shares outstanding-basic | 4,618,409 | 4,003,358 | ||||||||||||||||||||||||
| Effect of dilutive securities- | ||||||||||||||||||||||||||
| Warrants | 516,797 | -- | ||||||||||||||||||||||||
| Employee and director stock options | 21,750 | -- | ||||||||||||||||||||||||
| Average diluted shares | $ | 5,156,956 | $ | 4,003,358 | ||||||||||||||||||||||
| Schedule of Derivative Liabilities at Fair Value [Table Text Block] | ' | ' | ||||||||||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||||||
| Fair Value of Derivative Liability | $ | -- | $ | 2,348,484 | $ | -- | $ | 2,348,484 | ||||||||||||||||||
Note_3_25_Senior_Secured_Conve1
| Note 3 - 2.5% Senior Secured Convertible Notes Payable (Tables) | 6 Months Ended | 12 Months Ended | ||||||||||||||||
| Jun. 30, 2014 | Dec. 31, 2013 | |||||||||||||||||
| Debt Disclosure [Abstract] | ' | ' | ||||||||||||||||
| Schedule of Debt [Table Text Block] | ' | ' | ||||||||||||||||
| June 30, | December 31, | December 31, | December 31, | |||||||||||||||
| 2014 | 2013 | 2013 | 2012 | |||||||||||||||
| a. 2010 2.5% Convertible Notes | $ | 427,500 | $ | 427,500 | 2010 Convertible Notes | $ | 427,500 | $ | 427,500 | |||||||||
| b. 2012 2.5% Convertible Notes | 753,667 | 1,170,333 | 2012 Convertible Notes | 1,170,333 | 1,335,333 | |||||||||||||
| c. 2014 6% Convertible Notes | 1,906,500 | -- | $ | 1,597,833 | $ | 1,762,833 | ||||||||||||
| 3,087,667 | 1,597,833 | Less Valuation Discount | (844,577 | ) | (1,402,030 | ) | ||||||||||||
| Less Valuation Discount | (2,080,795 | ) | (844,577 | ) | ||||||||||||||
| 1,006,872 | 753,256 | Convertible Notes Payable, net | $ | 753,256 | $ | 360,803 | ||||||||||||
| Less Current Portion | (427,500 | ) | (390,123 | ) | ||||||||||||||
| Convertible Notes Payable, net | $ | 579,372 | $ | 363,133 | ||||||||||||||
Note_6_Committments_Tables
| Note 6 - Committments (Tables) | 12 Months Ended | ||||||||||||||||||||||||
| Dec. 31, 2013 | |||||||||||||||||||||||||
| Commitments and Contingencies Disclosure [Abstract] | ' | ||||||||||||||||||||||||
| Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block] | ' | ||||||||||||||||||||||||
| 2014 | 2015 | 2016 | 2017 | 2018 | Thereafter | ||||||||||||||||||||
| Minimum future payments | $ | 44,873 | $ | 46,030 | $ | 47,189 | $ | 48,346 | $ | 12,159 | -- | ||||||||||||||
Note_7_Stockholders_Equity_Def1
| Note 7 - Stockholders' Equity (Deficit) (Tables) | 6 Months Ended | 12 Months Ended | |||||||||||||||||||||||||||||||||||||
| Jun. 30, 2014 | Dec. 31, 2013 | ||||||||||||||||||||||||||||||||||||||
| Stockholders' Equity Note [Abstract] | ' | ' | |||||||||||||||||||||||||||||||||||||
| Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] | ' | ' | |||||||||||||||||||||||||||||||||||||
| Number of | Number of securities | ||||||||||||||||||||||||||||||||||||||
| securities to be | remaining available for | ||||||||||||||||||||||||||||||||||||||
| issued upon | Weighted-average | future issuance under | |||||||||||||||||||||||||||||||||||||
| exercise of | exercise price of | equity compensation | |||||||||||||||||||||||||||||||||||||
| outstanding | outstanding | plans (excluding | |||||||||||||||||||||||||||||||||||||
| options, | options, | securities reflected in | |||||||||||||||||||||||||||||||||||||
| and rights | and rights | column (a) | |||||||||||||||||||||||||||||||||||||
| Plan Category | (a) | (b) | (c) | ||||||||||||||||||||||||||||||||||||
| Equity compensation plans approved by stockholders | 434,000 | $ | 9.7 | 302,296 | |||||||||||||||||||||||||||||||||||
| Equity compensation plans approved by the Board of Directors | 134,950 | 3.9 | -- | ||||||||||||||||||||||||||||||||||||
| Total | 568,950 | $ | 8.3 | 302,296 | |||||||||||||||||||||||||||||||||||
| Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | ' | ' | |||||||||||||||||||||||||||||||||||||
| Shares | Weighted | Weighted | Aggregate | Shares | Weighted | Weighted | Aggregate | ||||||||||||||||||||||||||||||||
| average | Average | Intrinsic Value | average | Average | Intrinsic Value | ||||||||||||||||||||||||||||||||||
| exercise | Remaining | exercise | Remaining | ||||||||||||||||||||||||||||||||||||
| price | Contractual | price | Contractual | ||||||||||||||||||||||||||||||||||||
| Term (years) | Term (years) | ||||||||||||||||||||||||||||||||||||||
| Outstanding at December 31, 2013 | 568,950 | $ | 8.32 | 4.849 | $ | 86,271 | Outstanding at December 31, 2011 | 451,950 | $ | 11.29 | 6.163 | $ | 1,140,059 | ||||||||||||||||||||||||||
| Granted | 10,000 | 3.8 | 7 | -- | Granted | 10,000 | $ | 10 | 6.5 | -- | |||||||||||||||||||||||||||||
| Exercised | -- | -- | -- | -- | Exercised | -- | -- | -- | -- | ||||||||||||||||||||||||||||||
| Cancelled | (30,000 | ) | (5.000 | ) | -- | -- | Cancelled | (1,250 | ) | $ | 11.1 | -- | -- | ||||||||||||||||||||||||||
| Outstanding at June 30, 2014 | 548,950 | $ | 8.423 | 4.321 | $ | 0 | Outstanding at December 31, 2012 | 460,700 | $ | 9.87 | 5.189 | $ | 119,241 | ||||||||||||||||||||||||||
| Exercisable at June 30, 2014 | 390,105 | $ | 9.042 | 3.809 | $ | 0 | Granted | 208,250 | $ | 5.74 | 6.376 | -- | |||||||||||||||||||||||||||
| Exercised | -- | -- | -- | -- | |||||||||||||||||||||||||||||||||||
| Cancelled | (100,000 | ) | $ | 10.1 | -- | -- | |||||||||||||||||||||||||||||||||
| Outstanding at December 31, 2013 | 568,950 | $ | 8.32 | 4.849 | $ | 86,271 | |||||||||||||||||||||||||||||||||
| Exercisable at December 31, 2013 | 305,471 | $ | 9.52 | 3.942 | $ | 84,475 | |||||||||||||||||||||||||||||||||
| Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] | ' | ' | |||||||||||||||||||||||||||||||||||||
| Outstanding | Vested and Exercisable Weighted-Average | ||||||||||||||||||||||||||||||||||||||
| Price per share | Shares | Weighted- | Weighted- | Shares | Weighted- | Weighted- | |||||||||||||||||||||||||||||||||
| Average Price | Average | Average Price | Average | ||||||||||||||||||||||||||||||||||||
| per Share | Remaining | per Share | Remaining | ||||||||||||||||||||||||||||||||||||
| Contractual | Contractual | ||||||||||||||||||||||||||||||||||||||
| Life | Life | ||||||||||||||||||||||||||||||||||||||
| (in years) | (in years) | ||||||||||||||||||||||||||||||||||||||
| $2.23 – $6.90 | 263,200 | $ | 5.01 | 5.69 | 61,243 | $ | 2.57 | 3.48 | |||||||||||||||||||||||||||||||
| $7.00 – $12.50 | 279,750 | $ | 10.62 | 4.08 | 228,979 | $ | 10.64 | 4.05 | |||||||||||||||||||||||||||||||
| $13.00 – $23.80 | 26,000 | $ | 17.23 | 4.57 | 17,999 | $ | 19.5 | 4.37 | |||||||||||||||||||||||||||||||
| 568,950 | 308,221 | ||||||||||||||||||||||||||||||||||||||
| Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | ' | ' | |||||||||||||||||||||||||||||||||||||
| Three months ended June 30, | Six months ended June 30, | Year ended December 31, | |||||||||||||||||||||||||||||||||||||
| 2014 | 2013 | 2014 | 2013 | 2013 | 2012 | ||||||||||||||||||||||||||||||||||
| Expected volatility | 198% | 218 | % | 198%- 201 | % | 113%-226 | % | Expected volatility | 113-226 | % | 111-134 | % | |||||||||||||||||||||||||||
| Dividend yield | -- | -- | -- | -- | Dividend yield | -- | -- | ||||||||||||||||||||||||||||||||
| Expected term (in years) | 6.25 | 6.25 | 6.25 | 6.25 | Expected term (in years) | 5.50-6.25 | 1.75-6.25 | ||||||||||||||||||||||||||||||||
| Risk-free interest rate | 2.73 | % | 2.05 | % | 2.73 | % | 1.38-2.05 | % | Risk-free interest rate | 1.38-2.09 | % | 1.19-1.41 | % | ||||||||||||||||||||||||||
| Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | ' | ' | |||||||||||||||||||||||||||||||||||||
| Outstanding | Vested and Exercisable Weighted-Average | ||||||||||||||||||||||||||||||||||||||
| Price per share | Shares | Weighted- | Weighted- | Shares | Weighted- | Weighted- | |||||||||||||||||||||||||||||||||
| Average Price | Average | Average Price | Average | ||||||||||||||||||||||||||||||||||||
| per Share | Remaining | per Share | Remaining | ||||||||||||||||||||||||||||||||||||
| Contractual | Contractual | ||||||||||||||||||||||||||||||||||||||
| Life | Life | ||||||||||||||||||||||||||||||||||||||
| (in years) | (in years) | ||||||||||||||||||||||||||||||||||||||
| $ | 2.23 | 213,071 | $ | 2.23 | 1.2 | 213,071 | $ | 2.23 | 1.2 | ||||||||||||||||||||||||||||||
| $ | 3.93 | 190,880 | $ | 3.9393 | 0.42 | 190,880 | $ | 3.93 | 0.42 | ||||||||||||||||||||||||||||||
| $ | 5 | 7,100 | $ | 5 | 1.48 | 7,100 | $ | 5 | 1.48 | ||||||||||||||||||||||||||||||
| $ | 5.75 | 14,000 | $ | 5.75 | 3.83 | 14,000 | $ | 5.75 | 3.83 | ||||||||||||||||||||||||||||||
| $ | 6 | 92,386 | $ | 6 | 0.6 | 92,386 | $ | 6 | 0.6 | ||||||||||||||||||||||||||||||
| $ | 6.25 | 292,500 | $ | 6.25 | 2.75 | 292,500 | $ | 6.25 | 2.75 | ||||||||||||||||||||||||||||||
| $ | 7.5 | 24,001 | $ | 7.5 | 9.67 | 24,001 | $ | 7.5 | 9.67 | ||||||||||||||||||||||||||||||
| $ | 16.4 | 20,000 | $ | 16.4 | 2 | 20,000 | $ | 16.4 | 2 | ||||||||||||||||||||||||||||||
| 853,937 | 853,937 | ||||||||||||||||||||||||||||||||||||||
| Schedule of Share-based Compensation, Activity [Table Text Block] | ' | ' | |||||||||||||||||||||||||||||||||||||
| Shares | Weighted | Weighted | Aggregate | Shares | |||||||||||||||||||||||||||||||||||
| average | Average | Intrinsic Value | Balance at December 31, 2011 (at $2.23-$16.40) | 624,972 | |||||||||||||||||||||||||||||||||||
| exercise | Remaining | Granted (at $0.575 - $0.625) | 306,500 | ||||||||||||||||||||||||||||||||||||
| price | Contractual | Exercised | -- | ||||||||||||||||||||||||||||||||||||
| Term (years) | Balance at December 31, 2012 (at $2.23 - $16.40) | 931,472 | |||||||||||||||||||||||||||||||||||||
| Outstanding at December 31, 2013 | 853,946 | $ | 3.77 | 2.665 | $ | 783,258 | Granted (at $5.00 - $7.50) | 29,001 | |||||||||||||||||||||||||||||||
| Granted | 454,457 | 2.3 | 9.667 | -- | Exercised | (85,923 | ) | ||||||||||||||||||||||||||||||||
| Exercised | -- | -- | -- | -- | Cancelled | (20,612 | ) | ||||||||||||||||||||||||||||||||
| Cancelled | (80,139 | ) | (5.973 | ) | -- | -- | Ending balance at December 31, 2013 (at $2.23 - $16.40) | 853,937 | |||||||||||||||||||||||||||||||
| Outstanding at June 30, 2014 | 1,228,264 | $ | 3.987 | 7.039 | $ | 0 | |||||||||||||||||||||||||||||||||
| Exercisable at June 30, 2014 | 1,228,264 | $ | 3.987 | 7.039 | $ | 0 | |||||||||||||||||||||||||||||||||
Note_8_Income_Taxes_Tables
| Note 8 - Income Taxes (Tables) | 12 Months Ended | ||||||||
| Dec. 31, 2013 | |||||||||
| Income Tax Disclosure [Abstract] | ' | ||||||||
| Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | ' | ||||||||
| 2013 | 2012 | ||||||||
| Current Tax Provision: | |||||||||
| Federal | $ | -- | $ | -- | |||||
| State | 1,365 | 1,365 | |||||||
| Total current tax provision | $ | 1,365 | $ | 1,365 | |||||
| Deferred Tax Provision: | |||||||||
| Federal and state | |||||||||
| Loss carryforwards | $ | (2,360,000 | ) | $ | (933,000 | ) | |||
| Valuation allowance | 2,360,000 | 933,000 | |||||||
| Total deferred tax provision | $ | -- | $ | -- | |||||
| Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | ' | ||||||||
| 2013 | 2012 | ||||||||
| Loss carryforwards | $ | (4,261,000 | ) | $ | (1,901,000 | ) | |||
| Less – valuation allowance | 4,261,000 | 1,901,000 | |||||||
| Total net deferred tax assets | $ | -- | $ | -- | |||||
Note_9_Derivative_Liability_Ta
| Note 9 - Derivative Liability (Tables) | 6 Months Ended | 12 Months Ended | ||||||||||||||
| Jun. 30, 2014 | Dec. 31, 2013 | |||||||||||||||
| Derivative Instruments and Hedging Activities Disclosure [Abstract] | ' | ' | ||||||||||||||
| Schedule of Derivative Instruments [Table Text Block] | ' | ' | ||||||||||||||
| June 30, | February 12, | 15-Jun-12 | ||||||||||||||
| 2014 | 2014 (Issuance) | (Note & | ||||||||||||||
| (Unaudited) | (Unaudited) | Warrant | ||||||||||||||
| Conversion Feature : | Amendment | |||||||||||||||
| Risk-free interest rate | 0.88 | % | 0.74 | % | and | |||||||||||
| Expected volatility | 198 | % | 211 | % | Restatement | |||||||||||
| Expected life (in years) | 2.63 | 3 | Date) | |||||||||||||
| Expected dividend yield | 0 | % | 0 | % | Conversion feature : | |||||||||||
| Risk-free interest rate | 0.29% | |||||||||||||||
| Warrants : | Expected volatility | 111% | ||||||||||||||
| Risk-free interest rate | 2.53 | % | 2.8 | % | Expected life (in years) | 1.87 | ||||||||||
| Expected volatility | 198 | % | 211 | % | Expected dividend yield | 0.00% | ||||||||||
| Expected weighted average life (in years) | 9.58 | 10 | ||||||||||||||
| Expected dividend yield | 0 | % | 0 | % | Warrants : | |||||||||||
| Risk-free interest rate | 0.29% | |||||||||||||||
| Fair Value : | Expected volatility | 111% | ||||||||||||||
| Conversion feature | $ | 1,508,202 | $ | 2,951,785 | Expected weighted average life (in years) | 1.87 | ||||||||||
| Warrants | 840,282 | 1,635,781 | Expected dividend yield | 0.00% | ||||||||||||
| $ | 2,348,484 | $ | 4,587,566 | |||||||||||||
| Fair Value : | ||||||||||||||||
| Conversion feature | $ | 2,295,881 | ||||||||||||||
| Warrants | 1,176,668 | |||||||||||||||
| $ | 3,472,549 | |||||||||||||||
Note_1_Organization_Details
| Note 1 - Organization (Details) (USD $) | 1 Months Ended | 6 Months Ended | 12 Months Ended | 85 Months Ended | 1 Months Ended | 0 Months Ended | |||||||||||||||||||
| Jun. 23, 2010 | Jun. 30, 2014 | Dec. 31, 2012 | Dec. 31, 2013 | 21-May-10 | 21-May-10 | 21-May-10 | 21-May-10 | 31-May-10 | 31-May-10 | Jun. 23, 2010 | Jun. 23, 2010 | Jun. 23, 2010 | 21-May-10 | Jun. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | Dec. 31, 2009 | Dec. 31, 2008 | Dec. 31, 2007 | Apr. 22, 2014 | 13-May-10 | Apr. 22, 2014 | |
| Super-Voting Common Stock [Member] | Combined Super Voting Common Stock And Common Stock [Member] | Blank Check Preferred Stock [Member] | Super Voting Common Stock Exchanged For The Issued And Oustanding Shares Of Common Stock Of Athero Nova Operations [Member] | Outstanding Options And Warrants Assumed In Connection With The Merger [Member] | Common Stock Issued To Former Holders Upon Automatic Conversion Of Super Voting Common Stock [Member] | Number Of Shares Held By Existing Stockholders After Reverse Split [Member] | Number Of Shares Held By Existing Stockholders After Reverse Split Adjusted For Rounding [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Subsequent Event [Member] | 2.5% Senior Secured Convertible Notes ("Original Notes") [Member] | Reverse Stock Split [Member] | ||||||
| Percentage Held By Holders Approving Amendment To Certificate Of Incorporation [Member] | Percentage Held By Holders Approving Amendment To Certificate Of Incorporation [Member] | Percentage Held By Holders Approving Amendment To Certificate Of Incorporation [Member] | Reverse Stock Split [Member] | ||||||||||||||||||||||
| Note 1 - Organization (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Proceeds from Convertible Debt (in Dollars) | ' | $1,906,500 | $1,498,333 | $2,893,339 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $1,500,000 | ' |
| Debt Instrument, Interest Rate, Effective Percentage | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2.50% | ' |
| Percentage Of Oustanding Stock Held | ' | ' | ' | ' | ' | 98.00% | 77.10% | ' | ' | ' | ' | ' | ' | 90.70% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Common Stock, Par or Stated Value Per Share (in Dollars per share) | ' | $0.00 | $0.00 | $0.00 | $0.77 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Common Stock, Shares Authorized | ' | 100,000,000 | 100,000,000 | 100,000,000 | 100,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Preferred Stock, Shares Authorized | ' | 10,000,000 | 10,000,000 | 10,000,000 | ' | ' | ' | 10,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Stockholders' Equity Note, Stock Split, Conversion Ratio | 200 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10 | ' | 10 |
| Common Stock, Shares, Issued | 10,727,273 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,214,376 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Common Stock, Shares, Outstanding | 10,727,273 | 4,770,207 | 3,722,364 | 4,158,402 | ' | ' | ' | ' | ' | ' | ' | 60,765 | 9,017 | ' | 4,770,207 | 4,158,402 | 3,722,363 | 2,839,025 | 2,342,089 | 2,069,210 | 2,024,316 | 1,923,303 | ' | ' | ' |
| Sale of Stock, Number of Shares Issued in Transaction | ' | ' | ' | ' | ' | ' | ' | ' | 88,575,048 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights | ' | ' | 224,000 | 24,001 | ' | ' | ' | ' | ' | 16,552,227 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Convertible Preferred Stock, Shares Issued upon Conversion | 50 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Note_2_Basis_of_Presentation_a2
| Note 2 - Basis of Presentation and Summary of Significant Accounting Policies (Details) (USD $) | 3 Months Ended | 6 Months Ended | 12 Months Ended | 85 Months Ended | 12 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||||||
| Jun. 30, 2014 | Jun. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | Dec. 31, 2009 | Dec. 31, 2008 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Feb. 28, 2014 | Feb. 12, 2014 | Jun. 30, 2014 | Feb. 28, 2014 | Feb. 12, 2014 | Jun. 30, 2014 | Jun. 30, 2014 | Dec. 31, 2013 | |
| Common Stock Unit [Member] | Common Stock Unit [Member] | Subsequent Event [Member] | Subsequent Event [Member] | 6% Secured Convertible Notes [Member] | 6% Secured Convertible Notes [Member] | 6% Secured Convertible Notes [Member] | Reclassification of Consulting Fees to R&D Expenses [Member] | Reclassification of Consulting Fees to R&D Expenses [Member] | CardioNova [Member] | ||||||||||||
| Senior Secured 6% Notes [Member] | Senior Secured 6% Notes [Member] | ||||||||||||||||||||
| Note 2 - Basis of Presentation and Summary of Significant Accounting Policies (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Development Stage Enterprise, Deficit Accumulated During Development Stage | $27,632,441 | ' | $27,632,441 | ' | $22,029,794 | $14,215,072 | ' | ' | ' | ' | $22,029,794 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Retained Earnings (Accumulated Deficit) | ' | ' | ' | ' | -2,503,004 | ' | ' | ' | ' | ' | -2,503,004 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Net Cash Provided by (Used in) Operating Activities | ' | ' | -1,850,790 | -1,835,426 | -3,261,824 | -2,054,428 | ' | ' | ' | ' | -8,233,167 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Proceeds from Warrant Exercises | ' | ' | ' | ' | 150,047 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Proceeds from Issuance of Common Stock | ' | ' | ' | 267,047 | 787,048 | 2,061,787 | ' | ' | ' | ' | 5,366,503 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 117,000 |
| Proceeds from Issuance or Sale of Equity | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 520,001 | 2,061,787 | ' | ' | ' | ' | ' | ' | ' | ' |
| Debt Instrument, Face Amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,906,500 | 1,906,500 | ' | 1,906,500 | 1,906,500 | ' | ' | ' |
| Interest rate on senior secured convertible notes | 2.50% | ' | 2.50% | ' | 2.50% | 2.50% | ' | ' | ' | ' | 2.50% | ' | ' | 6.00% | 6.00% | 6.00% | 6.00% | 6.00% | ' | ' | ' |
| Research and Development Expense, Total | ' | ' | ' | ' | 4,399,294 | 986,261 | ' | ' | ' | ' | 6,258,630 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Common Stock, Capital Shares Reserved for Future Issuance (in Shares) | 83,824 | ' | 83,824 | ' | 3,000,000 | ' | ' | ' | ' | ' | 3,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| 155,074 | ' | 155,074 | ' | 1,170,712 | ' | ' | ' | ' | ' | 1,170,712 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Net Income (Loss) Attributable to Parent | 530,664 | -2,565,927 | -5,602,647 | -4,189,827 | -7,814,722 | -2,635,561 | 4,263,286 | -15,656,852 | -12,322 | -173,623 | -22,029,794 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Stockholders' Equity Attributable to Parent | -4,678,829 | ' | -4,678,829 | ' | -2,503,004 | 1,792,511 | -6,183,865 | -13,909,120 | 189,055 | 51,377 | -2,503,004 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Common Stock, Capital Shares, Reserved for Future Issuance, Fair Value | 155,074 | ' | 155,074 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Prior Period Reclassification Adjustment | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $140,076 | $251,911 | ' |
Note_2_Basis_of_Presentation_a3
| Note 2 - Basis of Presentation and Summary of Significant Accounting Policies (Details) - Antidilutive Securities Excluded From The Dilutive Calculations | 3 Months Ended | 12 Months Ended | ||
| Jun. 30, 2014 | Jun. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | |
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' | ' | ' |
| Antidilutive Securities Excluded from Dilutive Calculations | 2,474,867 | 1,907,471 | 1,973,863 | 2,000,045 |
| Convertible Debt Securities [Member] | ' | ' | ' | ' |
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' | ' | ' |
| Antidilutive Securities Excluded from Dilutive Calculations | 1,236,212 | 550,977 | 550,977 | 607,873 |
| Warrant [Member] | ' | ' | ' | ' |
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' | ' | ' |
| Antidilutive Securities Excluded from Dilutive Calculations | 711,455 | 835,544 | 853,937 | 931,472 |
| Equity Option [Member] | ' | ' | ' | ' |
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' | ' | ' |
| Antidilutive Securities Excluded from Dilutive Calculations | 527,200 | 520,950 | 568,950 | 460,700 |
Note_3_25_Senior_Secured_Conve2
| Note 3 - 2.5% Senior Secured Convertible Notes Payable (Details) (USD $) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | 85 Months Ended | 6 Months Ended | 12 Months Ended | 6 Months Ended | 12 Months Ended | 12 Months Ended | 6 Months Ended | 12 Months Ended | 0 Months Ended | 1 Months Ended | 0 Months Ended | 6 Months Ended | 12 Months Ended | 1 Months Ended | 6 Months Ended | 12 Months Ended | 12 Months Ended | 6 Months Ended | 6 Months Ended | 0 Months Ended | 1 Months Ended | 6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||
| Feb. 12, 2014 | Dec. 31, 2013 | Apr. 29, 2013 | Jun. 30, 2014 | Jun. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2013 | Jun. 30, 2012 | 13-May-10 | Jun. 30, 2014 | Jun. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Jun. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Jun. 30, 2014 | Dec. 31, 2012 | Feb. 12, 2014 | 13-May-10 | Feb. 12, 2014 | 13-May-10 | Feb. 12, 2014 | Dec. 31, 2012 | Dec. 31, 2012 | Jun. 30, 2014 | Dec. 31, 2012 | Dec. 31, 2012 | Dec. 31, 2013 | 13-May-10 | Feb. 12, 2014 | Aug. 31, 2013 | Oct. 31, 2012 | Oct. 31, 2012 | Dec. 31, 2012 | Dec. 31, 2012 | 13-May-10 | Jun. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Jul. 06, 2011 | Sep. 30, 2012 | Jun. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Jul. 23, 2012 | Jun. 15, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Jul. 06, 2011 | Jun. 30, 2014 | Jun. 15, 2012 | Jun. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Jun. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Feb. 12, 2014 | Feb. 12, 2014 | Jun. 30, 2014 | Feb. 28, 2014 | Dec. 31, 2013 | Dec. 31, 2013 | |
| Europa International Inc. [Member] | Europa International Inc. [Member] | Europa International Inc. [Member] | Europa International Inc. [Member] | Issued to Settle Accured Interest [Member] | Issued to Settle Accured Interest [Member] | Issued to Settle Accured Interest [Member] | Common Stock Issued To Settle Principal [Member] | Common Stock Issued To Settle Principal [Member] | Conversion Feature [Member] | Conversion Feature [Member] | Warrant [Member] | Warrant [Member] | Warrants Modified [Member] | Common Stock Issued To Settle Principal [Member] | Common Stock Issued To Settle Accrued Interest [Member] | Issuance Of Common Shares For Debt Conversion [Member] | Issuance Of Common Shares For Debt Conversion [Member] | Issuance Of Common Shares For Debt Conversion [Member] | Warrants Issued In Conjunction With Issuance Of 2010 Convertible Notes [Member] | Warrants Issued In Conjunction With Issuance Of 2010 Convertible Notes [Member] | Several Participants Who Participated in the 2014 Offering [Member] | Private Placements [Member] | Tranche 2 [Member] | Tranche 3 [Member] | Market Price On Date of Issuance [Member] | Market Price On Date of Issuance [Member] | 2.5% Senior Secured Convertible Notes ("Original Notes") [Member] | 2.5% Senior Secured Convertible Notes ("Original Notes") [Member] | 2.5% Senior Secured Convertible Notes ("Original Notes") [Member] | 2.5% Senior Secured Convertible Notes ("Original Notes") [Member] | 2.5% Senior Secured Convertible Notes ("Original Notes") [Member] | Amended And Restated Two Point Five Percent Senior Secured Convertible Notes Amended Notes [Member] | Second Amended Notes Without Warrants [Member] | Second Amended Notes Without Warrants [Member] | Second Amended Notes Without Warrants [Member] | Second Amended Notes Without Warrants [Member] | Second Amended Notes Without Warrants [Member] | Second Amended Notes Without Warrants [Member] | 2.5% Senior Convertible Note [Member] | 2.5% Senior Convertible Note [Member] | 2.5% Senior Convertible Note [Member] | 2.5% Senior Secured Convertible Notes (the "First Amended Notes") [Member] | 2.5% Senior Secured Convertible Notes (the "Second Amended Notes") [Member] | 2.5% Senior Secured Convertible Notes (the "Second Amended Notes") [Member] | 2010 Convertible Notes [Member] | 2010 Convertible Notes [Member] | 2010 Convertible Notes [Member] | 2012 Convertible Notes [Member] | 2012 Convertible Notes [Member] | 2012 Convertible Notes [Member] | 6% Secured Convertible Notes [Member] | 6% Secured Convertible Notes [Member] | 6% Secured Convertible Notes [Member] | 6% Secured Convertible Notes [Member] | Minimum [Member] | Maximum [Member] | ||||||||||||||
| 6% Secured Convertible Notes [Member] | Second Amended Notes Without Warrants [Member] | Second Amended Notes Without Warrants [Member] | Second Amended Notes Without Warrants [Member] | Second Amended Notes Without Warrants [Member] | Second Amended Notes Without Warrants [Member] | 2.5% Senior Convertible Note [Member] | 2.5% Senior Convertible Note [Member] | Second Amended Notes Without Warrants [Member] | Second Amended Notes Without Warrants [Member] | 2.5% Senior Convertible Note [Member] | Second Amended Notes Without Warrants [Member] | Second Amended Notes Without Warrants [Member] | Second Amended Notes Without Warrants [Member] | Second Amended Notes Without Warrants [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Minimum [Member] | Maximum [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Note 3 - 2.5% Senior Secured Convertible Notes Payable (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Interest rate on senior secured convertible notes | ' | 2.50% | ' | 2.50% | ' | 2.50% | ' | 2.50% | 2.50% | ' | 2.50% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2.50% | ' | 2.50% | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2.50% | 2.50% | ' | 2.50% | ' | 2.50% | ' | ' | ' | ' | ' | ' | 6.00% | 6.00% | 6.00% | 6.00% | ' | ' |
| Proceeds from Issuance of Senior Long-term Debt | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $1,500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $1,906,500 | ' | ' | ' | ' |
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | ' | 24,001 | ' | ' | ' | ' | ' | 24,001 | 224,000 | ' | 24,001 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 190,880 | 190,880 | 542,246 | 40,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 414,457 | 414,457 | ' | ' | ' | ' |
| Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Share) | ' | $7.50 | ' | ' | ' | ' | ' | $7.50 | ' | ' | $7.50 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $3.90 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $2.23 | $16.40 |
| Debt Instrument, Term | '3 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '4 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '4 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Debt Instrument, Interest Rate in Event of Default, Stated Percentage | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 12.00% | 12.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 12.00% | ' | ' | ' |
| Debt Instrument Percentage Of Unpaid Note Principal Plus Accrued Interest Owed Upon Default | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 120.00% | 120.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 120.00% | ' | ' | ' |
| Debt Instrument, Convertible, Conversion Price (in Dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $2.90 | ' | ' | ' | ' | ' | ' | $2.90 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $2.90 | ' | ' | ' | $2.90 | $2.90 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $2.30 | $2.30 | ' | ' | ' | ' |
| Potential Proceeds From Issuance Of Convertible Debt | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Premium Over Original Conversion Price If Benchmarks Are Not Attained | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 100.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| ' | 1,597,833 | ' | 3,087,667 | ' | 3,087,667 | ' | 1,597,833 | 1,762,833 | ' | 1,597,833 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 427,500 | ' | ' | ' | ' | 1,170,333 | 1,335,333 | ' | ' | 427,500 | ' | 955,351 | ' | ' | ' | 427,500 | 427,500 | 427,500 | 753,667 | 1,170,333 | 1,335,333 | ' | ' | ' | ' | ' | ' | |
| Debt Conversion, Original Debt, Amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 527,851 | 31,191 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 690,851 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Debt Conversion, Converted Instrument, Shares Issued (in Shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 143,678 | 56,167 | ' | ' | ' | ' | ' | 182,057 | 10,727 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 56,896 | ' | ' | ' | ' | 249,372 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Debt Conversion, Converted Instrument, Amount | ' | ' | ' | ' | ' | 436,315 | 169,765 | 169,765 | 1,448,130 | ' | 2,190,616 | ' | ' | ' | ' | ' | ' | ' | ' | 163,000 | 416,667 | ' | ' | ' | ' | ' | ' | ' | 69,552 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 165,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Interest Expense, Debt | ' | ' | ' | 254,143 | 260,323 | 736,553 | 381,518 | 601,664 | 871,431 | ' | 2,481,178 | ' | ' | ' | ' | ' | ' | 270,439 | 2,462 | 1,210 | 14,994 | ' | ' | ' | ' | ' | ' | ' | ' | 4,653 | 1,505 | 38,372 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 11,759 | 30,914 | 9,605 | ' | ' | 10,836 | 20,098 | ' | ' | ' | ' | 5,373 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Derivative Liability, Fair Value, Gross Liability | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,542,348 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,537,069 | 2,370,245 | 143,997 | 1,172,103 | 564,849 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Debt Instrument, Face Amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,500,000 | ' | ' | ' | ' | ' | ' | ' | 427,500 | ' | ' | 753,667 | 1,170,333 | ' | 1,906,500 | 1,906,500 | ' | 1,906,500 | ' | ' |
| Debt Issuance Cost | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,042,348 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,537,069 | ' | ' | ' | ' | ' |
| Debt Instrument, Unamortized Discount | ' | 844,577 | ' | 2,080,795 | ' | 2,080,795 | ' | 844,577 | 1,402,030 | ' | 844,577 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 37,375 | 144,252 | 559,696 | ' | ' | ' | 807,203 | 1,257,778 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 37,375 | ' | 419,405 | 807,202 | ' | ' | ' | ' | ' | ' | ' |
| Amortization of Debt Discount (Premium) | ' | ' | ' | ' | ' | 670,282 | 357,723 | 557,453 | 769,185 | ' | 2,266,942 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 106,878 | 415,444 | ' | ' | ' | 117,360 | 450,575 | 240,555 | ' | ' | ' | ' | ' | ' | ' | ' | 37,375 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Proceeds from Issuance of Debt | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 498,333 | 500,000 | ' | ' | ' | ' | ' | ' | ' | ' | 500,000 | ' | ' | 1,498,333 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Stock Issued During Period, Shares, Other (in Shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5,171 | 4,794 | 421 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Increase (Decrease) in Interest Payable, Net | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -19,647 | -2,303 | -2,727 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Stock Issued During Period, Value, Other | ' | ' | ' | ' | ' | ' | ' | 4,518 | 23,748 | 72,999 | ' | ' | ' | ' | ' | ' | ' | ' | 4,765 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Share Price (in Dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $7.90 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $5.80 | $8 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Due to Related Parties | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 300,000 | 1,094,167 | 1,094,167 | 1,094,167 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,094,167 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $2.90 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $2.30 | $2.30 | ' | ' | ' | ' |
| Interest Payable | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 44,900 | 31,453 | ' | 33,701 | ' | ' | ' | ' | ' | ' | ' | ' |
| Derivative Liability | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,443,569 | 4,443,569 | ' | ' | ' | ' |
| Extension of Warrants Expiration Term | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '10 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| ' | ' | ' | ' | ' | 3,340,030 | ' | ' | ' | ' | 2,148,307 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 564,849 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,340,030 | ' | ' | ' | ' | ' | |
| Warrants Not Settleable in Cash, Fair Value Disclosure | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 143,997 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Payments for Commissions | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 70,720 | ' | ' | ' | ' | ' |
| Stock Issued During Period, Shares, New Issues (in Shares) | ' | 199,716 | 160,541 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,535 | ' | ' | ' | ' | ' |
| Stock Issued During Period, Value, New Issues | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $23,395 | ' | ' | ' | ' | ' |
Note_3_25_Senior_Secured_Conve3
| Note 3 - 2.5% Senior Secured Convertible Notes Payable (Details) - Senior Secured Convertible Notes Payable (USD $) | Jun. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
| Note 3 - 2.5% Senior Secured Convertible Notes Payable (Details) - Senior Secured Convertible Notes Payable [Line Items] | ' | ' | ' |
| Convertible Notes, gross | $3,087,667 | $1,597,833 | $1,762,833 |
| Less Valuation Discount | -2,080,795 | -844,577 | -1,402,030 |
| Convertible Notes Payable, net | 1,006,872 | 753,256 | 360,803 |
| 2010 Convertible Notes [Member] | ' | ' | ' |
| Note 3 - 2.5% Senior Secured Convertible Notes Payable (Details) - Senior Secured Convertible Notes Payable [Line Items] | ' | ' | ' |
| Convertible Notes, gross | 427,500 | 427,500 | 427,500 |
| Less Valuation Discount | ' | -37,375 | ' |
| 2012 Convertible Notes [Member] | ' | ' | ' |
| Note 3 - 2.5% Senior Secured Convertible Notes Payable (Details) - Senior Secured Convertible Notes Payable [Line Items] | ' | ' | ' |
| Convertible Notes, gross | 753,667 | 1,170,333 | 1,335,333 |
| Less Valuation Discount | ($419,405) | ($807,202) | ' |
Note_4_CardioNova_Research_Agr1
| Note 4 - CardioNova Research Agreement (Details) (USD $) | 1 Months Ended | 6 Months Ended | 12 Months Ended | 85 Months Ended | 1 Months Ended | 1 Months Ended | 0 Months Ended | 1 Months Ended | 1 Months Ended | 12 Months Ended | |||||||||||||
| Dec. 31, 2013 | Apr. 29, 2013 | Jun. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Jun. 30, 2014 | Apr. 25, 2013 | Jun. 30, 2012 | Oct. 31, 2011 | Oct. 31, 2011 | Apr. 29, 2013 | Dec. 31, 2013 | Apr. 29, 2013 | Oct. 31, 2011 | Oct. 31, 2011 | Jun. 14, 2013 | Dec. 22, 2011 | Dec. 31, 2013 | Oct. 31, 2011 | Apr. 25, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | |
| Issued Upon Acceptance of Development Plan [Member] | Issued Upon Approval of Joint Steering Committee [Member] | Issued Upon Approval of Joint Steering Committee [Member] | Issued Upon Approval of Joint Steering Committee [Member] | Issued Upon Approval of Joint Steering Committee [Member] | Issued Upon Announcement of Phase 1 Results [Member] | Issued Upon Announcement of Phase 2 Results [Member] | Funding of Clinical Trials [Member] | Funding of Clinical Trials [Member] | Funding of Clinical Trials [Member] | Funding of Clinical Trials [Member] | Issued Upon Acceptance of Development Plan [Member] | Issued Upon Announcement of Phase 1 Results [Member] | CardioNova [Member] | ||||||||||
| Funding of Clinical Trials [Member] | Funding of Clinical Trials [Member] | Weighted Average [Member] | CardioNova [Member] | CardioNova [Member] | Funding of Clinical Trials [Member] | Funding of Clinical Trials [Member] | CardioNova [Member] | CardioNova [Member] | CardioNova [Member] | CardioNova [Member] | CardioNova [Member] | CardioNova [Member] | |||||||||||
| CardioNova [Member] | CardioNova [Member] | CardioNova [Member] | CardioNova [Member] | CardioNova [Member] | |||||||||||||||||||
| Note 4 - CardioNova Research Agreement (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Contractual Obligation (in Dollars) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $3,800,000 | ' | ' | ' |
| Percentage of Research Costs Issued in Stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10.00% | 20.00% | ' | ' | ' | 40.00% | 30.00% | ' | ' | ' | ' | ' | ' | ' |
| Share Price (in Dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | $7.90 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $9.70 | ' | ' | $7.30 |
| Stock Issued During Period, Shares, New Issues (in Shares) | 199,716 | 160,541 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 39,175 | ' | ' |
| Sale of Stock, Price Per Share (in Dollars per share) | $9.70 | ' | ' | $9.70 | ' | $9.70 | ' | $9,700,000 | ' | ' | ' | $4.73 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Percent of Budget | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 30.00% | 20.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Project Completion Percentage | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 80.00% | ' |
| (in Dollars) | 1,170,712 | ' | ' | 1,170,712 | ' | 1,170,712 | 155,074 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,170,712 | ' | ' | ' | ' |
| Common Stock, Capital Shares Reserved for Future Issuance (in Shares) | 3,000,000 | ' | ' | 3,000,000 | ' | 3,000,000 | 83,824 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 27,526 | ' | ' | ' |
| Stock Issued During Period, Shares, Issued for Services (in Shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 12,062 | 15,464 | ' | ' | ' | ' | 199,716 |
| Proceeds from Issuance of Common Stock (in Dollars) | ' | ' | $267,047 | $787,048 | $2,061,787 | $5,366,503 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $150,000 | ' | ' | ' | ' | $117,000 |
Note_5_Research_and_Developmen1
| Note 5 - Research and Development Projects (Details) (USD $) | 3 Months Ended | 6 Months Ended | 12 Months Ended | 85 Months Ended | 4 Months Ended | 12 Months Ended | 13 Months Ended | 3 Months Ended | 6 Months Ended | 22 Months Ended | 12 Months Ended | 16 Months Ended | 4 Months Ended | 12 Months Ended | |||||||
| Jun. 30, 2014 | Jun. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2014 | Jun. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | |
| Research and Development Expense [Member] | Contract Research In Additional Compounds Covered Under Pending Patents [Member] | Contract Research In Additional Compounds Covered Under Pending Patents [Member] | Contract Research In Additional Compounds Covered Under Pending Patents [Member] | Contract Research In Additional Compounds Covered Under Pending Patents [Member] | Contract Research In Additional Compounds Covered Under Pending Patents [Member] | Contract Research In Additional Compounds Covered Under Pending Patents [Member] | Testing Of The Oral Toxicity Of AHRO-001 [Member] | Testing Of The Oral Toxicity Of AHRO-001 [Member] | Testing Of The Oral Toxicity Of AHRO-001 [Member] | Testing Of The Oral Toxicity Of AHRO-001 [Member] | Pennsylvania-based Clinical Research Organization [Member] | Development Agreement [Member] | Development Agreement [Member] | ||||||||
| Testing Of The Oral Toxicity Of AHRO-001 [Member] | Major University in Southern California [Member] | Major University in Southern California [Member] | Major University in Southern California [Member] | Study Initiated in September 2012 [Member] | Study Initiated in September 2012 [Member] | Study Initiated in September 2012 [Member] | Study Initiated in August 2013 [Member] | Development Agreement [Member] | Pennsylvania-based Clinical Research Organization [Member] | Pennsylvania-based Clinical Research Organization [Member] | |||||||||||
| Study Initiated in August 2013 [Member] | |||||||||||||||||||||
| Note 5 - Research and Development Projects (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Long-term Purchase Commitment, Amount | ' | ' | ' | ' | ' | ' | ' | $49,000 | ' | ' | $236,323 | ' | ' | ' | ' | ' | $507,000 | $224,600 | $385,000 | ' | ' |
| Research and Development Expense | 833,893 | 438,157 | 1,401,046 | 872,916 | 2,030,285 | 986,261 | 3,889,621 | ' | 120,327 | 115,996 | ' | 349,785 | 521,965 | 236,323 | 389,785 | 116,545 | ' | 175,950 | ' | 166,422 | 218,847 |
| Other Research and Development Expense | ' | ' | ' | ' | $1,451,041 | $534,873 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Note_6_Committments_Details
| Note 6 - Committments (Details) (USD $) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | 85 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 26 Months Ended | 6 Months Ended | 12 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | 1 Months Ended | 3 Months Ended | 6 Months Ended | 22 Months Ended | 3 Months Ended | 3 Months Ended | 6 Months Ended | 19 Months Ended | 6 Months Ended | 3 Months Ended | ||||||||||||||||
| Dec. 31, 2013 | Apr. 29, 2013 | Oct. 31, 2012 | Jun. 30, 2014 | Jun. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Jun. 30, 2012 | Sep. 30, 2012 | Feb. 28, 2014 | Dec. 31, 2011 | Jun. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Jun. 30, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Jun. 30, 2014 | Dec. 31, 2013 | Jun. 30, 2014 | Jun. 30, 2014 | Jun. 30, 2014 | Feb. 28, 2014 | Jun. 30, 2014 | Jun. 30, 2014 | Jun. 30, 2014 | Jun. 30, 2014 | Jun. 30, 2014 | Jun. 30, 2014 | Jun. 30, 2014 | Oct. 31, 2011 | Dec. 31, 2013 | Jun. 30, 2014 | Jun. 30, 2014 | Jun. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2014 | |
| Major University in Southern California [Member] | Formulation Development [Member] | First Installment [Member] | Second Installment [Member] | Existing And Expansion Office Space [Member] | Existing And Expansion Office Space [Member] | Existing And Expansion Office Space [Member] | Existing And Expansion Office Space [Member] | Funding of Clinical Trials [Member] | First Two Milestones [Member] | Third Milestone [Member] | Third Milestone [Member] | Final Milestone [Member] | Contract Research In Additional Compounds Covered Under Pending Patents [Member] | Contract Research In Additional Compounds Covered Under Pending Patents [Member] | Contract Research In Additional Compounds Covered Under Pending Patents [Member] | Contract Research In Additional Compounds Covered Under Pending Patents [Member] | Contract Research In Additional Compounds Covered Under Pending Patents [Member] | Contract Research In Additional Compounds Covered Under Pending Patents [Member] | Contract Research In Additional Compounds Covered Under Pending Patents [Member] | Contract Research In Additional Compounds Covered Under Pending Patents [Member] | Remaining Cost to be Recorded in Future Periods [Member] | Remaining Cost to be Recorded in Future Periods [Member] | Funding of Clinical Trials [Member] | First Two Milestones [Member] | RUSSIAN FEDERATION | RUSSIAN FEDERATION | CardioNova [Member] | Pennsylvania-based Clinical Research Organization [Member] | Monthly Rent [Member] | ||||||||||||
| Contract Research In Additional Compounds Covered Under Pending Patents [Member] | Pennsylvania-based Clinical Research Organization [Member] | CardioNova [Member] | CardioNova [Member] | Minimum [Member] | Maximum [Member] | sqft | Final Milestone [Member] | Final Milestone [Member] | Expected Cost [Member] | Remaining Cost to be Recorded in Future Periods [Member] | AUSTRALIA | RUSSIAN FEDERATION | Pennsylvania-based Clinical Research Organization [Member] | Joint Steering Committee, Atheronova and CardioNova [Member] | |||||||||||||||||||||||||||
| Monthly Rent [Member] | Monthly Rent [Member] | ||||||||||||||||||||||||||||||||||||||||
| Note 6 - Committments (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Lease Term | ' | ' | 66 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 69 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Area of Real Estate Property (in Square Feet) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,930 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Payments for Rent | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $3,570 | $4,053 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Operating Leases, Rent Expense | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 47,214 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Contractual Obligation | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,800,000 | ' | ' | ' | ' | ' | ' |
| Stock Issued During Period, Shares, New Issues (in Shares) | 199,716 | 160,541 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15,464 | 12,062 | ' | ' | ' | ' | 199,730 | ' | 422,105 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 27,526 | ' | ' |
| Percentage of Achievement to Reach Third Milestone | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 30.00% | ' | 80.00% | 15.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Stock Issued During Period, Value, New Issues | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,198,297 | 2,152,736 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Share Price (in Dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $7.90 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $6 | ' | ' | $9.70 | ' | ' |
| ' | ' | ' | 155,074 | 1,198,297 | 1,137,097 | 1,198,297 | 2,369,009 | ' | 2,369,009 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 982,024 | 1,170,712 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Research and Development Expense | ' | ' | ' | 833,893 | 438,157 | 1,401,046 | 872,916 | 2,030,285 | 986,261 | 3,889,621 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 155,074 | 155,074 | 738,000 | 216,035 | 187,400 | 349,785 | 521,965 | 236,323 | 243,353 | 60,341 | ' | ' | 96,047 | 96,047 | ' | 160,309 | 67,715 |
| Proceeds from Issuance of Common Stock | ' | ' | ' | ' | ' | ' | 267,047 | 787,048 | 2,061,787 | 5,366,503 | ' | ' | ' | 150,000 | 117,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Long-term Purchase Commitment, Amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 236,323 | 220,650 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 339,400 | ' | ' | ' | ' |
| Other Commitment | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $81,662 | $81,662 | $81,662 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Note_6_Committments_Details_Mi
| Note 6 - Committments (Details) - Minimum Future Rent Obligations (USD $) | Dec. 31, 2013 |
| Minimum Future Rent Obligations [Abstract] | ' |
| Minimum future payments | $44,873 |
| Minimum future payments | 46,030 |
| Minimum future payments | 47,189 |
| Minimum future payments | 48,346 |
| Minimum future payments | $12,159 |
Note_7_Stockholders_Equity_Def2
| Note 7 - Stockholders' Equity (Deficit) (Details) (USD $) | 1 Months Ended | 2 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | 85 Months Ended | 6 Months Ended | 3 Months Ended | 12 Months Ended | 0 Months Ended | 12 Months Ended | 0 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 6 Months Ended | 12 Months Ended | 6 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 0 Months Ended | 0 Months Ended | 12 Months Ended | 6 Months Ended | 12 Months Ended | 6 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 6 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 6 Months Ended | 12 Months Ended | 6 Months Ended | 12 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 25 Months Ended | 12 Months Ended | 1 Months Ended | 6 Months Ended | 19 Months Ended | 12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Dec. 31, 2013 | Apr. 29, 2013 | Jun. 23, 2010 | 31-May-14 | Jun. 30, 2014 | Jun. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2013 | Jun. 30, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | Dec. 31, 2009 | Dec. 31, 2013 | Apr. 25, 2013 | Jun. 30, 2014 | Jun. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | 15-May-12 | Dec. 31, 2012 | Oct. 31, 2012 | Oct. 31, 2012 | 15-May-12 | Aug. 31, 2013 | Aug. 31, 2014 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Feb. 12, 2014 | 31-May-14 | Jun. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | Dec. 31, 2009 | Dec. 31, 2008 | Dec. 31, 2007 | Dec. 31, 2012 | Dec. 31, 2012 | Dec. 31, 2012 | Dec. 31, 2012 | Dec. 31, 2012 | Dec. 31, 2012 | Dec. 31, 2012 | Dec. 31, 2012 | Jun. 30, 2012 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Oct. 31, 2012 | Dec. 31, 2012 | 15-May-12 | Feb. 12, 2014 | Jun. 30, 2014 | Feb. 28, 2014 | Apr. 22, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Jun. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2013 | Jun. 30, 2014 | Jun. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Jun. 30, 2014 | Jun. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2012 | Mar. 31, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2012 | Jun. 30, 2014 | 31-May-14 | Dec. 31, 2013 | Dec. 31, 2013 | Jun. 30, 2014 | Dec. 31, 2013 | 31-May-10 | Dec. 31, 2012 | Dec. 31, 2012 | Dec. 31, 2013 | Mar. 31, 2014 | Jun. 30, 2013 | 31-May-13 | 31-May-11 | Dec. 31, 2013 | Dec. 31, 2011 | 31-May-13 | Dec. 31, 2012 | Dec. 31, 2012 | Dec. 31, 2012 | Dec. 31, 2012 | Oct. 31, 2012 | Jun. 30, 2014 | Jun. 30, 2013 | Dec. 31, 2013 | |
| General and Administrative Expense [Member] | General and Administrative Expense [Member] | Common Stock Unit [Member] | Common Stock Unit [Member] | Warrant "Cashless Exercise" [Member] | Issued In Conjunction With a Consulting Service Agreement [Member] | Issued In Conjunction With a Consulting Service Agreement [Member] | Holder 1 [Member] | Holder 2 [Member] | Holder 3 [Member] | Warrants Issued To Purchasers Of The Short Term Twelve Percent Notes Issued [Member] | Warrants Issued To Purchasers Of The Short Term Twelve Percent Notes Issued [Member] | Warrants Issued To Purchasers Of The Short Term Twelve Percent Notes Issued [Member] | Issued With 12 Convertible Notes Bridge Notes [Member] | Issued With 12 Convertible Notes Bridge Notes [Member] | Private Placements [Member] | Private Placements [Member] | Accrued Interest Converted [Member] | Warrant [Member] | Warrant "Cashless Exercise" [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Financing And Stock Issuance Commissions [Member] | Commissions Paid To PBC On The Short Term Notes Converted To Common Stock [Member] | Transaction 1 [Member] | Transaction 1 [Member] | Transaction 1 [Member] | Amount Of Accounts Payable Settled With Issuance Of Common Stock [Member] | Vested Upon Issuance [Member] | Vesting On Each Anniversary Date From Issuance [Member] | Repriced Exercise Price Options Granted During 2011 [Member] | Options Granted In Prior Years [Member] | 2.5% Senior Convertible Note [Member] | 2.5% Senior Convertible Note [Member] | 2.5% Senior Convertible Note [Member] | 2.5% Senior Convertible Note [Member] | Twelve Percent Convertible Notes Bridge Notes [Member] | Twelve Percent Convertible Notes Bridge Notes [Member] | Twelve Percent Convertible Notes Bridge Notes [Member] | 6% Secured Convertible Notes [Member] | 6% Secured Convertible Notes [Member] | 6% Secured Convertible Notes [Member] | Reverse Stock Split [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | Minimum [Member] | Minimum [Member] | Minimum [Member] | Minimum [Member] | Minimum [Member] | Minimum [Member] | Minimum [Member] | Accounts Payable and Accrued Liabilities [Member] | Common Stock Unit [Member] | Common Stock Unit [Member] | Units Sold [Member] | Shares Sold By Controlling Stockholder To Directors Of The Company At A Below-Market Price [Member] | Shares Transferred By Controlling Stockholder To Officers, Employees and Directors of the Company [Member] | Shares Transferred To Directors Officers And Employees By A Controlling Stockholder [Member] | Employee Stock Option [Member] | Employee Stock Option [Member] | Employee Stock Option [Member] | Employee Stock Option [Member] | Employee Stock Option [Member] | Employee Stock Option [Member] | Employee Stock Option [Member] | Employee Stock Option [Member] | Employee Stock Option [Member] | Employee Stock Option [Member] | Employee Stock Option [Member] | Employee Stock Option [Member] | Issued To Satisfy Accounts Payable [Member] | Director [Member] | Director [Member] | Consultant [Member] | Consultant [Member] | Consultant [Member] | Consultant [Member] | Consultant [Member] | Consultant [Member] | Consultant [Member] | Consultant [Member] | Employees And Directors [Member] | Various Legal And Miscellaneous Fees Directly Associated With The Sale Of The Units [Member] | Difference Between Value Of Common Stock Issued And Balance Of Account Payable Settled [Member] | Repricing Of Short Term Twelve Percent Notes [Member] | Outside of the the 2010 Plan [Member] | CardioNova [Member] | CardioNova [Member] | |||||||||||||||||
| Employee Stock Option [Member] | Consultant [Member] | Warrant [Member] | 2.5% Senior Convertible Note [Member] | 6% Secured Convertible Notes [Member] | CardioNova [Member] | Maximum [Member] | Minimum [Member] | Employee Stock Option [Member] | Employee Stock Option [Member] | Consultant [Member] | Employee Stock Option [Member] | Common Stock Issued To Settle Accrued Interest [Member] | To Account For The Current Market Price Of The Shares Issued To Settle The Unpaid Interest [Member] | Common Stock Unit [Member] | Common Stock Unit [Member] | Employee Stock Option [Member] | Employee Stock Option [Member] | Employee Stock Option [Member] | Consultant [Member] | Employee Stock Option [Member] | Consultant [Member] | Consultant [Member] | Director [Member] | Director [Member] | Members Of The Company's Board Of Directors [Member] | Consultant [Member] | Consultant [Member] | Employees And Directors [Member] | "2010 Plan" [Member] | "2010 Plan" [Member] | "2010 Plan" [Member] | Employees and Directors [Member] | "2010 Plan" [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Director [Member] | Director [Member] | Consultant [Member] | Members Of The Company's Board Of Directors [Member] | "2010 Plan" [Member] | "2010 Plan" [Member] | Members Of The Company's Board Of Directors [Member] | "2010 Plan" [Member] | "2010 Plan" [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| "2010 Plan" [Member] | "2010 Plan" [Member] | "2010 Plan" [Member] | "2010 Plan" [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Note 7 - Stockholders' Equity (Deficit) (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | ' | ' | ' | ' | ' | ' | 10,000 | ' | 10.1 | 208,250 | 10,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 162,500 | 9,500 | 11,500 | ' | 50,250 | ' | ' | ' | 10,000 | ' | ' | ' | ' | ' | ' | ' | 10,000 | ' | 10,000 | ' | ' | ' | 158,000 | ' | 150,000 | ' | ' | ' | ' | ' | ' | ' | ' |
| Allocated Share-based Compensation Expense (in Dollars) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $231,607 | $17,921 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $219,015 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $422,500 | $58,900 | ' | $38,124 | $52,652 | $98,094 | ' | $546,631 | ' | ' | ' | $596,676 | ' | ' | ' | ' | ' | ' | ' | ' | $117,257 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Common Stock Units | ' | ' | ' | ' | ' | ' | ' | ' | ' | 80,000 | 448,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Common Stock Unit, Price Per Unit (in Dollars per share) | $6.50 | ' | ' | ' | ' | ' | ' | ' | ' | $6.50 | $5 | ' | ' | ' | $6.50 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Common Stock Units, Number of Shares Per Unit | 1 | ' | ' | ' | ' | ' | ' | ' | ' | 1 | 1 | ' | ' | ' | 1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 24,001 | ' | ' | ' | ' | ' | ' | ' | ' | 24,001 | 224,000 | ' | ' | ' | 24,001 | ' | ' | ' | 0.3 | 0.5 | ' | 5,000 | ' | 56,071 | 33,643 | 11,214 | 14,000 | ' | ' | 68,500 | 14,000 | 40,000 | 40,000 | ' | 67,286 | 33,643 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 414,457 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Proceeds from Issuance or Sale of Equity (in Dollars) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 520,001 | 2,061,787 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Development Stage Entities, Stock Issued, Shares, Issued for Cash | ' | ' | ' | ' | ' | ' | ' | ' | ' | 80,000 | 448,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 448,000 | ' | 101,013 | 22,466 | 101,013 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 12,062 |
| Warrants, Term | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '3 years | '10 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '10 years | '4 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Share) | $7.50 | ' | ' | ' | ' | ' | ' | ' | ' | $7.50 | ' | ' | ' | ' | $7.50 | ' | ' | ' | ' | ' | ' | $5 | ' | $2.23 | $2.23 | $2.23 | $9 | ' | $5.75 | $6.25 | $9 | ' | ' | ' | $2.23 | $2.23 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $16.40 | ' | ' | ' | ' | ' | ' | $2.23 | ' | ' | $7.50 | $6.25 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Proceeds from Warrant Exercises (in Dollars) | ' | ' | ' | ' | ' | ' | ' | ' | ' | 150,047 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 125,039 | ' | 25,007 | ' | ' | ' | ' | ' | ' | ' | ' | 150,047 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Stock Issued During Period, Shares, New Issues | 199,716 | 160,541 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 18,638 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,535 | 422,105 | ' | ' | ' | ' | ' | ' | ' | 1,923,303 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,535 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 27,526 | ' |
| Cancellation of Shares Purchasable Under the Warrant | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15,005 | ' | ' | ' | 15,006 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Proceeds from Issuance of Common Stock (in Dollars) | ' | ' | ' | ' | ' | ' | ' | 267,047 | ' | 787,048 | 2,061,787 | ' | ' | ' | 5,366,503 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 117,000 |
| Sale of Stock, Price Per Share (in Dollars per share) | $9.70 | ' | ' | ' | ' | ' | ' | ' | ' | $9.70 | ' | ' | ' | ' | $9.70 | $9,700,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Stock Issued During Period, Shares, Issued for Services | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,535 | 199,716 | 45,960 | 46,657 | 5,000 | 22,428 | ' | ' | 9,960 | ' | ' | ' | 45,960 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 199,716 |
| Share Price (in Dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | $7.90 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $9.70 | $7.30 |
| Stock Issued During Period, Value, Issued for Services (in Dollars) | ' | ' | ' | ' | ' | ' | 23,395 | ' | ' | 1,198,297 | 256,100 | 140,500 | 72,500 | 50,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1 | 20 | 5 | 5 | ' | 2 | ' | ' | ' | ' | ' | ' | 256,100 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,198,297 |
| Stock Issued During Period, Shares, Conversion of Convertible Securities | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 148,849 | 57,691 | 386,372 | 158,516 | 25,194 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 57,691 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Interest rate on senior secured convertible notes | 2.50% | ' | ' | ' | 2.50% | ' | 2.50% | ' | ' | 2.50% | 2.50% | ' | ' | ' | 2.50% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2.50% | 2.50% | ' | 12.00% | 12.00% | 6.00% | 6.00% | 6.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Stock Issued During Period, Value, Conversion of Convertible Securities (in Dollars) | ' | ' | ' | ' | ' | ' | 436,315 | ' | ' | 169,765 | 1,448,130 | 473,698 | 99,014 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 14 | 6 | 39 | 16 | 2 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 165,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Increase (Decrease) in Interest Payable, Net (in Dollars) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -2,303 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Interest Expense, Debt (in Dollars) | ' | ' | ' | ' | 254,143 | 260,323 | 736,553 | 381,518 | ' | 601,664 | 871,431 | ' | ' | ' | 2,481,178 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,462 | 39,878 | 10,836 | 20,098 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 646 | 3,006 | 3,386 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,006 | ' | 646 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Stock Issued During Period, Value, Other (in Dollars) | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,518 | 23,748 | 72,999 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,518 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Increase (Decrease) in Accounts Payable (in Dollars) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 19,269 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -4,200 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| General and Administrative Expense (in Dollars) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 318 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,479 | ' | ' | ' | ' |
| Payments of Stock Issuance Costs (in Dollars) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 54,800 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 161,800 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Professional Fees (in Dollars) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 16,413 | ' | ' | ' | ' | ' |
| Stock Issued During Period, Value Issued For Services, Per Share (in Dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $10.10 | $6.20 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Debt Conversion, Converted Instrument, Shares Issued | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 249,372 | 137,000 | 137,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Debt Conversion, Original Debt, Amount (in Dollars) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 32,401 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 690,851 | 685,000 | 685,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Stock Issued During Period, Value, Fair Value Of Common Stock Issued To Settle Accounts Payable (in Dollars) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 23,748 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures (in Dollars) | ' | ' | ' | ' | ' | ' | 249,528 | ' | ' | 481,400 | 123,050 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 123,050 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 7,362,964 | 436,296 | ' | ' | ' | 436,296 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Stock Option Term | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '10 years | '10 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '7 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '7 years | '7 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | 568,950 | ' | ' | ' | 548,950 | ' | 548,950 | ' | ' | 568,950 | 460,700 | 451,950 | ' | ' | 568,950 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 434,000 | ' | 556,450 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 135,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Stock Granted, Value, Share-based Compensation, Gross (in Dollars) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 258,497 | 881,688 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | ' | ' | ' | ' | ' | ' | $3.80 | ' | ' | $5.74 | $10 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $12.50 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $6.90 | ' | ' | $6.90 | ' | ' | ' | ' | $4.30 | $3.80 | $4.30 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $10 | ' | ' | ' | ' | $10.10 | ' | $150,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '4 years | ' | ' | ' | ' | ' | ' | ' | '3 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '3 months | ' | ' | ' | '4 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Number | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 460,000 | ' | ' | ' | ' | ' | ' | ' | ' | 35,000 | ' | ' | ' | ' | ' | 450,000 | ' | ' | ' | ' | ' | ' |
| Share-based Compensation Arrangement by Share-based Payment Award, Options Cancelled in Period | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 100,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Share-based Compensation Arrangement by Share-based Payment Award, Options Cancelled in Period, Price Per Share (in Dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $10.10 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 487,000 | 1,183,387 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 427,000 | 1,304,110 | ' | ' | ' | ' | ' | ' |
| Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '3 years 219 days | ' | ' | ' | ' | ' | '2 years 6 months | '321 days | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Share-based Compensation Arrangement by Share-based Payment Award, Award, Vesting Period Percentage | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 25.00% | 25.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants In Period, Aggregate Grant Date Fair Value (in Dollars) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 88,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | ' | ' | ' | ' | ' | ' | 0.00% | ' | ' | 0.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Warrants Issued | ' | ' | ' | ' | ' | ' | ' | ' | ' | 24,001 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants (in Dollars) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 13,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | ' | ' | ' | ' | 2.73% | 2.05% | 2.73% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0.40% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2.05% | 2.09% | 1.41% | ' | ' | ' | ' | 1.38% | 1.38% | 1.19% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | ' | ' | ' | ' | 198.00% | 218.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 114.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 201.00% | 226.00% | 226.00% | 134.00% | ' | ' | ' | 198.00% | 113.00% | 113.00% | 111.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term | ' | ' | ' | ' | '6 years 3 months | '6 years 3 months | '6 years 3 months | '6 years 3 months | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '2 years 6 months | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '6 years 3 months | '6 years 3 months | ' | ' | ' | ' | ' | '5 years 6 months | '1 year 9 months | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Stock Issued During Period, Shares, Other | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 18,636 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 85,924 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Term Of Exercise Option On Warrants | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '66 months | ' | ' | '4 years | ' | '10 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '10 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Amortization of Debt Discount (Premium) (in Dollars) | ' | ' | ' | ' | ' | ' | 670,282 | 357,723 | ' | 557,453 | 769,185 | ' | ' | ' | 2,266,942 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 58,387 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Loss On Modification Of Short-term Notes And Warrants (in Dollars) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 866,083 | ' | ' | ' | 866,083 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 34,220 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 34,220 | ' | ' | ' |
| Warrants and Rights Outstanding (in Dollars) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 420,863 | 58,387 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Class of Warrant or Right, Outstanding | 853,937 | ' | ' | ' | ' | ' | ' | ' | ' | 853,937 | ' | ' | ' | ' | 853,937 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Class of Warrants or Rights, Outstanding, Intrinsic Value (in Dollars) | 334,521 | ' | ' | ' | ' | ' | ' | ' | ' | 334,521 | ' | ' | ' | ' | 334,521 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Stock Issued During Period, Value, New Issues (in Dollars) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $23,395 | $2,152,693 | ' | ' | ' | ' | ' | ' | ' | $192 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $23,395 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Stock Issued During Period, Shares, Stock Splits | ' | ' | ' | 34,316 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Stockholders' Equity Note, Stock Split, Conversion Ratio | ' | ' | 200 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 22,500 | ' | ' |
| Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 292,297 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '7 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $2.30 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $2.30 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Note_7_Stockholders_Equity_Def3
| Note 7 - Stockholders' Equity (Deficit) (Details) - Stock Option Compensation Arrangements (USD $) | Jun. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' |
| Balance Outstanding - Shares | 548,950 | 568,950 | 460,700 | 451,950 |
| Balance Outstanding - Weighted Average Exercise Price (in Dollars per share) | $8.42 | $8.32 | $9.87 | $11.29 |
| Number of securities remaining available for future issuance under equity compensation plan | ' | 302,296 | ' | ' |
| Equity Compensation Plans Approved By Stockholders [Member] | ' | ' | ' | ' |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' |
| Balance Outstanding - Shares | ' | 434,000 | ' | ' |
| Balance Outstanding - Weighted Average Exercise Price (in Dollars per share) | ' | $9.70 | ' | ' |
| Number of securities remaining available for future issuance under equity compensation plan | ' | 302,296 | ' | ' |
| Equity Compensation Plans Approved by the Board of Directors [Member] | ' | ' | ' | ' |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' |
| Balance Outstanding - Shares | ' | 134,950 | ' | ' |
| Balance Outstanding - Weighted Average Exercise Price (in Dollars per share) | ' | $3.90 | ' | ' |
Note_7_Stockholders_Equity_Def4
| Note 7 - Stockholders' Equity (Deficit) (Details) - Summary of Stock Options and Changes During Period (USD $) | 6 Months Ended | 12 Months Ended | |||
| Jun. 30, 2014 | Jun. 30, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
| Summary of Stock Options and Changes During Period [Abstract] | ' | ' | ' | ' | ' |
| Balance Outstanding - Shares | 548,950 | ' | 568,950 | 460,700 | 451,950 |
| Balance Outstanding - Weighted Average Exercise Price | $8.42 | ' | $8.32 | $9.87 | $11.29 |
| Balance Outstanding - Weighted Average Remaining Contractual Term | '4 years 117 days | ' | '4 years 309 days | '5 years 68 days | '6 years 59 days |
| Balance Outstanding - Aggregate Intrinsic Value | $0 | ' | $86,271 | $119,241 | $1,140,059 |
| Exercisable at December 31, 2013 | 390,105 | ' | 305,471 | ' | ' |
| Exercisable at December 31, 2013 | $9.04 | ' | $9.52 | ' | ' |
| Exercisable at December 31, 2013 | ' | ' | '3 years 343 days | ' | ' |
| Exercisable at December 31, 2013 | $0 | ' | $84,475 | ' | ' |
| Granted - Shares | 10,000 | 10.1 | 208,250 | 10,000 | ' |
| Granted - Weighted Average Exercise Price | $3.80 | ' | $5.74 | $10 | ' |
| Granted - Weighted Average Remaining Contractual Term | '7 years | ' | '6 years 137 days | '6 years 6 months | ' |
| Cancelled - Shares | -30,000 | ' | -100,000 | -1,250 | ' |
| Cancelled - Weighted Average Exercise Price | $5 | ' | $10.10 | $11.10 | ' |
Note_7_Stockholders_Equity_Def5
| Note 7 - Stockholders' Equity (Deficit) (Details) - Options Outstanding, Vested and Exercisable (USD $) | 6 Months Ended | 12 Months Ended | ||
| Jun. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
| Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ' | ' | ' | ' |
| Shares (in Shares) | 548,950 | 568,950 | 460,700 | 451,950 |
| Weighted-Average Price per Share | $8.42 | $8.32 | $9.87 | $11.29 |
| Weighted-Average Remaining Contractual Life | '4 years 117 days | '4 years 309 days | '5 years 68 days | '6 years 59 days |
| Shares (in Shares) | ' | 308,221 | ' | ' |
| Weighted-Average Remaining Contractual Life | ' | '3 years 343 days | ' | ' |
| $2.23 to $6.90 [Member] | ' | ' | ' | ' |
| Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ' | ' | ' | ' |
| Price per share - lower limit | ' | $2.23 | ' | ' |
| Price per share - upper limit | ' | $6.90 | ' | ' |
| Shares (in Shares) | ' | 263,200 | ' | ' |
| Weighted-Average Price per Share | ' | $5.01 | ' | ' |
| Weighted-Average Remaining Contractual Life | ' | '5 years 251 days | ' | ' |
| Shares (in Shares) | ' | 61,243 | ' | ' |
| Weighted-Average Price per Share | ' | $2.57 | ' | ' |
| Weighted-Average Remaining Contractual Life | ' | '3 years 175 days | ' | ' |
| $7.00 to $12.50 [Member] | ' | ' | ' | ' |
| Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ' | ' | ' | ' |
| Price per share - lower limit | ' | $7 | ' | ' |
| Price per share - upper limit | ' | $12.50 | ' | ' |
| Shares (in Shares) | ' | 279,750 | ' | ' |
| Weighted-Average Price per Share | ' | $10.62 | ' | ' |
| Weighted-Average Remaining Contractual Life | ' | '4 years 29 days | ' | ' |
| Shares (in Shares) | ' | 228,979 | ' | ' |
| Weighted-Average Price per Share | ' | $10.64 | ' | ' |
| Weighted-Average Remaining Contractual Life | ' | '4 years 18 days | ' | ' |
| $13.00 to $23.80 [Member] | ' | ' | ' | ' |
| Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ' | ' | ' | ' |
| Price per share - lower limit | ' | $13 | ' | ' |
| Price per share - upper limit | ' | $23.80 | ' | ' |
| Shares (in Shares) | ' | 26,000 | ' | ' |
| Weighted-Average Price per Share | ' | $17.23 | ' | ' |
| Weighted-Average Remaining Contractual Life | ' | '4 years 208 days | ' | ' |
| Shares (in Shares) | ' | 17,999 | ' | ' |
| Weighted-Average Price per Share | ' | $19.50 | ' | ' |
| Weighted-Average Remaining Contractual Life | ' | '4 years 135 days | ' | ' |
Note_7_Stockholders_Equity_Def6
| Note 7 - Stockholders' Equity (Deficit) (Details) - Weighted Average Assumptions | 3 Months Ended | 6 Months Ended | 12 Months Ended | 6 Months Ended | 12 Months Ended | |||||||
| Jun. 30, 2014 | Jun. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Jun. 30, 2014 | Jun. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | |
| Minimum [Member] | Minimum [Member] | Minimum [Member] | Minimum [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | |||||
| Note 7 - Stockholders' Equity (Deficit) (Details) - Weighted Average Assumptions [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Expected volatility | 198.00% | 218.00% | ' | ' | 198.00% | 113.00% | 113.00% | 111.00% | 201.00% | 226.00% | 226.00% | 134.00% |
| Expected term (in years) | '6 years 3 months | '6 years 3 months | '6 years 3 months | '6 years 3 months | ' | ' | '5 years 6 months | '1 year 9 months | ' | ' | '6 years 3 months | '6 years 3 months |
| Risk-free interest rate | 2.73% | 2.05% | 2.73% | ' | ' | 1.38% | 1.38% | 1.19% | ' | 2.05% | 2.09% | 1.41% |
Note_7_Stockholders_Equity_Def7
| Note 7 - Stockholders' Equity (Deficit) (Details) - Warrants Outstanding, Vested and Exercisable (USD $) | 6 Months Ended | 12 Months Ended | ||
| Jun. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
| Class of Warrant or Right [Line Items] | ' | ' | ' | ' |
| Price Per Share (in Dollars per Share) | ' | $7.50 | ' | ' |
| Warrant [Member] | $0.223 [Member] | ' | ' | ' | ' |
| Class of Warrant or Right [Line Items] | ' | ' | ' | ' |
| Price Per Share (in Dollars per Share) | ' | $2.23 | ' | ' |
| Shares - Outstanding | ' | 213,071 | ' | ' |
| Weighted-Average Price Per Share - Outstanding (in Dollars per share) | ' | $2.23 | ' | ' |
| Weighted-Average Remaining Contractual Life - Outstanding | ' | '1 year 73 days | ' | ' |
| Shares - Vested and Exercisable Weighted-Average | ' | 213,071 | ' | ' |
| Weighted-Average Price Per Share - Vested and Exercisable Weighted-Average (in Dollars per share) | ' | $2.23 | ' | ' |
| Weighted-Average Remaining Contractual Life - Vested and Exercisable Weighted-Average | ' | '1 year 73 days | ' | ' |
| Warrant [Member] | $0.393 [Member] | ' | ' | ' | ' |
| Class of Warrant or Right [Line Items] | ' | ' | ' | ' |
| Price Per Share (in Dollars per Share) | ' | $3.93 | ' | ' |
| Shares - Outstanding | ' | 190,880 | ' | ' |
| Weighted-Average Price Per Share - Outstanding (in Dollars per share) | ' | $3.94 | ' | ' |
| Weighted-Average Remaining Contractual Life - Outstanding | ' | '153 days | ' | ' |
| Shares - Vested and Exercisable Weighted-Average | ' | 190,880 | ' | ' |
| Weighted-Average Price Per Share - Vested and Exercisable Weighted-Average (in Dollars per share) | ' | $3.93 | ' | ' |
| Weighted-Average Remaining Contractual Life - Vested and Exercisable Weighted-Average | ' | '153 days | ' | ' |
| Warrant [Member] | $0.50 [Member] | ' | ' | ' | ' |
| Class of Warrant or Right [Line Items] | ' | ' | ' | ' |
| Price Per Share (in Dollars per Share) | ' | $5 | ' | ' |
| Shares - Outstanding | ' | 7,100 | ' | ' |
| Weighted-Average Price Per Share - Outstanding (in Dollars per share) | ' | $5 | ' | ' |
| Weighted-Average Remaining Contractual Life - Outstanding | ' | '1 year 175 days | ' | ' |
| Shares - Vested and Exercisable Weighted-Average | ' | 7,100 | ' | ' |
| Weighted-Average Price Per Share - Vested and Exercisable Weighted-Average (in Dollars per share) | ' | $5 | ' | ' |
| Weighted-Average Remaining Contractual Life - Vested and Exercisable Weighted-Average | ' | '1 year 175 days | ' | ' |
| Warrant [Member] | $0.575 [Member] | ' | ' | ' | ' |
| Class of Warrant or Right [Line Items] | ' | ' | ' | ' |
| Price Per Share (in Dollars per Share) | ' | $5.75 | ' | ' |
| Shares - Outstanding | ' | 14,000 | ' | ' |
| Weighted-Average Price Per Share - Outstanding (in Dollars per share) | ' | $5.75 | ' | ' |
| Weighted-Average Remaining Contractual Life - Outstanding | ' | '3 years 302 days | ' | ' |
| Shares - Vested and Exercisable Weighted-Average | ' | 14,000 | ' | ' |
| Weighted-Average Price Per Share - Vested and Exercisable Weighted-Average (in Dollars per share) | ' | $5.75 | ' | ' |
| Weighted-Average Remaining Contractual Life - Vested and Exercisable Weighted-Average | ' | '3 years 302 days | ' | ' |
| Warrant [Member] | $0.60 [Member] | ' | ' | ' | ' |
| Class of Warrant or Right [Line Items] | ' | ' | ' | ' |
| Price Per Share (in Dollars per Share) | ' | $6 | ' | ' |
| Shares - Outstanding | ' | 92,386 | ' | ' |
| Weighted-Average Price Per Share - Outstanding (in Dollars per share) | ' | $6 | ' | ' |
| Weighted-Average Remaining Contractual Life - Outstanding | ' | '219 days | ' | ' |
| Shares - Vested and Exercisable Weighted-Average | ' | 92,386 | ' | ' |
| Weighted-Average Price Per Share - Vested and Exercisable Weighted-Average (in Dollars per share) | ' | $6 | ' | ' |
| Weighted-Average Remaining Contractual Life - Vested and Exercisable Weighted-Average | ' | '219 days | ' | ' |
| Warrant [Member] | $0.625 [Member] | ' | ' | ' | ' |
| Class of Warrant or Right [Line Items] | ' | ' | ' | ' |
| Price Per Share (in Dollars per Share) | ' | $6.25 | ' | ' |
| Shares - Outstanding | ' | 292,500 | ' | ' |
| Weighted-Average Price Per Share - Outstanding (in Dollars per share) | ' | $6.25 | ' | ' |
| Weighted-Average Remaining Contractual Life - Outstanding | ' | '2 years 9 months | ' | ' |
| Shares - Vested and Exercisable Weighted-Average | ' | 292,500 | ' | ' |
| Weighted-Average Price Per Share - Vested and Exercisable Weighted-Average (in Dollars per share) | ' | $6.25 | ' | ' |
| Weighted-Average Remaining Contractual Life - Vested and Exercisable Weighted-Average | ' | '2 years 9 months | ' | ' |
| Warrant [Member] | $0.75 [Member] | ' | ' | ' | ' |
| Class of Warrant or Right [Line Items] | ' | ' | ' | ' |
| Price Per Share (in Dollars per Share) | ' | $7.50 | ' | ' |
| Shares - Outstanding | ' | 24,001 | ' | ' |
| Weighted-Average Price Per Share - Outstanding (in Dollars per share) | ' | $7.50 | ' | ' |
| Weighted-Average Remaining Contractual Life - Outstanding | ' | '9 years 244 days | ' | ' |
| Shares - Vested and Exercisable Weighted-Average | ' | 24,001 | ' | ' |
| Weighted-Average Price Per Share - Vested and Exercisable Weighted-Average (in Dollars per share) | ' | $7.50 | ' | ' |
| Weighted-Average Remaining Contractual Life - Vested and Exercisable Weighted-Average | ' | '9 years 244 days | ' | ' |
| Warrant [Member] | $1.64 [Member] | ' | ' | ' | ' |
| Class of Warrant or Right [Line Items] | ' | ' | ' | ' |
| Price Per Share (in Dollars per Share) | ' | $16.40 | ' | ' |
| Shares - Outstanding | ' | 20,000 | ' | ' |
| Weighted-Average Price Per Share - Outstanding (in Dollars per share) | ' | $16.40 | ' | ' |
| Weighted-Average Remaining Contractual Life - Outstanding | ' | '2 years | ' | ' |
| Shares - Vested and Exercisable Weighted-Average | ' | 20,000 | ' | ' |
| Weighted-Average Price Per Share - Vested and Exercisable Weighted-Average (in Dollars per share) | ' | $16.40 | ' | ' |
| Weighted-Average Remaining Contractual Life - Vested and Exercisable Weighted-Average | ' | '2 years | ' | ' |
| Warrant [Member] | ' | ' | ' | ' |
| Class of Warrant or Right [Line Items] | ' | ' | ' | ' |
| Price Per Share (in Dollars per Share) | ' | $2.23 | ' | ' |
| Shares - Outstanding | 1,228,264 | 853,937 | 931,472 | 624,972 |
| Weighted-Average Remaining Contractual Life - Outstanding | '7 years 14 days | '2 years 242 days | ' | ' |
| Shares - Vested and Exercisable Weighted-Average | ' | 853,937 | ' | ' |
Note_7_Stockholders_Equity_Def8
| Note 7 - Stockholders' Equity (Deficit) (Details) - Summary of Warrant Activity (Warrant [Member]) | 6 Months Ended | 12 Months Ended | |
| Jun. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
| Warrant [Member] | ' | ' | ' |
| Note 7 - Stockholders' Equity (Deficit) (Details) - Summary of Warrant Activity [Line Items] | ' | ' | ' |
| Balance Outstanding | 853,937 | 931,472 | 624,972 |
| Shares granted | 454,457 | 29,001 | 306,500 |
| Shares exercised | 0 | -85,923 | ' |
| Cancelled | ' | -20,612 | ' |
| Balance Outstanding | 1,228,264 | 853,937 | 931,472 |
Note_7_Stockholders_Equity_Def9
| Note 7 - Stockholders' Equity (Deficit) (Details) - Summary of Warrant Activity (Parentheticals) (Warrant [Member], USD $) | 12 Months Ended | |
| Dec. 31, 2013 | Dec. 31, 2012 | |
| Minimum [Member] | ' | ' |
| Note 7 - Stockholders' Equity (Deficit) (Details) - Summary of Warrant Activity (Parentheticals) [Line Items] | ' | ' |
| Shares Granted, Exercise Price | $5 | $0.57 |
| Balance, Exercise Price | $2.23 | $2.23 |
| Maximum [Member] | ' | ' |
| Note 7 - Stockholders' Equity (Deficit) (Details) - Summary of Warrant Activity (Parentheticals) [Line Items] | ' | ' |
| Shares Granted, Exercise Price | $7.50 | $0.63 |
| Balance, Exercise Price | $16.40 | $16.40 |
Note_8_Income_Taxes_Details
| Note 8 - Income Taxes (Details) (USD $) | 12 Months Ended | |
| Dec. 31, 2013 | Dec. 31, 2012 | |
| Income Tax Disclosure [Abstract] | ' | ' |
| Effective Income Tax Rate Reconciliation, Percent | 42.80% | 42.80% |
| Operating Loss Carryforwards (in Dollars) | $8,861,000 | ' |
Note_8_Income_Taxes_Details_Pr
| Note 8 - Income Taxes (Details) - Provision for Income Taxes (USD $) | 12 Months Ended | |
| Dec. 31, 2013 | Dec. 31, 2012 | |
| Provision for Income Taxes [Abstract] | ' | ' |
| State | $1,365 | $1,365 |
| Total current tax provision | 1,365 | 1,365 |
| Loss carryforwards | -2,360,000 | -933,000 |
| Valuation allowance | $2,360,000 | $933,000 |
Note_8_Income_Taxes_Details_De
| Note 8 - Income Taxes (Details) - Deferred Income Tax Assets (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
| Deferred Income Tax Assets [Abstract] | ' | ' |
| Loss carryforwards | ($4,261,000) | ($1,901,000) |
| Less – valuation allowance | $4,261,000 | $1,901,000 |
Note_9_Derivative_Liability_De
| Note 9 - Derivative Liability (Details) (USD $) | 3 Months Ended | 6 Months Ended | 12 Months Ended | 85 Months Ended | ||||||||
| Jun. 30, 2014 | Jun. 30, 2014 | Dec. 31, 2012 | Dec. 31, 2013 | Feb. 12, 2014 | Jun. 15, 2012 | Aug. 31, 2014 | Aug. 31, 2013 | Feb. 12, 2014 | Jun. 30, 2014 | Feb. 28, 2014 | Feb. 12, 2014 | |
| Private Placements [Member] | Private Placements [Member] | Warrants Issued at the same time as offering that are Variable [Member] | 6% Secured Convertible Notes [Member] | 6% Secured Convertible Notes [Member] | 6% Secured Convertible Notes [Member] | |||||||
| 6% Secured Convertible Notes [Member] | ||||||||||||
| Note 9 - Derivative Liability (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Derivative Liability, Current | $2,348,484 | $2,348,484 | ' | ' | $4,587,566 | $3,472,549 | ' | ' | ' | $2,348,483 | ' | ' |
| undefined | ' | ' | 97,975 | 909,368 | ' | ' | ' | ' | ' | ' | ' | ' |
| Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net | 2,484,433 | 2,239,082 | 2,640,497 | -839,569 | ' | ' | ' | ' | ' | ' | ' | ' |
| Interest rate on senior secured convertible notes | 2.50% | 2.50% | 2.50% | 2.50% | ' | ' | ' | ' | ' | 6.00% | 6.00% | 6.00% |
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | ' | ' | 224,000 | 24,001 | ' | ' | 40,000 | 40,000 | ' | ' | ' | 414,457 |
| Derivative Liability | ' | ' | ' | ' | ' | ' | ' | ' | $4,587,566 | ' | ' | $4,443,569 |
Note_9_Derivative_Liability_De1
| Note 9 - Derivative Liability (Details) - Derivative Liabilities (USD $) | 0 Months Ended | 5 Months Ended | |
| Feb. 12, 2014 | Jun. 15, 2012 | Jun. 30, 2014 | |
| Derivative [Line Items] | ' | ' | ' |
| Derivative Liability Fair Value (in Dollars) | $4,587,566 | $3,472,549 | $2,348,484 |
| Conversion Feature [Member] | ' | ' | ' |
| Derivative [Line Items] | ' | ' | ' |
| Risk-free interest rate | 0.74% | 0.29% | 0.88% |
| Expected volatility | 211.00% | 111.00% | 198.00% |
| Expected Life | '3 years | '1 year 317 days | '2 years 229 days |
| Expected dividend yield | 0.00% | 0.00% | 0.00% |
| Derivative Liability Fair Value (in Dollars) | 2,951,785 | 2,295,881 | 1,508,202 |
| Warrant [Member] | ' | ' | ' |
| Derivative [Line Items] | ' | ' | ' |
| Risk-free interest rate | 2.80% | 0.29% | 2.53% |
| Expected volatility | 211.00% | 111.00% | 198.00% |
| Expected Life | '10 years | '1 year 317 days | '9 years 211 days |
| Expected dividend yield | 0.00% | 0.00% | 0.00% |
| Derivative Liability Fair Value (in Dollars) | $1,635,781 | $1,176,668 | $840,282 |
Note_10_12_Convertible_Notes_P1
| Note 10 - 12 % Convertible Notes Payable (Details) (USD $) | 6 Months Ended | 12 Months Ended | 85 Months Ended | 0 Months Ended | 0 Months Ended | 0 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 3 Months Ended | 0 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | ||||||||
| Jun. 30, 2014 | Jun. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Oct. 31, 2012 | Oct. 31, 2012 | 15-May-12 | 15-May-12 | Oct. 31, 2012 | Oct. 31, 2012 | 15-May-12 | Dec. 31, 2012 | Oct. 31, 2012 | Oct. 31, 2012 | Dec. 31, 2012 | Mar. 31, 2012 | 15-May-12 | Oct. 31, 2012 | Dec. 31, 2012 | Oct. 31, 2012 | Oct. 31, 2012 | |
| Per Unit Price Paid By The Purchasers In A Private Placement Closed During The Month [Member] | Issued With 12 Convertible Notes Bridge Notes [Member] | Issued With 12 Convertible Notes Bridge Notes [Member] | Warrants Issued With 12% Convertible Notes Bridge Notes [Member] | Warrants Issued With 12% Convertible Notes Bridge Notes [Member] | Warrants Issued To Purchasers Of The Short Term Twelve Percent Notes Issued [Member] | Warrants Issued To Purchasers Of The Short Term Twelve Percent Notes Issued [Member] | Warrants Issued To Purchasers Of The Short Term Twelve Percent Notes Issued [Member] | Warrants Issued To Purchasers Of The Short Term Twelve Percent Notes Issued [Member] | Issued Upon Conversion Of Twelve Percent Convertible Notes Bridge Notes [Member] | Accrued Interest [Member] | Twelve Percent Convertible Notes Bridge Notes [Member] | Twelve Percent Convertible Notes Bridge Notes [Member] | Twelve Percent Convertible Notes Bridge Notes [Member] | Twelve Percent Convertible Notes Bridge Notes [Member] | Twelve Percent Convertible Notes Bridge Notes [Member] | Beneficial Conversion Feature Cost To Account For The Intrinsic Value In The Conversion Price Of The Bridge Notes And The Market Price Of The Companys Stock At The Date Of Conversion [Member] | ||||||
| Twelve Percent Convertible Notes Bridge Notes [Member] | Repriced Exercise Price To Reflect The Transaction Price Of The Private Placement Closing Member | Aggregate Of Fair Value Of Warrants Issued And Commission Fee For Debt Issuance [Member] | ||||||||||||||||||||
| Note 10 - 12 % Convertible Notes Payable (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Interest rate on senior secured convertible notes | 2.50% | ' | 2.50% | 2.50% | 2.50% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 12.00% | ' | 12.00% | ' | ' |
| Proceeds from Short-term Debt | ' | ' | ' | $645,200 | $645,200 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $700,000 | ' | ' | ' | ' |
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | ' | ' | 24,001 | 224,000 | 24,001 | ' | 68,500 | 14,000 | ' | ' | ' | 14,000 | ' | ' | 68,500 | ' | ' | ' | ' | ' | ' | ' |
| Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item) | ' | ' | $7.50 | ' | $7.50 | ' | $6.25 | $9 | ' | ' | $5.75 | $9 | ' | $5.75 | $6.30 | ' | ' | ' | ' | ' | ' | ' |
| Proceeds from Debt, Net of Issuance Costs | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 645,200 | ' | ' | ' | ' |
| Payments of Debt Issuance Costs | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 54,800 | ' | ' | ' | ' |
| Warrants and Rights Outstanding | ' | ' | ' | ' | ' | ' | 420,863 | 58,387 | ' | 420,863 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Fair Value Assumptions Stock Price (in Dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | $5.50 | ' | ' | ' | ' | ' | $8 | ' | ' | ' | ' | ' | ' | ' |
| Fair Value Assumptions, Exercise Price (in Dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | $9 | ' | ' | ' | ' | ' | $6.30 | ' | ' | ' | ' | ' | ' | ' |
| Fair Value Assumptions, Expected Term | ' | ' | ' | ' | ' | ' | ' | ' | '5 years 6 months | ' | ' | ' | ' | ' | '4 years | ' | ' | ' | ' | ' | ' | ' |
| Fair Value Assumptions, Risk Free Interest Rate | ' | ' | ' | ' | ' | ' | ' | ' | 0.70% | ' | ' | ' | ' | ' | 1.40% | ' | ' | ' | ' | ' | ' | ' |
| Fair Value Assumptions, Expected Dividend Rate | ' | ' | ' | ' | ' | ' | ' | ' | 0.00% | ' | ' | ' | ' | ' | 0.00% | ' | ' | ' | ' | ' | ' | ' |
| Fair Value Assumptions, Expected Volatility Rate | ' | ' | ' | ' | ' | ' | ' | ' | 113.00% | ' | ' | ' | ' | ' | 110.00% | ' | ' | ' | ' | ' | ' | ' |
| Amortization of Debt Discount (Premium) | 670,282 | 357,723 | 557,453 | 769,185 | 2,266,942 | ' | ' | ' | ' | ' | ' | ' | 58,387 | ' | ' | ' | 113,186 | ' | ' | ' | ' | ' |
| Debt Instrument, Convertible, Conversion Price (in Dollars per share) | ' | ' | ' | ' | ' | $5 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.90 | ' | ' | ' | ' |
| Repayments of Notes Payable | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15,000 | ' |
| Debt Conversion, Original Debt, Amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 685,000 | 685,000 | ' | ' |
| Debt Conversion, Converted Instrument, Shares Issued (in Shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 137,000 | 137,000 | ' | ' |
| Modification Costs, Short Term Notes And Warrants | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 411,000 |
| Loss On Modification Of Short-term Notes And Warrants | ' | ' | ' | 866,083 | 866,083 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 34,220 | ' | ' | ' |
| Term Of Exercise Option On Warrants | ' | ' | ' | ' | ' | ' | '4 years | ' | ' | ' | ' | '66 months | ' | ' | '4 years | ' | ' | ' | ' | ' | ' | ' |
| Repayments of Convertible Debt | ' | ' | ' | $15,000 | $15,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $32,666 | ' | ' | ' | ' | ' | ' |
Note_11_Subsequent_Events_Deta
| Note 11 - Subsequent Events (Details) (USD $) | 1 Months Ended | 6 Months Ended | 12 Months Ended | 85 Months Ended | 0 Months Ended | 5 Months Ended | 0 Months Ended | 2 Months Ended | 0 Months Ended | 1 Months Ended | 12 Months Ended | 0 Months Ended | 2 Months Ended | 1 Months Ended | 0 Months Ended | 0 Months Ended | ||||||||||||||||||
| Jun. 23, 2010 | Feb. 12, 2014 | Dec. 31, 2013 | Apr. 29, 2013 | Jun. 30, 2014 | Jun. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | 13-May-10 | Aug. 12, 2014 | Feb. 12, 2014 | Jun. 15, 2012 | Jun. 30, 2014 | 13-May-10 | Jan. 14, 2014 | Aug. 31, 2013 | Feb. 28, 2014 | Aug. 12, 2014 | Feb. 28, 2014 | Aug. 12, 2014 | Feb. 12, 2014 | Dec. 31, 2007 | Aug. 12, 2014 | Feb. 28, 2014 | Feb. 12, 2014 | Jul. 21, 2014 | Jul. 29, 2014 | Aug. 12, 2014 | Apr. 22, 2014 | Feb. 12, 2014 | Jun. 30, 2014 | Feb. 28, 2014 | Apr. 22, 2014 | |
| Warrant [Member] | Warrant [Member] | Warrant [Member] | Warrant [Member] | Warrant [Member] | Private Placements [Member] | Private Placements [Member] | Conversion Feature and Warrants [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Subsequent Event [Member] | Subsequent Event [Member] | Subsequent Event [Member] | Subsequent Event [Member] | Subsequent Event [Member] | Subsequent Event [Member] | Subsequent Event [Member] | 6% Secured Convertible Notes [Member] | 6% Secured Convertible Notes [Member] | 6% Secured Convertible Notes [Member] | Reverse Stock Split [Member] | |||||||||||
| Subsequent Event [Member] | Subsequent Event [Member] | Subsequent Event [Member] | Subsequent Event [Member] | Subsequent Event [Member] | Subsequent Event [Member] | 6% Secured Convertible Notes [Member] | Scenario, Plan [Member] | Senior Secured 6% Notes [Member] | Senior Secured 6% Notes [Member] | 6% Secured Convertible Notes [Member] | 6% Secured Convertible Notes [Member] | 8% Secured Convertible Notes [Member] | Reverse Stock Split [Member] | |||||||||||||||||||||
| 8% Secured Convertible Notes [Member] | Senior Secured 6% Notes [Member] | Issued Upon Consummation of Underwritten Offering [Member] | Senior Secured 6% Notes [Member] | 8% Secured Convertible Notes [Member] | 8% Secured Convertible Notes [Member] | |||||||||||||||||||||||||||||
| 8% Secured Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||
| Note 11 - Subsequent Events (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | ' | ' | 24,001 | ' | ' | ' | 24,001 | 224,000 | 24,001 | ' | ' | ' | ' | ' | ' | 40,001 | 40,000 | ' | ' | ' | ' | ' | ' | ' | ' | 414,456 | ' | ' | ' | ' | 414,457 | ' | ' | ' |
| Debt Instrument, Face Amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $1,906,500 | $1,906,500 | ' | ' | ' | ' | $1,906,500 | ' | $1,906,500 | ' |
| Interest rate on senior secured convertible notes | ' | ' | 2.50% | ' | 2.50% | ' | 2.50% | 2.50% | 2.50% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6.00% | 6.00% | ' | ' | 8.00% | ' | 6.00% | 6.00% | 6.00% | ' |
| Payments for Commissions | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 68,720 | ' | ' | ' | ' | ' | 70,720 | ' | ' | ' |
| Stock Issued During Period, Shares, New Issues (in Shares) | ' | ' | 199,716 | 160,541 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,535 | ' | 6,535 | 1,923,303 | ' | ' | ' | ' | ' | ' | ' | 6,535 | ' | ' | ' |
| Stock Issued During Period, Value, New Issues | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 23,395 | ' | 23,395 | 192 | ' | ' | ' | ' | ' | ' | ' | 23,395 | ' | ' | ' |
| Debt Instrument, Term | ' | '3 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '3 years | ' | ' | ' | '1 year | ' | ' | ' | ' | ' |
| Debt Instrument, Convertible, Conversion Price (in Dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $2 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $2.30 | ' | ' | ' | $1.11 | ' | $2.30 | ' | ' | ' |
| Warrants, Term | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '10 years | ' | ' | ' | '5 years | ' | ' | ' | ' | ' |
| Extension of Warrant Terms Held by Participants From Date of Original Issuance | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '10 years | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Debt Instrument, Convertible, Beneficial Conversion Feature | ' | ' | ' | ' | ' | ' | ' | 1,498,333 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,951,776 | ' | ' | ' | 275,356 | ' | ' | ' | ' | ' |
| Warrants and Rights Outstanding | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 224,644 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,491,780 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Derivative Liability, Fair Value, Gross Liability | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,542,348 | ' | 143,997 | ' | ' | 1,172,103 | ' | ' | 4,443,556 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Excess of Derivative Liabilities at Fair Value Over Note Value | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,537,056 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Aggregate Valuation Increase of Warrants | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 564,849 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Stockholders' Equity Note, Stock Split, Conversion Ratio | 200 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10 | ' | ' | ' | 10 |
| Debt Conversion, Converted Instrument, Shares Issued (in Shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 14,453 | 24,088 | ' | ' | ' | ' | ' | ' |
| Debt Conversion, Converted Instrument, Amount | ' | ' | ' | ' | 436,315 | 169,765 | 169,765 | 1,448,130 | 2,190,616 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15,000 | 25,000 | ' | ' | ' | ' | ' | ' |
| Debt Conversion Converted Instrument Accrued Interest Amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 393 | 654 | ' | ' | ' | ' | ' | ' |
| Proceeds from Convertible Debt | ' | ' | ' | ' | 1,906,500 | ' | ' | 1,498,333 | 2,893,339 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 500,000 | ' | ' | ' | ' | ' |
| Debt Instrument, Convertible, Number of Equity Instruments | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 225,228 | ' | 450,457 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 115.00% | ' | ' | ' | ' | ' |
| Percent of Principal Value of Convertible Notes Authorized Under Warrant | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 50.00% | ' | ' | ' | ' | ' |
| Amortization of Debt Discount (Premium) | ' | ' | ' | ' | $670,282 | $357,723 | $557,453 | $769,185 | $2,266,942 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Fair Value Assumptions, Risk Free Interest Rate | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1.83% | 2.80% | 0.29% | 2.53% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Fair Value Assumptions, Expected Dividend Rate | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0.00% | 0.00% | 0.00% | 0.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Fair Value Assumptions, Expected Volatility Rate | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 136.00% | 211.00% | 111.00% | 198.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Fair Value Assumptions, Expected Term | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '5 years | '10 years | '1 year 317 days | '9 years 211 days | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Note_2_Basis_of_Presentation_a4
| Note 2 - Basis of Presentation and Summary of Significant Accounting Policies (Details) - Reconciliation of Basic and Diluted Shares | 3 Months Ended | 6 Months Ended | ||
| Jun. 30, 2014 | Jun. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2013 | |
| Reconciliation of Basic and Diluted Shares [Abstract] | ' | ' | ' | ' |
| Average common shares outstanding-basic | 4,618,409 | 4,003,358 | 4,415,392 | 3,900,847 |
| Effect of dilutive securities- | ' | ' | ' | ' |
| Warrants | 516,797 | ' | ' | ' |
| Employee and director stock options | 21,750 | ' | ' | ' |
| Average diluted shares | 5,156,956 | 4,003,358 | 4,415,392 | 3,900,847 |
Note_2_Basis_of_Presentation_a5
| Note 2 - Basis of Presentation and Summary of Significant Accounting Policies (Details) - Antidilutive Securities Excluded from the Dilutive Calculations | 3 Months Ended | 12 Months Ended | ||
| Jun. 30, 2014 | Jun. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | |
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' | ' | ' |
| Antidilutive securities | 2,474,867 | 1,907,471 | 1,973,863 | 2,000,045 |
| Convertible Debt Securities [Member] | ' | ' | ' | ' |
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' | ' | ' |
| Antidilutive securities | 1,236,212 | 550,977 | 550,977 | 607,873 |
| Warrant [Member] | ' | ' | ' | ' |
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' | ' | ' |
| Antidilutive securities | 711,455 | 835,544 | 853,937 | 931,472 |
| Equity Option [Member] | ' | ' | ' | ' |
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' | ' | ' |
| Antidilutive securities | 527,200 | 520,950 | 568,950 | 460,700 |
Note_2_Basis_of_Presentation_a6
| Note 2 - Basis of Presentation and Summary of Significant Accounting Policies (Details) - Fair Value of Derivative Liability (USD $) | Jun. 30, 2014 | Feb. 12, 2014 | Jun. 15, 2012 |
| Note 2 - Basis of Presentation and Summary of Significant Accounting Policies (Details) - Fair Value of Derivative Liability [Line Items] | ' | ' | ' |
| Fair Value of Derivative Liability | $2,348,484 | $4,587,566 | $3,472,549 |
| Fair Value, Inputs, Level 2 [Member] | ' | ' | ' |
| Note 2 - Basis of Presentation and Summary of Significant Accounting Policies (Details) - Fair Value of Derivative Liability [Line Items] | ' | ' | ' |
| Fair Value of Derivative Liability | $2,348,484 | ' | ' |
Note_3_Senior_Secured_Converti
| Note 3 - Senior Secured Convertible Notes Payable (Details) - Senior Secured Convertible Notes Payable (USD $) | Jun. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
| Note 3 - Senior Secured Convertible Notes Payable (Details) - Senior Secured Convertible Notes Payable [Line Items] | ' | ' | ' |
| Convertible Notes | $3,087,667 | $1,597,833 | $1,762,833 |
| Less Valuation Discount | -2,080,795 | -844,577 | -1,402,030 |
| 1,006,872 | 753,256 | 360,803 | |
| Less Current Portion | -427,500 | -390,123 | ' |
| Convertible Notes Payable, net | 579,372 | 363,133 | 360,803 |
| 2010 Convertible Notes [Member] | ' | ' | ' |
| Note 3 - Senior Secured Convertible Notes Payable (Details) - Senior Secured Convertible Notes Payable [Line Items] | ' | ' | ' |
| Convertible Notes | 427,500 | 427,500 | 427,500 |
| Less Valuation Discount | ' | -37,375 | ' |
| 2012 Convertible Notes [Member] | ' | ' | ' |
| Note 3 - Senior Secured Convertible Notes Payable (Details) - Senior Secured Convertible Notes Payable [Line Items] | ' | ' | ' |
| Convertible Notes | 753,667 | 1,170,333 | 1,335,333 |
| Less Valuation Discount | -419,405 | -807,202 | ' |
| 2014 Convertible Notes [Member] | ' | ' | ' |
| Note 3 - Senior Secured Convertible Notes Payable (Details) - Senior Secured Convertible Notes Payable [Line Items] | ' | ' | ' |
| Convertible Notes | $1,906,500 | ' | ' |
Note_4_Derivative_Liability_De
| Note 4 - Derivative Liability (Details) - Derivative Liabilities (USD $) | 0 Months Ended | 5 Months Ended | |
| Feb. 12, 2014 | Jun. 15, 2012 | Jun. 30, 2014 | |
| Derivative [Line Items] | ' | ' | ' |
| Derivative Liability Fair Value (in Dollars) | $4,587,566 | $3,472,549 | $2,348,484 |
| Conversion Feature [Member] | ' | ' | ' |
| Derivative [Line Items] | ' | ' | ' |
| Risk-free interest rate | 0.74% | 0.29% | 0.88% |
| Expected volatility | 211.00% | 111.00% | 198.00% |
| Expected Life | '3 years | '1 year 317 days | '2 years 229 days |
| Expected dividend yield | 0.00% | 0.00% | 0.00% |
| Derivative Liability Fair Value (in Dollars) | 2,951,785 | 2,295,881 | 1,508,202 |
| Warrant [Member] | ' | ' | ' |
| Derivative [Line Items] | ' | ' | ' |
| Risk-free interest rate | 2.80% | 0.29% | 2.53% |
| Expected volatility | 211.00% | 111.00% | 198.00% |
| Expected Life | '10 years | '1 year 317 days | '9 years 211 days |
| Expected dividend yield | 0.00% | 0.00% | 0.00% |
| Derivative Liability Fair Value (in Dollars) | $1,635,781 | $1,176,668 | $840,282 |
Note_5_Stockholders_Equity_Det
| Note 5 - Stockholders' Equity (Details) - Summary of Stock Options and Changes During Period (USD $) | 6 Months Ended | 12 Months Ended | |||
| Jun. 30, 2014 | Jun. 30, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
| Summary of Stock Options and Changes During Period [Abstract] | ' | ' | ' | ' | ' |
| Shares | 548,950 | ' | 568,950 | 460,700 | 451,950 |
| Weighted average exercise price | $8.42 | ' | $8.32 | $9.87 | $11.29 |
| Weighted Average Remaining Contractual Term (years) | '4 years 117 days | ' | '4 years 309 days | '5 years 68 days | '6 years 59 days |
| Aggregate Intrinsic Value | $0 | ' | $86,271 | $119,241 | $1,140,059 |
| Exercisable at June 30, 2014 | 390,105 | ' | 305,471 | ' | ' |
| Exercisable at June 30, 2014 | $9.04 | ' | $9.52 | ' | ' |
| Exercisable at June 30, 2014 | '3 years 295 days | ' | ' | ' | ' |
| Exercisable at June 30, 2014 | $0 | ' | $84,475 | ' | ' |
| Granted | 10,000 | 10.1 | 208,250 | 10,000 | ' |
| Granted | $3.80 | ' | $5.74 | $10 | ' |
| Granted | '7 years | ' | '6 years 137 days | '6 years 6 months | ' |
| Cancelled | -30,000 | ' | -100,000 | -1,250 | ' |
| Cancelled | ($5) | ' | ($10.10) | ($11.10) | ' |
Note_5_Stockholders_Equity_Det1
| Note 5 - Stockholders' Equity (Details) - Weighted Average Assumptions | 3 Months Ended | 6 Months Ended | 12 Months Ended | 6 Months Ended | 12 Months Ended | |||||||
| Jun. 30, 2014 | Jun. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Jun. 30, 2014 | Jun. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | |
| Minimum [Member] | Minimum [Member] | Minimum [Member] | Minimum [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | |||||
| Note 5 - Stockholders' Equity (Details) - Weighted Average Assumptions [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Expected volatility | 198.00% | 218.00% | ' | ' | 198.00% | 113.00% | 113.00% | 111.00% | 201.00% | 226.00% | 226.00% | 134.00% |
| Expected term (in years) | '6 years 3 months | '6 years 3 months | '6 years 3 months | '6 years 3 months | ' | ' | '5 years 6 months | '1 year 9 months | ' | ' | '6 years 3 months | '6 years 3 months |
| Risk-free interest rate | 2.73% | 2.05% | 2.73% | ' | ' | 1.38% | 1.38% | 1.19% | ' | 2.05% | 2.09% | 1.41% |
Note_5_Stockholders_Equity_Det2
| Note 5 - Stockholders' Equity (Details) - Summary of Warrant Activity (USD $) | 6 Months Ended | 12 Months Ended | ||
| Jun. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
| Note 5 - Stockholders' Equity (Details) - Summary of Warrant Activity [Line Items] | ' | ' | ' | ' |
| Granted | '7 years | '6 years 137 days | '6 years 6 months | ' |
| Warrant [Member] | ' | ' | ' | ' |
| Note 5 - Stockholders' Equity (Details) - Summary of Warrant Activity [Line Items] | ' | ' | ' | ' |
| Balance Outstanding | 1,228,264 | 853,937 | 931,472 | 624,972 |
| Weighted average exercise price (in Dollars per share) | $3.99 | $3.77 | ' | ' |
| Weighted Average Remaining Contractual Term (years) | '7 years 14 days | '2 years 242 days | ' | ' |
| Aggregate Intrinsic Value (in Dollars) | $0 | $783,258 | ' | ' |
| Exercisable at June 30, 2014 | 1,228,264 | ' | ' | ' |
| Exercisable at June 30, 2014 (in Dollars per share) | $3.99 | ' | ' | ' |
| Exercisable at June 30, 2014 | '7 years 14 days | ' | ' | ' |
| Exercisable at June 30, 2014 (in Dollars) | $0 | ' | ' | ' |
| Granted | 454,457 | 29,001 | 306,500 | ' |
| Granted (in Dollars per share) | $2.30 | ' | ' | ' |
| Granted | '9 years 243 days | ' | ' | ' |
| Exercised | 0 | 85,923 | ' | ' |
| Cancelled | -80,139 | ' | ' | ' |
| Cancelled (in Dollars per share) | ($5.97) | ' | ' | ' |
Note_7_Related_Party_Transacti1
| Note 7 - Related Party Transactions (Details) (USD $) | Jun. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
| Note 7 - Related Party Transactions (Details) [Line Items] | ' | ' | ' |
| Accounts Payable, Related Parties | $65,917 | $50,841 | ' |
| Europa International Inc. [Member] | 6% Secured Convertible Notes [Member] | ' | ' | ' |
| Note 7 - Related Party Transactions (Details) [Line Items] | ' | ' | ' |
| Due to Related Parties | 300,000 | ' | ' |
| Europa International Inc. [Member] | ' | ' | ' |
| Note 7 - Related Party Transactions (Details) [Line Items] | ' | ' | ' |
| Due to Related Parties | 1,094,167 | 1,094,167 | 1,094,167 |
| 2.5% Senior Secured Convertible Notes (the "Second Amended Notes") [Member] | ' | ' | ' |
| Note 7 - Related Party Transactions (Details) [Line Items] | ' | ' | ' |
| Due to Related Parties | $1,094,167 | ' | ' |